EP1966158A1 - Substituierte cinnolinderivate als modulatoren des gabaa-rezeptors und verfahren zu ihrer synthese - Google Patents
Substituierte cinnolinderivate als modulatoren des gabaa-rezeptors und verfahren zu ihrer syntheseInfo
- Publication number
- EP1966158A1 EP1966158A1 EP06824527A EP06824527A EP1966158A1 EP 1966158 A1 EP1966158 A1 EP 1966158A1 EP 06824527 A EP06824527 A EP 06824527A EP 06824527 A EP06824527 A EP 06824527A EP 1966158 A1 EP1966158 A1 EP 1966158A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- amino
- carboxamide
- alkyl
- cinnoline
- arylalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 139
- 108091008681 GABAA receptors Proteins 0.000 title claims description 43
- 102000027484 GABAA receptors Human genes 0.000 title claims description 42
- 125000000259 cinnolinyl group Chemical class N1=NC(=CC2=CC=CC=C12)* 0.000 title description 12
- 238000003786 synthesis reaction Methods 0.000 title description 11
- 230000015572 biosynthetic process Effects 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 323
- 150000003839 salts Chemical class 0.000 claims abstract description 74
- 239000002243 precursor Substances 0.000 claims abstract description 45
- 208000019022 Mood disease Diseases 0.000 claims abstract description 17
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 16
- 208000010877 cognitive disease Diseases 0.000 claims abstract description 15
- 238000011282 treatment Methods 0.000 claims abstract description 15
- 206010012289 Dementia Diseases 0.000 claims abstract description 12
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 792
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 296
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 266
- 125000001188 haloalkyl group Chemical group 0.000 claims description 256
- 125000003118 aryl group Chemical group 0.000 claims description 255
- 125000001072 heteroaryl group Chemical group 0.000 claims description 249
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 239
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 210
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 178
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims description 178
- 125000005843 halogen group Chemical group 0.000 claims description 140
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 130
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 128
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 93
- 229910052799 carbon Inorganic materials 0.000 claims description 79
- 229910052739 hydrogen Inorganic materials 0.000 claims description 78
- 125000003545 alkoxy group Chemical group 0.000 claims description 67
- 229910052701 rubidium Inorganic materials 0.000 claims description 61
- 125000003282 alkyl amino group Chemical group 0.000 claims description 59
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 57
- 125000001424 substituent group Chemical group 0.000 claims description 55
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 49
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 48
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 37
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 36
- 239000003054 catalyst Substances 0.000 claims description 34
- ZMXDDKWLCZADIW-UHFFFAOYSA-N Vilsmeier-Haack reagent Natural products CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 33
- 125000004076 pyridyl group Chemical group 0.000 claims description 30
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 29
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 29
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical group [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 28
- 125000001041 indolyl group Chemical group 0.000 claims description 28
- 125000001624 naphthyl group Chemical group 0.000 claims description 28
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 28
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical group [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 claims description 27
- 125000005493 quinolyl group Chemical group 0.000 claims description 27
- 102000005962 receptors Human genes 0.000 claims description 26
- 108020003175 receptors Proteins 0.000 claims description 26
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 24
- LBGQERGEZNQMAT-UHFFFAOYSA-N cinnoline-3-carboxamide Chemical compound C1=CC=C2N=NC(C(=O)N)=CC2=C1 LBGQERGEZNQMAT-UHFFFAOYSA-N 0.000 claims description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 20
- 239000003960 organic solvent Substances 0.000 claims description 20
- 239000002904 solvent Substances 0.000 claims description 19
- 229910052717 sulfur Inorganic materials 0.000 claims description 17
- 125000003342 alkenyl group Chemical group 0.000 claims description 16
- 125000004429 atom Chemical group 0.000 claims description 16
- 229910052705 radium Inorganic materials 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 15
- 239000001257 hydrogen Substances 0.000 claims description 15
- 125000000304 alkynyl group Chemical group 0.000 claims description 14
- 229910052763 palladium Inorganic materials 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 125000004432 carbon atom Chemical group C* 0.000 claims description 13
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 12
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical group [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 12
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 11
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical group COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 10
- 125000001246 bromo group Chemical group Br* 0.000 claims description 10
- 125000002346 iodo group Chemical group I* 0.000 claims description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 7
- 229910052796 boron Inorganic materials 0.000 claims description 7
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 6
- KYDURMHFWXCKMW-UHFFFAOYSA-N 4-amino-8-(2-fluoro-6-methoxyphenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=C(F)C=CC=C1OC KYDURMHFWXCKMW-UHFFFAOYSA-N 0.000 claims description 5
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical group [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 5
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 238000010189 synthetic method Methods 0.000 claims description 5
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 4
- NVWCZRPXYVDQEE-UHFFFAOYSA-N 4-amino-8-(2,5-dimethoxyphenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC(OC)=CC=C1OC NVWCZRPXYVDQEE-UHFFFAOYSA-N 0.000 claims description 4
- VHGIDFXNMYWNMX-UHFFFAOYSA-N 4-amino-8-(4-methoxypyridin-3-yl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CN=CC=C1OC VHGIDFXNMYWNMX-UHFFFAOYSA-N 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- CKXAAXAUGQVKMV-UHFFFAOYSA-N 4-amino-7-chloro-8-phenyl-n-propylcinnoline-3-carboxamide Chemical compound ClC=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=CC=C1 CKXAAXAUGQVKMV-UHFFFAOYSA-N 0.000 claims description 3
- UTLPDTOXOFRETH-UHFFFAOYSA-N 4-amino-7-fluoro-8-phenyl-n-propylcinnoline-3-carboxamide Chemical compound FC=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=CC=C1 UTLPDTOXOFRETH-UHFFFAOYSA-N 0.000 claims description 3
- RJUQWFAOLNQUTM-UHFFFAOYSA-N 4-amino-7-methoxy-8-phenyl-n-propylcinnoline-3-carboxamide Chemical compound COC=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=CC=C1 RJUQWFAOLNQUTM-UHFFFAOYSA-N 0.000 claims description 3
- UJGYNTKWBYEZEI-UHFFFAOYSA-N 4-amino-8-(1-methylpyrazol-4-yl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C=1C=NN(C)C=1 UJGYNTKWBYEZEI-UHFFFAOYSA-N 0.000 claims description 3
- ANDSRHCEJZAOQC-UHFFFAOYSA-N 4-amino-8-(1h-indol-5-yl)-n-propylcinnoline-3-carboxamide Chemical compound C1=C2NC=CC2=CC(C=2C3=NN=C(C(=C3C=CC=2)N)C(=O)NCCC)=C1 ANDSRHCEJZAOQC-UHFFFAOYSA-N 0.000 claims description 3
- IFQYHSKTVYMWGG-UHFFFAOYSA-N 4-amino-8-(2,3-dimethoxyphenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=CC(OC)=C1OC IFQYHSKTVYMWGG-UHFFFAOYSA-N 0.000 claims description 3
- QMHPXSLLDJXMCH-UHFFFAOYSA-N 4-amino-8-(2,4-difluorophenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=C(F)C=C1F QMHPXSLLDJXMCH-UHFFFAOYSA-N 0.000 claims description 3
- URWAOABXZDWESI-UHFFFAOYSA-N 4-amino-8-(2,5-dichlorophenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC(Cl)=CC=C1Cl URWAOABXZDWESI-UHFFFAOYSA-N 0.000 claims description 3
- TVXFLMRBGGGVGJ-UHFFFAOYSA-N 4-amino-8-(2,5-difluorophenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC(F)=CC=C1F TVXFLMRBGGGVGJ-UHFFFAOYSA-N 0.000 claims description 3
- NTSIBLRVVRGOLO-UHFFFAOYSA-N 4-amino-8-(2,5-dimethylphenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC(C)=CC=C1C NTSIBLRVVRGOLO-UHFFFAOYSA-N 0.000 claims description 3
- IVVODHMVRGRGDD-UHFFFAOYSA-N 4-amino-8-(2,5-dimethylpyrazol-3-yl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC(C)=NN1C IVVODHMVRGRGDD-UHFFFAOYSA-N 0.000 claims description 3
- ZBTRXQMOEXJWEU-UHFFFAOYSA-N 4-amino-8-(2-fluoro-3-methoxyphenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=CC(OC)=C1F ZBTRXQMOEXJWEU-UHFFFAOYSA-N 0.000 claims description 3
- VJCCUKHKFFYRTC-UHFFFAOYSA-N 4-amino-8-(2-fluoro-5-methylphenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC(C)=CC=C1F VJCCUKHKFFYRTC-UHFFFAOYSA-N 0.000 claims description 3
- MKPZUOHXAIRIAF-UHFFFAOYSA-N 4-amino-8-(2-fluoropyridin-3-yl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=CN=C1F MKPZUOHXAIRIAF-UHFFFAOYSA-N 0.000 claims description 3
- GTGGDPMSPFTXEJ-UHFFFAOYSA-N 4-amino-8-(2-methoxy-5-methylphenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC(C)=CC=C1OC GTGGDPMSPFTXEJ-UHFFFAOYSA-N 0.000 claims description 3
- ZTDWGOGAYMPMGY-UHFFFAOYSA-N 4-amino-8-(3,4-difluorophenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=C(F)C(F)=C1 ZTDWGOGAYMPMGY-UHFFFAOYSA-N 0.000 claims description 3
- DPQQSMAXDWKBPS-UHFFFAOYSA-N 4-amino-8-(3,4-dimethoxyphenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=C(OC)C(OC)=C1 DPQQSMAXDWKBPS-UHFFFAOYSA-N 0.000 claims description 3
- BBWBRMSUDDRWFH-UHFFFAOYSA-N 4-amino-8-(3,5-difluoro-2-methoxyphenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC(F)=CC(F)=C1OC BBWBRMSUDDRWFH-UHFFFAOYSA-N 0.000 claims description 3
- CYIACUSKYQIBPS-UHFFFAOYSA-N 4-amino-8-(3-cyanophenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=CC(C#N)=C1 CYIACUSKYQIBPS-UHFFFAOYSA-N 0.000 claims description 3
- XLPIYDAKOUQWHP-UHFFFAOYSA-N 4-amino-8-(3-methylsulfonylphenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=CC(S(C)(=O)=O)=C1 XLPIYDAKOUQWHP-UHFFFAOYSA-N 0.000 claims description 3
- AERKPQVNNIUWON-UHFFFAOYSA-N 4-amino-8-(5-chloro-6-methoxypyridin-3-yl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CN=C(OC)C(Cl)=C1 AERKPQVNNIUWON-UHFFFAOYSA-N 0.000 claims description 3
- IGGRMKCLFNXGCZ-UHFFFAOYSA-N 4-amino-8-[3,5-bis(trifluoromethyl)phenyl]-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 IGGRMKCLFNXGCZ-UHFFFAOYSA-N 0.000 claims description 3
- DBBOPGCIRSZYFW-UHFFFAOYSA-N 4-amino-8-[3-(dimethylamino)phenyl]-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=CC(N(C)C)=C1 DBBOPGCIRSZYFW-UHFFFAOYSA-N 0.000 claims description 3
- HKLKTYGKDWPHDG-UHFFFAOYSA-N 4-amino-8-[4-methoxy-2-(trifluoromethyl)phenyl]-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=C(OC)C=C1C(F)(F)F HKLKTYGKDWPHDG-UHFFFAOYSA-N 0.000 claims description 3
- QZVKETIPEADKQP-UHFFFAOYSA-N 4-amino-8-naphthalen-2-yl-n-propylcinnoline-3-carboxamide Chemical compound C1=CC=CC2=CC(C=3C4=NN=C(C(=C4C=CC=3)N)C(=O)NCCC)=CC=C21 QZVKETIPEADKQP-UHFFFAOYSA-N 0.000 claims description 3
- IKRSLHDZHQIINP-UHFFFAOYSA-N 4-amino-n-propyl-8-(1h-pyrazol-4-yl)cinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C=1C=NNC=1 IKRSLHDZHQIINP-UHFFFAOYSA-N 0.000 claims description 3
- LSMMAMOXRXZTIP-UHFFFAOYSA-N 4-amino-n-propyl-8-pyridin-2-ylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=CC=N1 LSMMAMOXRXZTIP-UHFFFAOYSA-N 0.000 claims description 3
- YMSVDRXGODMHAS-UHFFFAOYSA-N 4-amino-n-propyl-8-quinolin-3-ylcinnoline-3-carboxamide Chemical compound C1=CC=CC2=CC(C=3C4=NN=C(C(=C4C=CC=3)N)C(=O)NCCC)=CN=C21 YMSVDRXGODMHAS-UHFFFAOYSA-N 0.000 claims description 3
- PKWJRCVJHNOJPY-UHFFFAOYSA-N 4-amino-n-propyl-8-quinolin-6-ylcinnoline-3-carboxamide Chemical compound N1=CC=CC2=CC(C=3C4=NN=C(C(=C4C=CC=3)N)C(=O)NCCC)=CC=C21 PKWJRCVJHNOJPY-UHFFFAOYSA-N 0.000 claims description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
- 229910000160 potassium phosphate Inorganic materials 0.000 claims description 3
- 235000011009 potassium phosphates Nutrition 0.000 claims description 3
- NURVRRVXBZFKHJ-UHFFFAOYSA-N 4-amino-7-chloro-8-(2,5-dimethylphenyl)-n-propylcinnoline-3-carboxamide Chemical compound ClC=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC(C)=CC=C1C NURVRRVXBZFKHJ-UHFFFAOYSA-N 0.000 claims description 2
- NDRCTVXAHQAWNT-UHFFFAOYSA-N 4-amino-7-chloro-8-(2-methoxy-5-methylphenyl)-n-propylcinnoline-3-carboxamide Chemical compound ClC=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC(C)=CC=C1OC NDRCTVXAHQAWNT-UHFFFAOYSA-N 0.000 claims description 2
- RGVSDPWAUKWCJM-UHFFFAOYSA-N 4-amino-7-fluoro-8-(4-methoxypyridin-3-yl)-n-propylcinnoline-3-carboxamide Chemical compound FC=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CN=CC=C1OC RGVSDPWAUKWCJM-UHFFFAOYSA-N 0.000 claims description 2
- XEKGYNOGHFVELS-UHFFFAOYSA-N 4-amino-8-(1,3-benzodioxol-4-yl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=CC2=C1OCO2 XEKGYNOGHFVELS-UHFFFAOYSA-N 0.000 claims description 2
- VSHXOPWIANIYJK-UHFFFAOYSA-N 4-amino-8-(2,3-difluorophenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=CC(F)=C1F VSHXOPWIANIYJK-UHFFFAOYSA-N 0.000 claims description 2
- MFHPKPPNZZGFKR-UHFFFAOYSA-N 4-amino-8-(2,3-dimethylphenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=CC(C)=C1C MFHPKPPNZZGFKR-UHFFFAOYSA-N 0.000 claims description 2
- JRCQRBJGHBZPRG-UHFFFAOYSA-N 4-amino-8-(2,4-dimethylphenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=C(C)C=C1C JRCQRBJGHBZPRG-UHFFFAOYSA-N 0.000 claims description 2
- ZDFKPTFDMSEEJC-UHFFFAOYSA-N 4-amino-8-(2,5-difluoro-4-methoxyphenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC(F)=C(OC)C=C1F ZDFKPTFDMSEEJC-UHFFFAOYSA-N 0.000 claims description 2
- PFZUQESQYBPRGB-UHFFFAOYSA-N 4-amino-8-(2,5-dimethoxyphenyl)-7-fluoro-n-propylcinnoline-3-carboxamide Chemical compound FC=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC(OC)=CC=C1OC PFZUQESQYBPRGB-UHFFFAOYSA-N 0.000 claims description 2
- APUNYVRQQYUBJR-UHFFFAOYSA-N 4-amino-8-(2,5-dimethoxyphenyl)-n-(2-hydroxypropyl)cinnoline-3-carboxamide Chemical compound COC1=CC=C(OC)C(C=2C3=NN=C(C(N)=C3C=CC=2)C(=O)NCC(C)O)=C1 APUNYVRQQYUBJR-UHFFFAOYSA-N 0.000 claims description 2
- MGUKATBPDDNUIF-UHFFFAOYSA-N 4-amino-8-(2,5-dimethoxyphenyl)-n-(2-methylpropyl)cinnoline-3-carboxamide Chemical compound COC1=CC=C(OC)C(C=2C3=NN=C(C(N)=C3C=CC=2)C(=O)NCC(C)C)=C1 MGUKATBPDDNUIF-UHFFFAOYSA-N 0.000 claims description 2
- WFCALMPXVKUYLO-UHFFFAOYSA-N 4-amino-8-(2,5-dimethoxyphenyl)-n-ethylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCC)=NN=C2C=1C1=CC(OC)=CC=C1OC WFCALMPXVKUYLO-UHFFFAOYSA-N 0.000 claims description 2
- FKATWOUWYYENKU-UHFFFAOYSA-N 4-amino-8-(2,5-dimethoxyphenyl)-n-methylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NC)=NN=C2C=1C1=CC(OC)=CC=C1OC FKATWOUWYYENKU-UHFFFAOYSA-N 0.000 claims description 2
- SJXZYPIUGXPYNZ-UHFFFAOYSA-N 4-amino-8-(2,6-dimethoxypyridin-3-yl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=C(OC)N=C1OC SJXZYPIUGXPYNZ-UHFFFAOYSA-N 0.000 claims description 2
- VOVGYBOEGUOGJQ-UHFFFAOYSA-N 4-amino-8-(2,6-dimethylphenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=C(C)C=CC=C1C VOVGYBOEGUOGJQ-UHFFFAOYSA-N 0.000 claims description 2
- SFBCNFHSPXZYIU-UHFFFAOYSA-N 4-amino-8-(2-fluoro-4,6-dimethoxyphenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=C(F)C=C(OC)C=C1OC SFBCNFHSPXZYIU-UHFFFAOYSA-N 0.000 claims description 2
- YJGFELIVBWEJLR-UHFFFAOYSA-N 4-amino-8-(2-fluoro-4-methoxyphenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=C(OC)C=C1F YJGFELIVBWEJLR-UHFFFAOYSA-N 0.000 claims description 2
- VXRYAIDFMDSNOD-UHFFFAOYSA-N 4-amino-8-(2-fluoro-4-methylphenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=C(C)C=C1F VXRYAIDFMDSNOD-UHFFFAOYSA-N 0.000 claims description 2
- PVVPNFHTAFOMLD-UHFFFAOYSA-N 4-amino-8-(2-fluoro-5-methoxyphenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC(OC)=CC=C1F PVVPNFHTAFOMLD-UHFFFAOYSA-N 0.000 claims description 2
- YVGMIRYHNHFUEO-UHFFFAOYSA-N 4-amino-8-(2-methoxy-5-methylphenyl)-n-methylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NC)=NN=C2C=1C1=CC(C)=CC=C1OC YVGMIRYHNHFUEO-UHFFFAOYSA-N 0.000 claims description 2
- MRUOPNGPXPMKRC-UHFFFAOYSA-N 4-amino-8-(2-methoxypyridin-3-yl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=CN=C1OC MRUOPNGPXPMKRC-UHFFFAOYSA-N 0.000 claims description 2
- JMRHVJPVNLBGRZ-UHFFFAOYSA-N 4-amino-8-(2-methylphenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=CC=C1C JMRHVJPVNLBGRZ-UHFFFAOYSA-N 0.000 claims description 2
- AYUWBRCLPWDVRE-UHFFFAOYSA-N 4-amino-8-(3,4-dimethylphenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=C(C)C(C)=C1 AYUWBRCLPWDVRE-UHFFFAOYSA-N 0.000 claims description 2
- XEGFESJWGGJFRD-UHFFFAOYSA-N 4-amino-8-(3,5-dichlorophenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC(Cl)=CC(Cl)=C1 XEGFESJWGGJFRD-UHFFFAOYSA-N 0.000 claims description 2
- XDCYTRVYQOYYHP-UHFFFAOYSA-N 4-amino-8-(3,5-dimethoxyphenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC(OC)=CC(OC)=C1 XDCYTRVYQOYYHP-UHFFFAOYSA-N 0.000 claims description 2
- TWMIXDWRCUPFIR-UHFFFAOYSA-N 4-amino-8-(3,5-dimethyl-1h-pyrazol-4-yl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C=1C(C)=NNC=1C TWMIXDWRCUPFIR-UHFFFAOYSA-N 0.000 claims description 2
- IACRYXFWKJOMEI-UHFFFAOYSA-N 4-amino-8-(3,5-dimethylphenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC(C)=CC(C)=C1 IACRYXFWKJOMEI-UHFFFAOYSA-N 0.000 claims description 2
- BARDEYCLOVDZCK-UHFFFAOYSA-N 4-amino-8-(3-chlorophenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=CC(Cl)=C1 BARDEYCLOVDZCK-UHFFFAOYSA-N 0.000 claims description 2
- GJCFQBAZNNBFFI-UHFFFAOYSA-N 4-amino-8-(3-fluoro-2-methoxyphenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=CC(F)=C1OC GJCFQBAZNNBFFI-UHFFFAOYSA-N 0.000 claims description 2
- GKLOECGCAXRMDC-UHFFFAOYSA-N 4-amino-8-(3-fluoro-4-methoxyphenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=C(OC)C(F)=C1 GKLOECGCAXRMDC-UHFFFAOYSA-N 0.000 claims description 2
- FLGUXGCCCIUPKD-UHFFFAOYSA-N 4-amino-8-(3-methoxyphenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=CC(OC)=C1 FLGUXGCCCIUPKD-UHFFFAOYSA-N 0.000 claims description 2
- LCNUELABLMGVTP-UHFFFAOYSA-N 4-amino-8-(3-methylphenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=CC(C)=C1 LCNUELABLMGVTP-UHFFFAOYSA-N 0.000 claims description 2
- RQNJMMXNQLTSIR-UHFFFAOYSA-N 4-amino-8-(4,5-difluoro-2-methoxyphenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC(F)=C(F)C=C1OC RQNJMMXNQLTSIR-UHFFFAOYSA-N 0.000 claims description 2
- VPLCPOOBSXMKCG-UHFFFAOYSA-N 4-amino-8-(4-chlorophenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=C(Cl)C=C1 VPLCPOOBSXMKCG-UHFFFAOYSA-N 0.000 claims description 2
- OFTOSZGOUAYABG-UHFFFAOYSA-N 4-amino-8-(4-fluorophenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=C(F)C=C1 OFTOSZGOUAYABG-UHFFFAOYSA-N 0.000 claims description 2
- GVPINAUAOMQJBS-UHFFFAOYSA-N 4-amino-8-(4-methoxy-3,5-dimethylphenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC(C)=C(OC)C(C)=C1 GVPINAUAOMQJBS-UHFFFAOYSA-N 0.000 claims description 2
- IFOVTZBDAYSEGM-UHFFFAOYSA-N 4-amino-8-(4-methoxy-3-methylphenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=C(OC)C(C)=C1 IFOVTZBDAYSEGM-UHFFFAOYSA-N 0.000 claims description 2
- BBRGCPWGNDJVGL-UHFFFAOYSA-N 4-amino-8-(4-methoxyphenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=C(OC)C=C1 BBRGCPWGNDJVGL-UHFFFAOYSA-N 0.000 claims description 2
- ACTMIDNPHOXYRX-UHFFFAOYSA-N 4-amino-8-(4-methoxypyridin-3-yl)-n-(2-methylpropyl)cinnoline-3-carboxamide Chemical compound COC1=CC=NC=C1C1=CC=CC2=C(N)C(C(=O)NCC(C)C)=NN=C12 ACTMIDNPHOXYRX-UHFFFAOYSA-N 0.000 claims description 2
- AKIBTOCVMBMKRW-UHFFFAOYSA-N 4-amino-8-(4-methylphenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=C(C)C=C1 AKIBTOCVMBMKRW-UHFFFAOYSA-N 0.000 claims description 2
- JJZPGZLHCWHBCZ-UHFFFAOYSA-N 4-amino-8-(4-methylpyridin-3-yl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CN=CC=C1C JJZPGZLHCWHBCZ-UHFFFAOYSA-N 0.000 claims description 2
- OIGDKTMOOHPODK-UHFFFAOYSA-N 4-amino-8-(5-fluoro-2-methylphenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC(F)=CC=C1C OIGDKTMOOHPODK-UHFFFAOYSA-N 0.000 claims description 2
- ZVKCJAXKENGMDP-UHFFFAOYSA-N 4-amino-8-(5-methoxy-2-methylphenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC(OC)=CC=C1C ZVKCJAXKENGMDP-UHFFFAOYSA-N 0.000 claims description 2
- QBJKYLZHJZZIMO-UHFFFAOYSA-N 4-amino-8-(5-methoxypyridin-3-yl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CN=CC(OC)=C1 QBJKYLZHJZZIMO-UHFFFAOYSA-N 0.000 claims description 2
- IWCZUMXCBGOERP-UHFFFAOYSA-N 4-amino-8-(6-methoxy-2-methylpyridin-3-yl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=C(OC)N=C1C IWCZUMXCBGOERP-UHFFFAOYSA-N 0.000 claims description 2
- CPIIQKSCWBCNRB-UHFFFAOYSA-N 4-amino-8-(6-methoxy-4-methylpyridin-3-yl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CN=C(OC)C=C1C CPIIQKSCWBCNRB-UHFFFAOYSA-N 0.000 claims description 2
- XLIKWXFQSCRWDJ-UHFFFAOYSA-N 4-amino-8-(6-methoxypyridin-3-yl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=C(OC)N=C1 XLIKWXFQSCRWDJ-UHFFFAOYSA-N 0.000 claims description 2
- MABWJYHNHRWBSC-UHFFFAOYSA-N 4-amino-8-(6-methylpyridin-3-yl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=C(C)N=C1 MABWJYHNHRWBSC-UHFFFAOYSA-N 0.000 claims description 2
- GBYWXUWYLRYFKH-UHFFFAOYSA-N 4-amino-8-[3-(azetidine-1-carbonyl)phenyl]-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C(C=1)=CC=CC=1C(=O)N1CCC1 GBYWXUWYLRYFKH-UHFFFAOYSA-N 0.000 claims description 2
- VOXPEFBXXDMWGO-UHFFFAOYSA-N 4-amino-8-[5-(azetidine-1-carbonyl)-2-methoxyphenyl]-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C(C(=CC=1)OC)=CC=1C(=O)N1CCC1 VOXPEFBXXDMWGO-UHFFFAOYSA-N 0.000 claims description 2
- RYVLKFFXUKUJJH-UHFFFAOYSA-N 4-amino-8-[5-(azetidine-1-carbonyl)-2-methylphenyl]-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C(C(=CC=1)C)=CC=1C(=O)N1CCC1 RYVLKFFXUKUJJH-UHFFFAOYSA-N 0.000 claims description 2
- KBVPVXNDPJZODA-UHFFFAOYSA-N 4-amino-n-(2-hydroxypropyl)-8-(2-methoxy-5-methylphenyl)cinnoline-3-carboxamide Chemical compound COC1=CC=C(C)C=C1C1=CC=CC2=C(N)C(C(=O)NCC(C)O)=NN=C12 KBVPVXNDPJZODA-UHFFFAOYSA-N 0.000 claims description 2
- RINRTVBSMKHYQY-UHFFFAOYSA-N 4-amino-n-butyl-8-(2,5-dimethoxyphenyl)cinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCCC)=NN=C2C=1C1=CC(OC)=CC=C1OC RINRTVBSMKHYQY-UHFFFAOYSA-N 0.000 claims description 2
- IONGEDVRUKNHDI-UHFFFAOYSA-N 4-amino-n-butyl-8-(4-methoxypyridin-3-yl)cinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCCC)=NN=C2C=1C1=CN=CC=C1OC IONGEDVRUKNHDI-UHFFFAOYSA-N 0.000 claims description 2
- NZHQRVWDMSJDRJ-UHFFFAOYSA-N 4-amino-n-ethyl-8-(4-methoxypyridin-3-yl)cinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCC)=NN=C2C=1C1=CN=CC=C1OC NZHQRVWDMSJDRJ-UHFFFAOYSA-N 0.000 claims description 2
- SVLORJLICYYEEW-UHFFFAOYSA-N 4-amino-n-propyl-8-(3,4,5-trimethoxyphenyl)cinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC(OC)=C(OC)C(OC)=C1 SVLORJLICYYEEW-UHFFFAOYSA-N 0.000 claims description 2
- HBOCIEQHPNRRKU-UHFFFAOYSA-N 4-amino-n-propyl-8-[2-(trifluoromethyl)phenyl]cinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=CC=C1C(F)(F)F HBOCIEQHPNRRKU-UHFFFAOYSA-N 0.000 claims description 2
- WIUQJLSDOXXQIV-UHFFFAOYSA-N 4-amino-n-propyl-8-[3-(trifluoromethoxy)phenyl]cinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=CC(OC(F)(F)F)=C1 WIUQJLSDOXXQIV-UHFFFAOYSA-N 0.000 claims description 2
- NUBHLJUKCPPYOW-UHFFFAOYSA-N 4-amino-n-propyl-8-pyrazin-2-ylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CN=CC=N1 NUBHLJUKCPPYOW-UHFFFAOYSA-N 0.000 claims description 2
- WQLCFVZOYKHCQS-UHFFFAOYSA-N 4-amino-n-propyl-8-pyridin-4-ylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=NC=C1 WQLCFVZOYKHCQS-UHFFFAOYSA-N 0.000 claims description 2
- ZVHNAJTUCRXRNS-UHFFFAOYSA-N 4-amino-n-propyl-8-thiophen-3-ylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C=1C=CSC=1 ZVHNAJTUCRXRNS-UHFFFAOYSA-N 0.000 claims description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 2
- 208000020401 Depressive disease Diseases 0.000 claims description 2
- ABBZJHFBQXYTLU-UHFFFAOYSA-N but-3-enamide Chemical compound NC(=O)CC=C ABBZJHFBQXYTLU-UHFFFAOYSA-N 0.000 claims description 2
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- UMBHXQNJEMMKIG-UHFFFAOYSA-N 4-amino-8-(2,4-dimethoxyphenyl)-7-fluoro-n-propylcinnoline-3-carboxamide Chemical compound FC=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=C(OC)C=C1OC UMBHXQNJEMMKIG-UHFFFAOYSA-N 0.000 claims 2
- CTDABRUPUXABAF-UHFFFAOYSA-N 4-amino-n-cyclobutyl-8-(2-methoxy-5-methylphenyl)cinnoline-3-carboxamide Chemical compound COC1=CC=C(C)C=C1C1=CC=CC2=C(N)C(C(=O)NC3CCC3)=NN=C12 CTDABRUPUXABAF-UHFFFAOYSA-N 0.000 claims 2
- ZAPCLWCCAKMTLQ-UHFFFAOYSA-N 3-[4-amino-3-(propylcarbamoyl)cinnolin-8-yl]benzoic acid Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=CC(C(O)=O)=C1 ZAPCLWCCAKMTLQ-UHFFFAOYSA-N 0.000 claims 1
- OYQYXZCKDDXTPF-UHFFFAOYSA-N 4-amino-7-chloro-8-(4-methoxypyridin-3-yl)-n-propylcinnoline-3-carboxamide Chemical compound ClC=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CN=CC=C1OC OYQYXZCKDDXTPF-UHFFFAOYSA-N 0.000 claims 1
- AOIADMYQYQNQQA-UHFFFAOYSA-N 4-amino-7-cyano-8-(2,4-dimethoxyphenyl)-n-propylcinnoline-3-carboxamide Chemical compound N#CC=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=C(OC)C=C1OC AOIADMYQYQNQQA-UHFFFAOYSA-N 0.000 claims 1
- JIPOSXPSJNNHFK-UHFFFAOYSA-N 4-amino-7-fluoro-8-(2-fluoro-3-methoxyphenyl)-n-propylcinnoline-3-carboxamide Chemical compound FC=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=CC(OC)=C1F JIPOSXPSJNNHFK-UHFFFAOYSA-N 0.000 claims 1
- WANPRCYMAZZPRB-UHFFFAOYSA-N 4-amino-7-fluoro-8-(2-fluoro-4-methoxyphenyl)-n-propylcinnoline-3-carboxamide Chemical compound FC=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=C(OC)C=C1F WANPRCYMAZZPRB-UHFFFAOYSA-N 0.000 claims 1
- PBPWIXYEJKGPPC-UHFFFAOYSA-N 4-amino-7-fluoro-8-(2-fluoro-6-methoxyphenyl)-n-propylcinnoline-3-carboxamide Chemical compound FC=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=C(F)C=CC=C1OC PBPWIXYEJKGPPC-UHFFFAOYSA-N 0.000 claims 1
- DSWQZNCLAOIYSJ-UHFFFAOYSA-N 4-amino-7-fluoro-8-(4-fluoro-2-methoxyphenyl)-n-propylcinnoline-3-carboxamide Chemical compound FC=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=C(F)C=C1OC DSWQZNCLAOIYSJ-UHFFFAOYSA-N 0.000 claims 1
- XDRKDCWONVJGSD-UHFFFAOYSA-N 4-amino-7-fluoro-8-(5-fluoro-2-methoxyphenyl)-n-propylcinnoline-3-carboxamide Chemical compound FC=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC(F)=CC=C1OC XDRKDCWONVJGSD-UHFFFAOYSA-N 0.000 claims 1
- OYUSRTOGCZDUFX-UHFFFAOYSA-N 4-amino-7-fluoro-8-(5-fluoro-2-methylphenyl)-n-propylcinnoline-3-carboxamide Chemical compound FC=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC(F)=CC=C1C OYUSRTOGCZDUFX-UHFFFAOYSA-N 0.000 claims 1
- SULDIERSSHILHR-UHFFFAOYSA-N 4-amino-8-(2,3-dichlorophenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=CC(Cl)=C1Cl SULDIERSSHILHR-UHFFFAOYSA-N 0.000 claims 1
- UZQFTJKZYNXOGO-UHFFFAOYSA-N 4-amino-8-(2,3-dimethylphenyl)-7-fluoro-n-propylcinnoline-3-carboxamide Chemical compound FC=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=CC(C)=C1C UZQFTJKZYNXOGO-UHFFFAOYSA-N 0.000 claims 1
- DUZPHCBBXXBYQE-UHFFFAOYSA-N 4-amino-8-(2,4-dimethoxyphenyl)-n-ethylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCC)=NN=C2C=1C1=CC=C(OC)C=C1OC DUZPHCBBXXBYQE-UHFFFAOYSA-N 0.000 claims 1
- CBNYNHQJHZNTHK-UHFFFAOYSA-N 4-amino-8-(2,4-dimethoxyphenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=C(OC)C=C1OC CBNYNHQJHZNTHK-UHFFFAOYSA-N 0.000 claims 1
- SDSQWUZHOYASDR-UHFFFAOYSA-N 4-amino-8-(2,4-dimethoxypyrimidin-5-yl)-n-(2-hydroxypropyl)cinnoline-3-carboxamide Chemical compound COC1=NC(OC)=NC=C1C1=CC=CC2=C(N)C(C(=O)NCC(C)O)=NN=C12 SDSQWUZHOYASDR-UHFFFAOYSA-N 0.000 claims 1
- BYTFPQHOTXJIIA-UHFFFAOYSA-N 4-amino-8-(2,4-dimethoxypyrimidin-5-yl)-n-(2-methylpropyl)cinnoline-3-carboxamide Chemical compound COC1=NC(OC)=NC=C1C1=CC=CC2=C(N)C(C(=O)NCC(C)C)=NN=C12 BYTFPQHOTXJIIA-UHFFFAOYSA-N 0.000 claims 1
- AOEQMJKWEXMPSS-UHFFFAOYSA-N 4-amino-8-(2,4-dimethoxypyrimidin-5-yl)-n-(oxolan-2-ylmethyl)cinnoline-3-carboxamide Chemical compound COC1=NC(OC)=NC=C1C1=CC=CC2=C(N)C(C(=O)NCC3OCCC3)=NN=C12 AOEQMJKWEXMPSS-UHFFFAOYSA-N 0.000 claims 1
- PQMRYOBAPCXOPQ-UHFFFAOYSA-N 4-amino-8-(2,4-dimethoxypyrimidin-5-yl)-n-ethyl-7-fluorocinnoline-3-carboxamide Chemical compound FC=1C=CC2=C(N)C(C(=O)NCC)=NN=C2C=1C1=CN=C(OC)N=C1OC PQMRYOBAPCXOPQ-UHFFFAOYSA-N 0.000 claims 1
- JSCLMFPUMDRWER-UHFFFAOYSA-N 4-amino-8-(2,4-dimethoxypyrimidin-5-yl)-n-methylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NC)=NN=C2C=1C1=CN=C(OC)N=C1OC JSCLMFPUMDRWER-UHFFFAOYSA-N 0.000 claims 1
- HHHLFJCNWMQOSS-UHFFFAOYSA-N 4-amino-8-(2,5-difluorophenyl)-7-fluoro-n-propylcinnoline-3-carboxamide Chemical compound FC=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC(F)=CC=C1F HHHLFJCNWMQOSS-UHFFFAOYSA-N 0.000 claims 1
- XLIRBKWLVJGYBI-UHFFFAOYSA-N 4-amino-8-(2,5-dimethoxyphenyl)-n-(3,3,3-trifluoropropyl)cinnoline-3-carboxamide Chemical compound COC1=CC=C(OC)C(C=2C3=NN=C(C(N)=C3C=CC=2)C(=O)NCCC(F)(F)F)=C1 XLIRBKWLVJGYBI-UHFFFAOYSA-N 0.000 claims 1
- LYMKITHSOPJALL-UHFFFAOYSA-N 4-amino-8-(2,5-dimethoxyphenyl)-n-(oxolan-2-ylmethyl)cinnoline-3-carboxamide Chemical compound COC1=CC=C(OC)C(C=2C3=NN=C(C(N)=C3C=CC=2)C(=O)NCC2OCCC2)=C1 LYMKITHSOPJALL-UHFFFAOYSA-N 0.000 claims 1
- BGGCZORPGAXQJX-UHFFFAOYSA-N 4-amino-8-(2,5-dimethoxyphenyl)-n-ethyl-7-fluorocinnoline-3-carboxamide Chemical compound FC=1C=CC2=C(N)C(C(=O)NCC)=NN=C2C=1C1=CC(OC)=CC=C1OC BGGCZORPGAXQJX-UHFFFAOYSA-N 0.000 claims 1
- GSOLDGRRHZQLOS-UHFFFAOYSA-N 4-amino-8-(2,5-dimethoxyphenyl)cinnoline-3-carboxylic acid Chemical compound COC1=CC=C(OC)C(C=2C3=NN=C(C(N)=C3C=CC=2)C(O)=O)=C1 GSOLDGRRHZQLOS-UHFFFAOYSA-N 0.000 claims 1
- PKJQXUNWQWVUMY-UHFFFAOYSA-N 4-amino-8-(2-chloro-5-methoxyphenyl)-7-fluoro-n-propylcinnoline-3-carboxamide Chemical compound FC=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC(OC)=CC=C1Cl PKJQXUNWQWVUMY-UHFFFAOYSA-N 0.000 claims 1
- DIVPUAQGKLPBRZ-UHFFFAOYSA-N 4-amino-8-(2-chloro-6-methoxyphenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=C(Cl)C=CC=C1OC DIVPUAQGKLPBRZ-UHFFFAOYSA-N 0.000 claims 1
- WTPKKJMJVMDVLK-UHFFFAOYSA-N 4-amino-8-(2-methoxy-5-methylphenyl)-n-(2-methylpropyl)cinnoline-3-carboxamide Chemical compound COC1=CC=C(C)C=C1C1=CC=CC2=C(N)C(C(=O)NCC(C)C)=NN=C12 WTPKKJMJVMDVLK-UHFFFAOYSA-N 0.000 claims 1
- UKDKRBAYEQUTDC-UHFFFAOYSA-N 4-amino-8-(3,5-difluoro-2-methoxyphenyl)-7-fluoro-n-propylcinnoline-3-carboxamide Chemical compound FC=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC(F)=CC(F)=C1OC UKDKRBAYEQUTDC-UHFFFAOYSA-N 0.000 claims 1
- XIFWIILTOULPRA-UHFFFAOYSA-N 4-amino-8-(4-chlorophenyl)-7-fluoro-n-propylcinnoline-3-carboxamide Chemical compound FC=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=C(Cl)C=C1 XIFWIILTOULPRA-UHFFFAOYSA-N 0.000 claims 1
- UOYXROPJIZZCOK-UHFFFAOYSA-N 4-amino-8-(4-chlorophenyl)-n-cyclobutylcinnoline-3-carboxamide Chemical compound C1=CC=C2C(N)=C(C(=O)NC3CCC3)N=NC2=C1C1=CC=C(Cl)C=C1 UOYXROPJIZZCOK-UHFFFAOYSA-N 0.000 claims 1
- OAMDUTFLWXGQOY-UHFFFAOYSA-N 4-amino-8-(4-methoxypyridin-3-yl)-n-(oxolan-2-ylmethyl)cinnoline-3-carboxamide Chemical compound COC1=CC=NC=C1C1=CC=CC2=C(N)C(C(=O)NCC3OCCC3)=NN=C12 OAMDUTFLWXGQOY-UHFFFAOYSA-N 0.000 claims 1
- JOEWKKBZJFTFDE-UHFFFAOYSA-N 4-amino-n-(cyclopropylmethyl)-8-phenylcinnoline-3-carboxamide Chemical compound C1=CC=C2C(N)=C(C(=O)NCC3CC3)N=NC2=C1C1=CC=CC=C1 JOEWKKBZJFTFDE-UHFFFAOYSA-N 0.000 claims 1
- BRGAPYGSMFLISV-UHFFFAOYSA-N 4-amino-n-butyl-8-(2,4-dimethoxypyrimidin-5-yl)cinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCCC)=NN=C2C=1C1=CN=C(OC)N=C1OC BRGAPYGSMFLISV-UHFFFAOYSA-N 0.000 claims 1
- RAVRSJTYRYJFNY-UHFFFAOYSA-N 4-amino-n-butyl-8-(2-methoxy-5-methylphenyl)cinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCCC)=NN=C2C=1C1=CC(C)=CC=C1OC RAVRSJTYRYJFNY-UHFFFAOYSA-N 0.000 claims 1
- BIAZMECQFVVFOU-UHFFFAOYSA-N 4-amino-n-cyclobutyl-7-fluoro-8-(2-fluoro-3-methoxyphenyl)cinnoline-3-carboxamide Chemical compound COC1=CC=CC(C=2C3=NN=C(C(N)=C3C=CC=2F)C(=O)NC2CCC2)=C1F BIAZMECQFVVFOU-UHFFFAOYSA-N 0.000 claims 1
- FAHWMYUTCGOCFL-UHFFFAOYSA-N 4-amino-n-cyclobutyl-7-fluoro-8-(2-fluoro-6-methoxyphenyl)cinnoline-3-carboxamide Chemical compound COC1=CC=CC(F)=C1C1=C(F)C=CC2=C(N)C(C(=O)NC3CCC3)=NN=C12 FAHWMYUTCGOCFL-UHFFFAOYSA-N 0.000 claims 1
- QGFJRDRILUEZKI-UHFFFAOYSA-N 4-amino-n-cyclobutyl-7-fluoro-8-(2-methoxy-5-methylphenyl)cinnoline-3-carboxamide Chemical compound COC1=CC=C(C)C=C1C1=C(F)C=CC2=C(N)C(C(=O)NC3CCC3)=NN=C12 QGFJRDRILUEZKI-UHFFFAOYSA-N 0.000 claims 1
- UIVADFQRYLPCMI-UHFFFAOYSA-N 4-amino-n-cyclobutyl-7-fluoro-8-(2-methoxyphenyl)cinnoline-3-carboxamide Chemical compound COC1=CC=CC=C1C1=C(F)C=CC2=C(N)C(C(=O)NC3CCC3)=NN=C12 UIVADFQRYLPCMI-UHFFFAOYSA-N 0.000 claims 1
- ADKDKRNMADBBFK-UHFFFAOYSA-N 4-amino-n-cyclobutyl-7-fluoro-8-(2-methoxypyridin-3-yl)cinnoline-3-carboxamide Chemical compound COC1=NC=CC=C1C1=C(F)C=CC2=C(N)C(C(=O)NC3CCC3)=NN=C12 ADKDKRNMADBBFK-UHFFFAOYSA-N 0.000 claims 1
- XLRWTNVSSSIHBP-UHFFFAOYSA-N 4-amino-n-cyclobutyl-7-fluoro-8-(5-fluoro-2-methoxyphenyl)cinnoline-3-carboxamide Chemical compound COC1=CC=C(F)C=C1C1=C(F)C=CC2=C(N)C(C(=O)NC3CCC3)=NN=C12 XLRWTNVSSSIHBP-UHFFFAOYSA-N 0.000 claims 1
- GPCDJZRFYYEABZ-UHFFFAOYSA-N 4-amino-n-cyclobutyl-8-(2,3,4-trimethoxyphenyl)cinnoline-3-carboxamide Chemical compound COC1=C(OC)C(OC)=CC=C1C1=CC=CC2=C(N)C(C(=O)NC3CCC3)=NN=C12 GPCDJZRFYYEABZ-UHFFFAOYSA-N 0.000 claims 1
- UQWVZWRKNGBQJU-UHFFFAOYSA-N 4-amino-n-cyclobutyl-8-(2,3-dimethoxyphenyl)-7-fluorocinnoline-3-carboxamide Chemical compound COC1=CC=CC(C=2C3=NN=C(C(N)=C3C=CC=2F)C(=O)NC2CCC2)=C1OC UQWVZWRKNGBQJU-UHFFFAOYSA-N 0.000 claims 1
- DTMAJJSDICLMNO-UHFFFAOYSA-N 4-amino-n-cyclobutyl-8-(2,3-dimethoxyphenyl)cinnoline-3-carboxamide Chemical compound COC1=CC=CC(C=2C3=NN=C(C(N)=C3C=CC=2)C(=O)NC2CCC2)=C1OC DTMAJJSDICLMNO-UHFFFAOYSA-N 0.000 claims 1
- XTVSISHQAALVBN-UHFFFAOYSA-N 4-amino-n-cyclobutyl-8-(2,4-dimethoxyphenyl)-7-fluorocinnoline-3-carboxamide Chemical compound COC1=CC(OC)=CC=C1C1=C(F)C=CC2=C(N)C(C(=O)NC3CCC3)=NN=C12 XTVSISHQAALVBN-UHFFFAOYSA-N 0.000 claims 1
- SEYYVTORSSKEPB-UHFFFAOYSA-N 4-amino-n-cyclobutyl-8-(2,4-dimethoxyphenyl)cinnoline-3-carboxamide Chemical compound COC1=CC(OC)=CC=C1C1=CC=CC2=C(N)C(C(=O)NC3CCC3)=NN=C12 SEYYVTORSSKEPB-UHFFFAOYSA-N 0.000 claims 1
- SGRIYJAGCGDCSC-UHFFFAOYSA-N 4-amino-n-cyclobutyl-8-(2,4-dimethoxypyrimidin-5-yl)-7-fluorocinnoline-3-carboxamide Chemical compound COC1=NC(OC)=NC=C1C1=C(F)C=CC2=C(N)C(C(=O)NC3CCC3)=NN=C12 SGRIYJAGCGDCSC-UHFFFAOYSA-N 0.000 claims 1
- MCYIPNCHRDOKHB-UHFFFAOYSA-N 4-amino-n-cyclobutyl-8-(2,5-difluorophenyl)cinnoline-3-carboxamide Chemical compound C1=CC=C2C(N)=C(C(=O)NC3CCC3)N=NC2=C1C1=CC(F)=CC=C1F MCYIPNCHRDOKHB-UHFFFAOYSA-N 0.000 claims 1
- PJJIBDKSCTVKGK-UHFFFAOYSA-N 4-amino-n-cyclobutyl-8-(2,6-dimethoxypyridin-3-yl)-7-fluorocinnoline-3-carboxamide Chemical compound COC1=NC(OC)=CC=C1C1=C(F)C=CC2=C(N)C(C(=O)NC3CCC3)=NN=C12 PJJIBDKSCTVKGK-UHFFFAOYSA-N 0.000 claims 1
- QYGSVGPJSGKJJV-UHFFFAOYSA-N 4-amino-n-cyclobutyl-8-(2-fluoro-6-methoxyphenyl)cinnoline-3-carboxamide Chemical compound COC1=CC=CC(F)=C1C1=CC=CC2=C(N)C(C(=O)NC3CCC3)=NN=C12 QYGSVGPJSGKJJV-UHFFFAOYSA-N 0.000 claims 1
- TXNJVFMIQWCYRZ-UHFFFAOYSA-N 4-amino-n-cyclobutyl-8-(2-methoxyphenyl)cinnoline-3-carboxamide Chemical compound COC1=CC=CC=C1C1=CC=CC2=C(N)C(C(=O)NC3CCC3)=NN=C12 TXNJVFMIQWCYRZ-UHFFFAOYSA-N 0.000 claims 1
- NWKXWXCIRSNSGR-UHFFFAOYSA-N 4-amino-n-cyclobutyl-8-(2-methoxypyridin-3-yl)cinnoline-3-carboxamide Chemical compound COC1=NC=CC=C1C1=CC=CC2=C(N)C(C(=O)NC3CCC3)=NN=C12 NWKXWXCIRSNSGR-UHFFFAOYSA-N 0.000 claims 1
- JRSSJWZRJMWYDL-UHFFFAOYSA-N 4-amino-n-cyclobutyl-8-(3,4-dimethoxyphenyl)cinnoline-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC=CC2=C(N)C(C(=O)NC3CCC3)=NN=C12 JRSSJWZRJMWYDL-UHFFFAOYSA-N 0.000 claims 1
- WILUSWBLQIDCTI-UHFFFAOYSA-N 4-amino-n-cyclobutyl-8-(3-methylphenyl)cinnoline-3-carboxamide Chemical compound CC1=CC=CC(C=2C3=NN=C(C(N)=C3C=CC=2)C(=O)NC2CCC2)=C1 WILUSWBLQIDCTI-UHFFFAOYSA-N 0.000 claims 1
- RIEYDCWCIWECAI-UHFFFAOYSA-N 4-amino-n-cyclobutyl-8-(4-methoxypyridin-3-yl)cinnoline-3-carboxamide Chemical compound COC1=CC=NC=C1C1=CC=CC2=C(N)C(C(=O)NC3CCC3)=NN=C12 RIEYDCWCIWECAI-UHFFFAOYSA-N 0.000 claims 1
- ZAFVWRNNFXIZMI-UHFFFAOYSA-N 4-amino-n-cyclobutyl-8-(4-methylpyridin-3-yl)cinnoline-3-carboxamide Chemical compound CC1=CC=NC=C1C1=CC=CC2=C(N)C(C(=O)NC3CCC3)=NN=C12 ZAFVWRNNFXIZMI-UHFFFAOYSA-N 0.000 claims 1
- YWPNYUWPMCNWSX-UHFFFAOYSA-N 4-amino-n-cyclobutyl-8-(6-methylpyridin-3-yl)cinnoline-3-carboxamide Chemical compound C1=NC(C)=CC=C1C1=CC=CC2=C(N)C(C(=O)NC3CCC3)=NN=C12 YWPNYUWPMCNWSX-UHFFFAOYSA-N 0.000 claims 1
- UCLIFJVUEPZJQH-UHFFFAOYSA-N 4-amino-n-cyclopropyl-7-fluoro-8-(2-fluoro-3-methoxyphenyl)cinnoline-3-carboxamide Chemical compound COC1=CC=CC(C=2C3=NN=C(C(N)=C3C=CC=2F)C(=O)NC2CC2)=C1F UCLIFJVUEPZJQH-UHFFFAOYSA-N 0.000 claims 1
- MLZNIGPXKJBBJZ-UHFFFAOYSA-N 4-amino-n-cyclopropyl-7-fluoro-8-(2-fluoro-6-methoxyphenyl)cinnoline-3-carboxamide Chemical compound COC1=CC=CC(F)=C1C1=C(F)C=CC2=C(N)C(C(=O)NC3CC3)=NN=C12 MLZNIGPXKJBBJZ-UHFFFAOYSA-N 0.000 claims 1
- WOSQQAJQSXKKTC-UHFFFAOYSA-N 4-amino-n-cyclopropyl-7-fluoro-8-(2-methoxy-5-methylphenyl)cinnoline-3-carboxamide Chemical compound COC1=CC=C(C)C=C1C1=C(F)C=CC2=C(N)C(C(=O)NC3CC3)=NN=C12 WOSQQAJQSXKKTC-UHFFFAOYSA-N 0.000 claims 1
- STNQDCWYBBVJIB-UHFFFAOYSA-N 4-amino-n-cyclopropyl-7-fluoro-8-(2-methoxypyridin-3-yl)cinnoline-3-carboxamide Chemical compound COC1=NC=CC=C1C1=C(F)C=CC2=C(N)C(C(=O)NC3CC3)=NN=C12 STNQDCWYBBVJIB-UHFFFAOYSA-N 0.000 claims 1
- IAVOXRLPQMFVLO-UHFFFAOYSA-N 4-amino-n-cyclopropyl-7-fluoro-8-(4-methylpyridin-3-yl)cinnoline-3-carboxamide Chemical compound CC1=CC=NC=C1C1=C(F)C=CC2=C(N)C(C(=O)NC3CC3)=NN=C12 IAVOXRLPQMFVLO-UHFFFAOYSA-N 0.000 claims 1
- UWJWJNBBVUUIKJ-UHFFFAOYSA-N 4-amino-n-cyclopropyl-7-fluoro-8-(5-fluoro-6-methoxypyridin-3-yl)cinnoline-3-carboxamide Chemical compound C1=C(F)C(OC)=NC=C1C1=C(F)C=CC2=C(N)C(C(=O)NC3CC3)=NN=C12 UWJWJNBBVUUIKJ-UHFFFAOYSA-N 0.000 claims 1
- ROLRBHDSPMDBJZ-UHFFFAOYSA-N 4-amino-n-cyclopropyl-8-(2,4-dimethoxyphenyl)cinnoline-3-carboxamide Chemical compound COC1=CC(OC)=CC=C1C1=CC=CC2=C(N)C(C(=O)NC3CC3)=NN=C12 ROLRBHDSPMDBJZ-UHFFFAOYSA-N 0.000 claims 1
- DZSUGXJQOPHPEX-UHFFFAOYSA-N 4-amino-n-cyclopropyl-8-(2,4-dimethoxypyrimidin-5-yl)-7-fluorocinnoline-3-carboxamide Chemical compound COC1=NC(OC)=NC=C1C1=C(F)C=CC2=C(N)C(C(=O)NC3CC3)=NN=C12 DZSUGXJQOPHPEX-UHFFFAOYSA-N 0.000 claims 1
- CRNXVCLAFOOUQS-UHFFFAOYSA-N 4-amino-n-cyclopropyl-8-(2,4-dimethoxypyrimidin-5-yl)cinnoline-3-carboxamide Chemical compound COC1=NC(OC)=NC=C1C1=CC=CC2=C(N)C(C(=O)NC3CC3)=NN=C12 CRNXVCLAFOOUQS-UHFFFAOYSA-N 0.000 claims 1
- WEFRNUXPTYTOEU-UHFFFAOYSA-N 4-amino-n-cyclopropyl-8-(2,5-dimethoxyphenyl)-7-fluorocinnoline-3-carboxamide Chemical compound COC1=CC=C(OC)C(C=2C3=NN=C(C(N)=C3C=CC=2F)C(=O)NC2CC2)=C1 WEFRNUXPTYTOEU-UHFFFAOYSA-N 0.000 claims 1
- FGOCJZANGVRDDB-UHFFFAOYSA-N 4-amino-n-cyclopropyl-8-(2,6-dimethoxypyridin-3-yl)-7-fluorocinnoline-3-carboxamide Chemical compound COC1=NC(OC)=CC=C1C1=C(F)C=CC2=C(N)C(C(=O)NC3CC3)=NN=C12 FGOCJZANGVRDDB-UHFFFAOYSA-N 0.000 claims 1
- CVPIFYLDDVUHDA-UHFFFAOYSA-N 4-amino-n-cyclopropyl-8-(2-fluoro-6-methylpyridin-3-yl)cinnoline-3-carboxamide Chemical compound FC1=NC(C)=CC=C1C1=CC=CC2=C(N)C(C(=O)NC3CC3)=NN=C12 CVPIFYLDDVUHDA-UHFFFAOYSA-N 0.000 claims 1
- YYBUYGWOPKUUFL-UHFFFAOYSA-N 4-amino-n-cyclopropyl-8-(2-methoxy-5-methylphenyl)cinnoline-3-carboxamide Chemical compound COC1=CC=C(C)C=C1C1=CC=CC2=C(N)C(C(=O)NC3CC3)=NN=C12 YYBUYGWOPKUUFL-UHFFFAOYSA-N 0.000 claims 1
- NUZGPJJEGHOCLE-UHFFFAOYSA-N 4-amino-n-cyclopropyl-8-(2-methoxypyridin-3-yl)cinnoline-3-carboxamide Chemical compound COC1=NC=CC=C1C1=CC=CC2=C(N)C(C(=O)NC3CC3)=NN=C12 NUZGPJJEGHOCLE-UHFFFAOYSA-N 0.000 claims 1
- GAWPEDODWCGCAO-UHFFFAOYSA-N 4-amino-n-cyclopropyl-8-(4-methoxypyridin-3-yl)cinnoline-3-carboxamide Chemical compound COC1=CC=NC=C1C1=CC=CC2=C(N)C(C(=O)NC3CC3)=NN=C12 GAWPEDODWCGCAO-UHFFFAOYSA-N 0.000 claims 1
- DAPRLGHZVPTCIU-UHFFFAOYSA-N 4-amino-n-cyclopropyl-8-(5-fluoro-2-methoxyphenyl)cinnoline-3-carboxamide Chemical compound COC1=CC=C(F)C=C1C1=CC=CC2=C(N)C(C(=O)NC3CC3)=NN=C12 DAPRLGHZVPTCIU-UHFFFAOYSA-N 0.000 claims 1
- JTBTYSVYDVPYHN-UHFFFAOYSA-N 4-amino-n-cyclopropyl-8-(5-fluoro-6-methoxypyridin-3-yl)cinnoline-3-carboxamide Chemical compound C1=C(F)C(OC)=NC=C1C1=CC=CC2=C(N)C(C(=O)NC3CC3)=NN=C12 JTBTYSVYDVPYHN-UHFFFAOYSA-N 0.000 claims 1
- PZNRWXRSHFLGKB-UHFFFAOYSA-N 4-amino-n-cyclopropyl-8-(6-methylpyridin-3-yl)cinnoline-3-carboxamide Chemical compound C1=NC(C)=CC=C1C1=CC=CC2=C(N)C(C(=O)NC3CC3)=NN=C12 PZNRWXRSHFLGKB-UHFFFAOYSA-N 0.000 claims 1
- HPSWSAPWFONNFP-UHFFFAOYSA-N 4-amino-n-ethyl-7-fluoro-8-(2-fluoro-3-methoxyphenyl)cinnoline-3-carboxamide Chemical compound FC=1C=CC2=C(N)C(C(=O)NCC)=NN=C2C=1C1=CC=CC(OC)=C1F HPSWSAPWFONNFP-UHFFFAOYSA-N 0.000 claims 1
- LFBWAWBJLZQWSN-UHFFFAOYSA-N 4-amino-n-ethyl-7-fluoro-8-(2-fluoro-6-methoxyphenyl)cinnoline-3-carboxamide Chemical compound FC=1C=CC2=C(N)C(C(=O)NCC)=NN=C2C=1C1=C(F)C=CC=C1OC LFBWAWBJLZQWSN-UHFFFAOYSA-N 0.000 claims 1
- FFEVOXROQXTZSC-UHFFFAOYSA-N 4-amino-n-ethyl-7-fluoro-8-(2-methoxypyridin-3-yl)cinnoline-3-carboxamide Chemical compound FC=1C=CC2=C(N)C(C(=O)NCC)=NN=C2C=1C1=CC=CN=C1OC FFEVOXROQXTZSC-UHFFFAOYSA-N 0.000 claims 1
- AIMPHZZAKBQPAB-UHFFFAOYSA-N 4-amino-n-ethyl-7-fluoro-8-(5-fluoro-2-methoxyphenyl)cinnoline-3-carboxamide Chemical compound FC=1C=CC2=C(N)C(C(=O)NCC)=NN=C2C=1C1=CC(F)=CC=C1OC AIMPHZZAKBQPAB-UHFFFAOYSA-N 0.000 claims 1
- KXWBDLUCSKYTNI-UHFFFAOYSA-N 4-amino-n-ethyl-8-(2-fluoro-6-methoxyphenyl)cinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCC)=NN=C2C=1C1=C(F)C=CC=C1OC KXWBDLUCSKYTNI-UHFFFAOYSA-N 0.000 claims 1
- XGNNJLIVQDFNDC-UHFFFAOYSA-N 4-amino-n-ethyl-8-(2-methoxy-5-methylphenyl)cinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCC)=NN=C2C=1C1=CC(C)=CC=C1OC XGNNJLIVQDFNDC-UHFFFAOYSA-N 0.000 claims 1
- JOVOPQZPKNUMBP-UHFFFAOYSA-N 4-amino-n-ethyl-8-(4-methylpyridin-3-yl)cinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCC)=NN=C2C=1C1=CN=CC=C1C JOVOPQZPKNUMBP-UHFFFAOYSA-N 0.000 claims 1
- MCEPYVILYRNQIE-UHFFFAOYSA-N 4-amino-n-ethyl-8-(5-fluoro-2-methoxyphenyl)cinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCC)=NN=C2C=1C1=CC(F)=CC=C1OC MCEPYVILYRNQIE-UHFFFAOYSA-N 0.000 claims 1
- MHWHGBMRVXCKBP-UHFFFAOYSA-N 4-amino-n-ethyl-8-(6-methylpyridin-3-yl)cinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCC)=NN=C2C=1C1=CC=C(C)N=C1 MHWHGBMRVXCKBP-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 48
- 238000011321 prophylaxis Methods 0.000 abstract description 6
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 abstract description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 143
- -1 pyrazol-4-yl Chemical group 0.000 description 112
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 108
- 239000007787 solid Substances 0.000 description 97
- 238000005160 1H NMR spectroscopy Methods 0.000 description 81
- 238000004128 high performance liquid chromatography Methods 0.000 description 78
- 238000006243 chemical reaction Methods 0.000 description 53
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 51
- GPJGJCJYUOVPPW-UHFFFAOYSA-N 4-amino-8-bromo-n-propylcinnoline-3-carboxamide Chemical compound BrC1=CC=CC2=C(N)C(C(=O)NCCC)=NN=C21 GPJGJCJYUOVPPW-UHFFFAOYSA-N 0.000 description 44
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 44
- 235000019439 ethyl acetate Nutrition 0.000 description 36
- 239000000243 solution Substances 0.000 description 35
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 26
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 25
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 20
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 20
- 239000011541 reaction mixture Substances 0.000 description 20
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 19
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 18
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 18
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 18
- 150000002148 esters Chemical class 0.000 description 17
- 125000000623 heterocyclic group Chemical group 0.000 description 17
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 239000002207 metabolite Substances 0.000 description 15
- 229910052757 nitrogen Inorganic materials 0.000 description 15
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 14
- 238000005859 coupling reaction Methods 0.000 description 14
- 238000003818 flash chromatography Methods 0.000 description 14
- 241000282414 Homo sapiens Species 0.000 description 13
- 239000002253 acid Substances 0.000 description 13
- 229940049706 benzodiazepine Drugs 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- 241000124008 Mammalia Species 0.000 description 12
- 150000001557 benzodiazepines Chemical class 0.000 description 12
- 239000000741 silica gel Substances 0.000 description 12
- 229910002027 silica gel Inorganic materials 0.000 description 12
- 238000002560 therapeutic procedure Methods 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 11
- 239000002244 precipitate Substances 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 10
- 239000012044 organic layer Substances 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- 239000000543 intermediate Substances 0.000 description 9
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 9
- DBNJXMNCNDXEFU-UHFFFAOYSA-N 4-amino-8-iodo-n-propylcinnoline-3-carboxamide Chemical compound IC1=CC=CC2=C(N)C(C(=O)NCCC)=NN=C21 DBNJXMNCNDXEFU-UHFFFAOYSA-N 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 208000020925 Bipolar disease Diseases 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 206010026749 Mania Diseases 0.000 description 8
- 230000000949 anxiolytic effect Effects 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 231100000252 nontoxic Toxicity 0.000 description 8
- 230000003000 nontoxic effect Effects 0.000 description 8
- 229940002612 prodrug Drugs 0.000 description 8
- 239000000651 prodrug Substances 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 8
- 150000001204 N-oxides Chemical class 0.000 description 7
- 229940125717 barbiturate Drugs 0.000 description 7
- 150000001639 boron compounds Chemical class 0.000 description 7
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 206010010904 Convulsion Diseases 0.000 description 6
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 6
- 239000002249 anxiolytic agent Substances 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 125000005638 hydrazono group Chemical group 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 235000019341 magnesium sulphate Nutrition 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- 150000007522 mineralic acids Chemical class 0.000 description 6
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 6
- 239000001301 oxygen Chemical group 0.000 description 6
- 125000006413 ring segment Chemical group 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 239000011593 sulfur Chemical group 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 6
- 229960000604 valproic acid Drugs 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
- 102000005915 GABA Receptors Human genes 0.000 description 5
- 108010005551 GABA Receptors Proteins 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 229940005530 anxiolytics Drugs 0.000 description 5
- 150000001543 aryl boronic acids Chemical class 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000007819 coupling partner Substances 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 229940093915 gynecological organic acid Drugs 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 230000001537 neural effect Effects 0.000 description 5
- 208000004296 neuralgia Diseases 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 229960005017 olanzapine Drugs 0.000 description 5
- 150000007524 organic acids Chemical class 0.000 description 5
- 235000005985 organic acids Nutrition 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229940086542 triethylamine Drugs 0.000 description 5
- LKGKUACPLXCVOF-UHFFFAOYSA-N (2,4-dimethoxypyrimidin-5-yl)boronic acid Chemical compound COC1=NC=C(B(O)O)C(OC)=N1 LKGKUACPLXCVOF-UHFFFAOYSA-N 0.000 description 4
- UBPDKIDWEADHPP-UHFFFAOYSA-N 2-iodoaniline Chemical compound NC1=CC=CC=C1I UBPDKIDWEADHPP-UHFFFAOYSA-N 0.000 description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 4
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 229960000623 carbamazepine Drugs 0.000 description 4
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 229960004592 isopropanol Drugs 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 4
- 229960004431 quetiapine Drugs 0.000 description 4
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 4
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 229940102566 valproate Drugs 0.000 description 4
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 4
- RXWRMSBYWKMFMQ-VCHYOVAHSA-N (1e)-n-(3-chloro-2-iodoanilino)-2-oxo-2-(propylamino)ethanimidoyl cyanide Chemical compound CCCNC(=O)C(\C#N)=N\NC1=CC=CC(Cl)=C1I RXWRMSBYWKMFMQ-VCHYOVAHSA-N 0.000 description 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 3
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 3
- RDHCFMIWCSJGJM-UHFFFAOYSA-N 2-cyano-n-cyclopropylacetamide Chemical compound N#CCC(=O)NC1CC1 RDHCFMIWCSJGJM-UHFFFAOYSA-N 0.000 description 3
- QXWFLDZVDBAJAG-UHFFFAOYSA-N 2-cyano-n-propylacetamide Chemical compound CCCNC(=O)CC#N QXWFLDZVDBAJAG-UHFFFAOYSA-N 0.000 description 3
- NNVUXUJYVIVRKU-UHFFFAOYSA-N 3-chloro-2-iodoaniline Chemical group NC1=CC=CC(Cl)=C1I NNVUXUJYVIVRKU-UHFFFAOYSA-N 0.000 description 3
- NFWZONJYGXYPRQ-UHFFFAOYSA-N 4-amino-7-chloro-8-iodo-n-propylcinnoline-3-carboxamide Chemical compound IC1=C(Cl)C=CC2=C(N)C(C(=O)NCCC)=NN=C21 NFWZONJYGXYPRQ-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 208000011688 Generalised anxiety disease Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 3
- 208000016285 Movement disease Diseases 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 229960004372 aripiprazole Drugs 0.000 description 3
- 239000003693 atypical antipsychotic agent Substances 0.000 description 3
- SQKLESHVRHQGNI-UHFFFAOYSA-N azetidin-1-yl-(5-trimethylstannylpyridin-3-yl)methanone Chemical compound C[Sn](C)(C)C1=CN=CC(C(=O)N2CCC2)=C1 SQKLESHVRHQGNI-UHFFFAOYSA-N 0.000 description 3
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 229960004782 chlordiazepoxide Drugs 0.000 description 3
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960004170 clozapine Drugs 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 229960002866 duloxetine Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- CXFCZOHIEXNOCL-UHFFFAOYSA-N ethyl 2-[(2-bromophenyl)hydrazinylidene]-2-cyanoacetate Chemical compound CCOC(=O)C(C#N)=NNC1=CC=CC=C1Br CXFCZOHIEXNOCL-UHFFFAOYSA-N 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 125000002541 furyl group Chemical group 0.000 description 3
- 230000003371 gabaergic effect Effects 0.000 description 3
- 229960002870 gabapentin Drugs 0.000 description 3
- 208000029364 generalized anxiety disease Diseases 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 150000002576 ketones Chemical group 0.000 description 3
- 229960001848 lamotrigine Drugs 0.000 description 3
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 206010027599 migraine Diseases 0.000 description 3
- 230000000897 modulatory effect Effects 0.000 description 3
- 239000002808 molecular sieve Substances 0.000 description 3
- 208000021722 neuropathic pain Diseases 0.000 description 3
- 208000019906 panic disease Diseases 0.000 description 3
- 239000003495 polar organic solvent Substances 0.000 description 3
- 208000028173 post-traumatic stress disease Diseases 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 229960001534 risperidone Drugs 0.000 description 3
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 3
- 229910001415 sodium ion Inorganic materials 0.000 description 3
- 125000003107 substituted aryl group Chemical group 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229960000607 ziprasidone Drugs 0.000 description 3
- OOMZKLJLVGQZGV-UHFFFAOYSA-N (2,5-dimethylphenyl)boronic acid Chemical compound CC1=CC=C(C)C(B(O)O)=C1 OOMZKLJLVGQZGV-UHFFFAOYSA-N 0.000 description 2
- YUTPAZKVEOJQCY-UHFFFAOYSA-N (4-methoxypyridin-3-yl)boronic acid Chemical compound COC1=CC=NC=C1B(O)O YUTPAZKVEOJQCY-UHFFFAOYSA-N 0.000 description 2
- GBBSUAFBMRNDJC-MRXNPFEDSA-N (5R)-zopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-MRXNPFEDSA-N 0.000 description 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 2
- VSWBSWWIRNCQIJ-GJZGRUSLSA-N (R,R)-asenapine Chemical compound O1C2=CC=CC=C2[C@@H]2CN(C)C[C@H]2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-GJZGRUSLSA-N 0.000 description 2
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 2
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 2
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 2
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 2
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 2
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 2
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 2
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 2
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 2
- ARGCQEVBJHPOGB-UHFFFAOYSA-N 2,5-dihydrofuran Chemical compound C1OCC=C1 ARGCQEVBJHPOGB-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- ICCYFVWQNFMENX-UHFFFAOYSA-N 2-chloro-6-nitrophenol Chemical group OC1=C(Cl)C=CC=C1[N+]([O-])=O ICCYFVWQNFMENX-UHFFFAOYSA-N 0.000 description 2
- IFRKLXQWQFINOQ-UHFFFAOYSA-N 2-cyano-n-(cyclopropylmethyl)acetamide Chemical compound N#CCC(=O)NCC1CC1 IFRKLXQWQFINOQ-UHFFFAOYSA-N 0.000 description 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 2
- HRLBFLFGNKLHQT-UHFFFAOYSA-N 3-fluoro-2-iodoaniline;hydrochloride Chemical compound Cl.NC1=CC=CC(F)=C1I HRLBFLFGNKLHQT-UHFFFAOYSA-N 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- PCTRYMLLRKWXGF-UHFFFAOYSA-N 4-(butylamino)-1-ethyl-6-methyl-5-pyrazolo[3,4-b]pyridinecarboxylic acid ethyl ester Chemical compound CCCCNC1=C(C(=O)OCC)C(C)=NC2=C1C=NN2CC PCTRYMLLRKWXGF-UHFFFAOYSA-N 0.000 description 2
- OZMRJGZGCDFQFD-UHFFFAOYSA-N 4-amino-8-(5-fluoro-6-methoxypyridin-3-yl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CN=C(OC)C(F)=C1 OZMRJGZGCDFQFD-UHFFFAOYSA-N 0.000 description 2
- QRBJSKJZLSFENH-UHFFFAOYSA-N 4-amino-8-[2-chloro-5-(trifluoromethyl)phenyl]-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC(C(F)(F)F)=CC=C1Cl QRBJSKJZLSFENH-UHFFFAOYSA-N 0.000 description 2
- ZRHJFOQMTHUEKL-UHFFFAOYSA-N 4-amino-8-[5-(azetidine-1-carbonyl)pyridin-3-yl]-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C(C=1)=CN=CC=1C(=O)N1CCC1 ZRHJFOQMTHUEKL-UHFFFAOYSA-N 0.000 description 2
- IOCLBSGWUXPQED-UHFFFAOYSA-N 4-amino-8-bromo-n-cyclopropylcinnoline-3-carboxamide Chemical compound N1=NC2=C(Br)C=CC=C2C(N)=C1C(=O)NC1CC1 IOCLBSGWUXPQED-UHFFFAOYSA-N 0.000 description 2
- WPTFBAURAYCWHY-UHFFFAOYSA-N 4-amino-8-bromocinnoline-3-carboxylic acid Chemical compound C1=CC=C2C(N)=C(C(O)=O)N=NC2=C1Br WPTFBAURAYCWHY-UHFFFAOYSA-N 0.000 description 2
- JFDFMBNFQREYGP-UHFFFAOYSA-N 4-amino-n-propyl-8-(2,3,4-trimethoxyphenyl)cinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=C(OC)C(OC)=C1OC JFDFMBNFQREYGP-UHFFFAOYSA-N 0.000 description 2
- XWVOEFLBOSSYGM-UHFFFAOYSA-N 4-morpholinyl-(3,4,5-trimethoxyphenyl)methanone Chemical compound COC1=C(OC)C(OC)=CC(C(=O)N2CCOCC2)=C1 XWVOEFLBOSSYGM-UHFFFAOYSA-N 0.000 description 2
- 125000005986 4-piperidonyl group Chemical group 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 description 2
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 2
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 2
- CYGODHVAJQTCBG-UHFFFAOYSA-N Bifeprunox Chemical compound C=12OC(=O)NC2=CC=CC=1N(CC1)CCN1CC(C=1)=CC=CC=1C1=CC=CC=C1 CYGODHVAJQTCBG-UHFFFAOYSA-N 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 208000012661 Dyskinesia Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010019196 Head injury Diseases 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 238000005684 Liebig rearrangement reaction Methods 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 102000001419 Melatonin receptor Human genes 0.000 description 2
- 108050009605 Melatonin receptor Proteins 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 206010027944 Mood disorder due to a general medical condition Diseases 0.000 description 2
- 208000008238 Muscle Spasticity Diseases 0.000 description 2
- 208000002033 Myoclonus Diseases 0.000 description 2
- 206010061533 Myotonia Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- PWRPUAKXMQAFCJ-UHFFFAOYSA-N Perlapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2CC2=CC=CC=C12 PWRPUAKXMQAFCJ-UHFFFAOYSA-N 0.000 description 2
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 206010041250 Social phobia Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- 241000269370 Xenopus <genus> Species 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001299 aldehydes Chemical group 0.000 description 2
- 229960003036 amisulpride Drugs 0.000 description 2
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 description 2
- VIROVYVQCGLCII-UHFFFAOYSA-N amobarbital Chemical compound CC(C)CCC1(CC)C(=O)NC(=O)NC1=O VIROVYVQCGLCII-UHFFFAOYSA-N 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 229960005245 asenapine Drugs 0.000 description 2
- GOTLMBNOANDTNT-UHFFFAOYSA-N azetidin-1-yl-(5-bromopyridin-3-yl)methanone Chemical compound BrC1=CN=CC(C(=O)N2CCC2)=C1 GOTLMBNOANDTNT-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 229950009087 bifeprunox Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 208000028683 bipolar I disease Diseases 0.000 description 2
- 208000025307 bipolar depression Diseases 0.000 description 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 150000003857 carboxamides Chemical class 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Chemical class 0.000 description 2
- 229920002678 cellulose Chemical class 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000003874 central nervous system depressant Substances 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960001076 chlorpromazine Drugs 0.000 description 2
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 2
- 208000026725 cyclothymic disease Diseases 0.000 description 2
- 230000003001 depressive effect Effects 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 208000024732 dysthymic disease Diseases 0.000 description 2
- 201000006517 essential tremor Diseases 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- GBBSUAFBMRNDJC-INIZCTEOSA-N eszopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-INIZCTEOSA-N 0.000 description 2
- 229960001578 eszopiclone Drugs 0.000 description 2
- ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 2
- 229960002200 flunitrazepam Drugs 0.000 description 2
- 229960002464 fluoxetine Drugs 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000010914 gene-directed enzyme pro-drug therapy Methods 0.000 description 2
- 229960003878 haloperidol Drugs 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 description 2
- 229960003162 iloperidone Drugs 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 229960001078 lithium Drugs 0.000 description 2
- 229960000423 loxapine Drugs 0.000 description 2
- YQZBAXDVDZTKEQ-UHFFFAOYSA-N loxapine succinate Chemical compound [H+].[H+].[O-]C(=O)CCC([O-])=O.C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 YQZBAXDVDZTKEQ-UHFFFAOYSA-N 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- 235000014380 magnesium carbonate Nutrition 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 208000024714 major depressive disease Diseases 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- SLVMESMUVMCQIY-UHFFFAOYSA-N mesoridazine Chemical compound CN1CCCCC1CCN1C2=CC(S(C)=O)=CC=C2SC2=CC=CC=C21 SLVMESMUVMCQIY-UHFFFAOYSA-N 0.000 description 2
- 229960000300 mesoridazine Drugs 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229960003793 midazolam Drugs 0.000 description 2
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- XYMFSNIAOXHTAM-UHFFFAOYSA-N n-(2-bromoanilino)-2-(butylamino)-2-oxoethanimidoyl cyanide Chemical compound CCCCNC(=O)C(C#N)=NNC1=CC=CC=C1Br XYMFSNIAOXHTAM-UHFFFAOYSA-N 0.000 description 2
- BMGUTMSLPDITCE-UHFFFAOYSA-N n-(2-bromoanilino)-2-(cyclopropylamino)-2-oxoethanimidoyl cyanide Chemical compound BrC1=CC=CC=C1NN=C(C#N)C(=O)NC1CC1 BMGUTMSLPDITCE-UHFFFAOYSA-N 0.000 description 2
- JDYWUQQDRJFBCI-UHFFFAOYSA-N n-(2-bromoanilino)-2-(ethylamino)-2-oxoethanimidoyl cyanide Chemical compound CCNC(=O)C(C#N)=NNC1=CC=CC=C1Br JDYWUQQDRJFBCI-UHFFFAOYSA-N 0.000 description 2
- IRYVBCMHNSDYHP-UHFFFAOYSA-N n-(2-bromoanilino)-2-(methylamino)-2-oxoethanimidoyl cyanide Chemical compound CNC(=O)C(C#N)=NNC1=CC=CC=C1Br IRYVBCMHNSDYHP-UHFFFAOYSA-N 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 229960001057 paliperidone Drugs 0.000 description 2
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- 229950009253 perlapine Drugs 0.000 description 2
- 229960000762 perphenazine Drugs 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229950000688 phenothiazine Drugs 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 2
- 229960003634 pimozide Drugs 0.000 description 2
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 2
- 125000003367 polycyclic group Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 229940074439 potassium sodium tartrate Drugs 0.000 description 2
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 2
- 229960003111 prochlorperazine Drugs 0.000 description 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 2
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 2
- 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- MQTUXRKNJYPMCG-CYBMUJFWSA-N robalzotan Chemical compound C1CCC1N([C@H]1COC=2C(F)=CC=C(C=2C1)C(=O)N)C1CCC1 MQTUXRKNJYPMCG-CYBMUJFWSA-N 0.000 description 2
- 229950003023 robalzotan Drugs 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- KQPKPCNLIDLUMF-UHFFFAOYSA-N secobarbital Chemical compound CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O KQPKPCNLIDLUMF-UHFFFAOYSA-N 0.000 description 2
- 229960002060 secobarbital Drugs 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 description 2
- 229960000652 sertindole Drugs 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 229940035044 sorbitan monolaurate Drugs 0.000 description 2
- 208000018198 spasticity Diseases 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000012258 stirred mixture Substances 0.000 description 2
- 201000009032 substance abuse Diseases 0.000 description 2
- 231100000736 substance abuse Toxicity 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 229960004940 sulpiride Drugs 0.000 description 2
- IBAUKGNDWVSETP-UHFFFAOYSA-N suproclone Chemical compound C1CN(C(=O)CC)CCN1C(=O)OC1C(SCCS2)=C2C(=O)N1C1=CC=C(C=CC(Cl)=N2)C2=N1 IBAUKGNDWVSETP-UHFFFAOYSA-N 0.000 description 2
- 229950003877 suproclone Drugs 0.000 description 2
- RMXOUBDDDQUBKD-UHFFFAOYSA-N suriclone Chemical compound C1CN(C)CCN1C(=O)OC1C(SCCS2)=C2C(=O)N1C1=CC=C(C=CC(Cl)=N2)C2=N1 RMXOUBDDDQUBKD-UHFFFAOYSA-N 0.000 description 2
- 229950006866 suriclone Drugs 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 229960002784 thioridazine Drugs 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 229950002859 tracazolate Drugs 0.000 description 2
- 125000004306 triazinyl group Chemical group 0.000 description 2
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 description 2
- 229960002324 trifluoperazine Drugs 0.000 description 2
- CCRMAATUKBYMPA-UHFFFAOYSA-N trimethyltin Chemical compound C[Sn](C)C.C[Sn](C)C CCRMAATUKBYMPA-UHFFFAOYSA-N 0.000 description 2
- 229950001577 trimetozine Drugs 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 229960000820 zopiclone Drugs 0.000 description 2
- HDOZVRUNCMBHFH-UHFFFAOYSA-N zotepine Chemical compound CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12 HDOZVRUNCMBHFH-UHFFFAOYSA-N 0.000 description 2
- 229960004496 zotepine Drugs 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- UKSZBOKPHAQOMP-SVLSSHOZSA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 UKSZBOKPHAQOMP-SVLSSHOZSA-N 0.000 description 1
- LDQLSQRFSNMANA-UHFFFAOYSA-N (2,3,4-trimethoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C(OC)=C1OC LDQLSQRFSNMANA-UHFFFAOYSA-N 0.000 description 1
- TYIKXPOMOYDGCS-UHFFFAOYSA-N (2,3-dichlorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(Cl)=C1Cl TYIKXPOMOYDGCS-UHFFFAOYSA-N 0.000 description 1
- SZYXKFKWFYUOGZ-UHFFFAOYSA-N (2,3-difluorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(F)=C1F SZYXKFKWFYUOGZ-UHFFFAOYSA-N 0.000 description 1
- VREWSCMOGIXMDQ-UHFFFAOYSA-N (2,3-dimethoxyphenyl)boronic acid Chemical compound COC1=CC=CC(B(O)O)=C1OC VREWSCMOGIXMDQ-UHFFFAOYSA-N 0.000 description 1
- QQLRSCZSKQTFGY-UHFFFAOYSA-N (2,4-difluorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(F)C=C1F QQLRSCZSKQTFGY-UHFFFAOYSA-N 0.000 description 1
- SQTUYFKNCCBFRR-UHFFFAOYSA-N (2,4-dimethoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C(OC)=C1 SQTUYFKNCCBFRR-UHFFFAOYSA-N 0.000 description 1
- NNTFPBXQPOQRBT-UHFFFAOYSA-N (2,5-dichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=CC=C1Cl NNTFPBXQPOQRBT-UHFFFAOYSA-N 0.000 description 1
- BRMUXDWCSVTVPQ-UHFFFAOYSA-N (2,5-difluoro-4-methoxyphenyl)boronic acid Chemical compound COC1=CC(F)=C(B(O)O)C=C1F BRMUXDWCSVTVPQ-UHFFFAOYSA-N 0.000 description 1
- KTOJGSDLJNUAEP-UHFFFAOYSA-N (2,5-difluorophenyl)boronic acid Chemical compound OB(O)C1=CC(F)=CC=C1F KTOJGSDLJNUAEP-UHFFFAOYSA-N 0.000 description 1
- QOZLFNQLIKOGDR-UHFFFAOYSA-N (2,5-dimethoxyphenyl)boronic acid Chemical compound COC1=CC=C(OC)C(B(O)O)=C1 QOZLFNQLIKOGDR-UHFFFAOYSA-N 0.000 description 1
- JCKZNMSBFBPDPM-UHFFFAOYSA-N (2-fluoro-3-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC(B(O)O)=C1F JCKZNMSBFBPDPM-UHFFFAOYSA-N 0.000 description 1
- LIXXGOMAGHXIMP-UHFFFAOYSA-N (2-fluoro-4-methylphenyl)boronic acid Chemical compound CC1=CC=C(B(O)O)C(F)=C1 LIXXGOMAGHXIMP-UHFFFAOYSA-N 0.000 description 1
- ZLODKAZZRDLUKX-UHFFFAOYSA-N (2-fluoro-5-methylphenyl)boronic acid Chemical compound CC1=CC=C(F)C(B(O)O)=C1 ZLODKAZZRDLUKX-UHFFFAOYSA-N 0.000 description 1
- CSVKZOZMPSRLTC-UHFFFAOYSA-N (2-methoxy-5-methylphenyl)boronic acid Chemical compound COC1=CC=C(C)C=C1B(O)O CSVKZOZMPSRLTC-UHFFFAOYSA-N 0.000 description 1
- YPWAJLGHACDYQS-UHFFFAOYSA-N (2-methoxypyrimidin-5-yl)boronic acid Chemical compound COC1=NC=C(B(O)O)C=N1 YPWAJLGHACDYQS-UHFFFAOYSA-N 0.000 description 1
- LHYMPSWMHXUWSK-STZFKDTASA-N (2z)-4-(3,4-dichlorophenyl)-2-[[2-(4-methylpiperazin-1-yl)phenyl]methylidene]thiomorpholin-3-one Chemical compound C1CN(C)CCN1C1=CC=CC=C1\C=C/1C(=O)N(C=2C=C(Cl)C(Cl)=CC=2)CCS\1 LHYMPSWMHXUWSK-STZFKDTASA-N 0.000 description 1
- RULQUTYJXDLRFL-UHFFFAOYSA-N (3,4,5-trimethoxyphenyl)boronic acid Chemical compound COC1=CC(B(O)O)=CC(OC)=C1OC RULQUTYJXDLRFL-UHFFFAOYSA-N 0.000 description 1
- RMGYQBHKEWWTOY-UHFFFAOYSA-N (3,4-difluorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(F)C(F)=C1 RMGYQBHKEWWTOY-UHFFFAOYSA-N 0.000 description 1
- RCVDPBFUMYUKPB-UHFFFAOYSA-N (3,4-dimethoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1OC RCVDPBFUMYUKPB-UHFFFAOYSA-N 0.000 description 1
- DKYRKAIKWFHQHM-UHFFFAOYSA-N (3,5-dichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=CC(Cl)=C1 DKYRKAIKWFHQHM-UHFFFAOYSA-N 0.000 description 1
- QWQBQRYFWNIDOC-UHFFFAOYSA-N (3,5-difluorophenyl)boronic acid Chemical compound OB(O)C1=CC(F)=CC(F)=C1 QWQBQRYFWNIDOC-UHFFFAOYSA-N 0.000 description 1
- XDBHWPLGGBLUHH-UHFFFAOYSA-N (3-cyanophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(C#N)=C1 XDBHWPLGGBLUHH-UHFFFAOYSA-N 0.000 description 1
- ABTBKKHOMBEJGL-UHFFFAOYSA-N (3-fluoro-2-methoxyphenyl)boronic acid Chemical compound COC1=C(F)C=CC=C1B(O)O ABTBKKHOMBEJGL-UHFFFAOYSA-N 0.000 description 1
- NLLGFYPSWCMUIV-UHFFFAOYSA-N (3-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC(B(O)O)=C1 NLLGFYPSWCMUIV-UHFFFAOYSA-N 0.000 description 1
- HZFFUMBZBGETES-UHFFFAOYSA-N (3-methylsulfonylphenyl)boronic acid Chemical compound CS(=O)(=O)C1=CC=CC(B(O)O)=C1 HZFFUMBZBGETES-UHFFFAOYSA-N 0.000 description 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- FJIKWRGCXUCUIG-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1-methyl-3h-1,4-benzodiazepin-2-one Chemical compound O=C([C@H](O)N=1)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1Cl FJIKWRGCXUCUIG-HNNXBMFYSA-N 0.000 description 1
- LOLPLMDQLOJSDH-UHFFFAOYSA-N (5-chloro-6-methoxypyridin-3-yl)boronic acid Chemical compound COC1=NC=C(B(O)O)C=C1Cl LOLPLMDQLOJSDH-UHFFFAOYSA-N 0.000 description 1
- OCWTXKZPAZAQQW-UHFFFAOYSA-N (5-fluoro-6-methoxypyridin-3-yl)boronic acid Chemical compound COC1=NC=C(B(O)O)C=C1F OCWTXKZPAZAQQW-UHFFFAOYSA-N 0.000 description 1
- ICPHJSKVAZMKIV-QGZVFWFLSA-N (5r)-7,8-dimethoxy-3-methyl-5-phenyl-1,2,4,5-tetrahydro-3-benzazepine Chemical compound C1([C@H]2CN(C)CCC=3C=C(C(=CC=32)OC)OC)=CC=CC=C1 ICPHJSKVAZMKIV-QGZVFWFLSA-N 0.000 description 1
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 description 1
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 description 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- ZEHYJZXQEQOSON-AATRIKPKSA-N (e)-1-chloro-3-ethylpent-1-en-4-yn-3-ol Chemical compound CCC(O)(C#C)\C=C\Cl ZEHYJZXQEQOSON-AATRIKPKSA-N 0.000 description 1
- QECAKYKTTYQVKX-RMKNXTFCSA-N (e)-3-(2,5-dihydropyrrol-1-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one Chemical compound COC1=C(OC)C(OC)=CC(C(=O)\C=C\N2CC=CC2)=C1 QECAKYKTTYQVKX-RMKNXTFCSA-N 0.000 description 1
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- TZJUVVIWVWFLCD-UHFFFAOYSA-N 1,1-dioxo-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,2-benzothiazol-3-one Chemical compound O=S1(=O)C2=CC=CC=C2C(=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 TZJUVVIWVWFLCD-UHFFFAOYSA-N 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- UNFQKKSADLVQJE-UHFFFAOYSA-N 1-(3-chlorophenyl)-3-(3-methyl-5-oxo-4h-imidazol-2-yl)urea;hydrate Chemical compound O.CN1CC(=O)N=C1NC(=O)NC1=CC=CC(Cl)=C1 UNFQKKSADLVQJE-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- QEMSVZNTSXPFJA-HNAYVOBHSA-N 1-[(1s,2s)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]-4-phenylpiperidin-4-ol Chemical compound C1([C@H](O)[C@H](C)N2CCC(O)(CC2)C=2C=CC=CC=2)=CC=C(O)C=C1 QEMSVZNTSXPFJA-HNAYVOBHSA-N 0.000 description 1
- XADPCRFTWLAXEV-UHFFFAOYSA-N 1-fluoro-2-iodo-3-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC(F)=C1I XADPCRFTWLAXEV-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- UFMBERDMCRCVSM-UHFFFAOYSA-N 1h-cinnolin-4-one Chemical class C1=CC=C2C(O)=CN=NC2=C1 UFMBERDMCRCVSM-UHFFFAOYSA-N 0.000 description 1
- VHADYSUJZAPXOW-UHFFFAOYSA-N 1h-indol-5-ylboronic acid Chemical compound OB(O)C1=CC=C2NC=CC2=C1 VHADYSUJZAPXOW-UHFFFAOYSA-N 0.000 description 1
- KYWMWUUMCDZISK-UHFFFAOYSA-N 2,2,5,5-tetrakis(trifluoromethyl)-1h-imidazol-4-amine Chemical compound NC1=NC(C(F)(F)F)(C(F)(F)F)NC1(C(F)(F)F)C(F)(F)F KYWMWUUMCDZISK-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- CZYHRTIJLUONKY-UHFFFAOYSA-N 2-(3,5-dimethoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound COC1=CC(OC)=CC(B2OC(C)(C)C(C)(C)O2)=C1 CZYHRTIJLUONKY-UHFFFAOYSA-N 0.000 description 1
- XTDQIZXLSJWLRH-UHFFFAOYSA-N 2-(cyclopropylamino)-N-(3-fluoro-2-iodoanilino)-2-oxoethanimidoyl cyanide Chemical group FC1=CC=CC(NN=C(C#N)C(=O)NC2CC2)=C1I XTDQIZXLSJWLRH-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
- AOPBDRUWRLBSDB-UHFFFAOYSA-N 2-bromoaniline Chemical group NC1=CC=CC=C1Br AOPBDRUWRLBSDB-UHFFFAOYSA-N 0.000 description 1
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 1
- HIGRXCJEFUYRNW-UHFFFAOYSA-N 2-fluoro-6-nitrophenol Chemical compound OC1=C(F)C=CC=C1[N+]([O-])=O HIGRXCJEFUYRNW-UHFFFAOYSA-N 0.000 description 1
- FTZQXOJYPFINKJ-UHFFFAOYSA-N 2-fluoroaniline Chemical compound NC1=CC=CC=C1F FTZQXOJYPFINKJ-UHFFFAOYSA-N 0.000 description 1
- 125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 1
- TWBPWBPGNQWFSJ-UHFFFAOYSA-N 2-phenylaniline Chemical group NC1=CC=CC=C1C1=CC=CC=C1 TWBPWBPGNQWFSJ-UHFFFAOYSA-N 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- FXZJKVODWNYPKK-UHFFFAOYSA-N 3-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-1h-quinazoline-2,4-dione Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(C4=CC=CC=C4NC3=O)=O)CC2)=C1 FXZJKVODWNYPKK-UHFFFAOYSA-N 0.000 description 1
- DBVFWZMQJQMJCB-UHFFFAOYSA-N 3-boronobenzoic acid Chemical compound OB(O)C1=CC=CC(C(O)=O)=C1 DBVFWZMQJQMJCB-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- 125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 description 1
- NPFSUSOBJUKTDE-UHFFFAOYSA-N 4-amino-7-chloro-8-(2,4-dimethoxypyrimidin-5-yl)-n-propylcinnoline-3-carboxamide Chemical compound ClC=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CN=C(OC)N=C1OC NPFSUSOBJUKTDE-UHFFFAOYSA-N 0.000 description 1
- LKZIQUXLNRWIHK-UHFFFAOYSA-N 4-amino-7-chloro-8-(2,5-dimethoxyphenyl)-n-propylcinnoline-3-carboxamide Chemical compound ClC=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC(OC)=CC=C1OC LKZIQUXLNRWIHK-UHFFFAOYSA-N 0.000 description 1
- XDPMVZBFKCIPKQ-UHFFFAOYSA-N 4-amino-7-fluoro-8-(2-methoxy-5-methylphenyl)-n-propylcinnoline-3-carboxamide Chemical compound FC=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC(C)=CC=C1OC XDPMVZBFKCIPKQ-UHFFFAOYSA-N 0.000 description 1
- CPINNOOMSXYFKX-UHFFFAOYSA-N 4-amino-7-fluoro-8-iodo-n-propylcinnoline-3-carboxamide Chemical compound IC1=C(F)C=CC2=C(N)C(C(=O)NCCC)=NN=C21 CPINNOOMSXYFKX-UHFFFAOYSA-N 0.000 description 1
- IOKYXDQPVWMVCR-UHFFFAOYSA-N 4-amino-8-(2,4-dimethoxypyrimidin-5-yl)-7-fluoro-n-propylcinnoline-3-carboxamide Chemical compound FC=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CN=C(OC)N=C1OC IOKYXDQPVWMVCR-UHFFFAOYSA-N 0.000 description 1
- MMBJQNHQQHDAKU-UHFFFAOYSA-N 4-amino-8-(2,4-dimethoxypyrimidin-5-yl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CN=C(OC)N=C1OC MMBJQNHQQHDAKU-UHFFFAOYSA-N 0.000 description 1
- RJXUYHMPJGHZBF-UHFFFAOYSA-N 4-amino-8-(2-fluoro-5-methylpyridin-3-yl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC(C)=CN=C1F RJXUYHMPJGHZBF-UHFFFAOYSA-N 0.000 description 1
- QQIUBQGUHFEXIG-UHFFFAOYSA-N 4-amino-8-(3,5-difluorophenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC(F)=CC(F)=C1 QQIUBQGUHFEXIG-UHFFFAOYSA-N 0.000 description 1
- BUYFDFSKHAUJLU-UHFFFAOYSA-N 4-amino-8-(4-fluoro-2-methoxyphenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=C(F)C=C1OC BUYFDFSKHAUJLU-UHFFFAOYSA-N 0.000 description 1
- ZWBGUBYKLJZNEM-UHFFFAOYSA-N 4-amino-8-(4-methoxypyridin-3-yl)-n-methylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NC)=NN=C2C=1C1=CN=CC=C1OC ZWBGUBYKLJZNEM-UHFFFAOYSA-N 0.000 description 1
- BRCQJGSFYQTQHT-UHFFFAOYSA-N 4-amino-8-(5-chloro-2-methoxyphenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC(Cl)=CC=C1OC BRCQJGSFYQTQHT-UHFFFAOYSA-N 0.000 description 1
- FWOUFCGOUBZEIZ-UHFFFAOYSA-N 4-amino-8-(5-fluoro-2-methoxyphenyl)-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC(F)=CC=C1OC FWOUFCGOUBZEIZ-UHFFFAOYSA-N 0.000 description 1
- BSESBIKVHMACIL-UHFFFAOYSA-N 4-amino-8-[4-(dimethylamino)phenyl]-n-propylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=C(N(C)C)C=C1 BSESBIKVHMACIL-UHFFFAOYSA-N 0.000 description 1
- HWULCSHHOZRUTN-UHFFFAOYSA-N 4-amino-8-bromo-n-methylcinnoline-3-carboxamide;hydrochloride Chemical compound Cl.BrC1=CC=CC2=C(N)C(C(=O)NC)=NN=C21 HWULCSHHOZRUTN-UHFFFAOYSA-N 0.000 description 1
- FOASNHUIEWZTOT-UHFFFAOYSA-N 4-amino-n-(2-hydroxypropyl)-8-(4-methoxypyridin-3-yl)cinnoline-3-carboxamide Chemical compound COC1=CC=NC=C1C1=CC=CC2=C(N)C(C(=O)NCC(C)O)=NN=C12 FOASNHUIEWZTOT-UHFFFAOYSA-N 0.000 description 1
- BQLSAFCZAMVJRS-UHFFFAOYSA-N 4-amino-n-propyl-8-(1,3,5-trimethylpyrazol-4-yl)cinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C=1C(C)=NN(C)C=1C BQLSAFCZAMVJRS-UHFFFAOYSA-N 0.000 description 1
- QGTLLJJHPUCWCR-UHFFFAOYSA-N 4-amino-n-propyl-8-(2,4,6-trifluoro-3-methoxyphenyl)cinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=C(F)C=C(F)C(OC)=C1F QGTLLJJHPUCWCR-UHFFFAOYSA-N 0.000 description 1
- CWTYIYSAZBYXNX-UHFFFAOYSA-N 4-amino-n-propyl-8-[4-(trifluoromethoxy)phenyl]cinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=C(OC(F)(F)F)C=C1 CWTYIYSAZBYXNX-UHFFFAOYSA-N 0.000 description 1
- IWNUSPFKFRARKW-UHFFFAOYSA-N 4-amino-n-propyl-8-pyridin-3-ylcinnoline-3-carboxamide Chemical compound C=1C=CC2=C(N)C(C(=O)NCCC)=NN=C2C=1C1=CC=CN=C1 IWNUSPFKFRARKW-UHFFFAOYSA-N 0.000 description 1
- FYNPIPMUJCTETE-UHFFFAOYSA-N 4-amino-n-propyl-8-trimethylstannylcinnoline-3-carboxamide Chemical compound C[Sn](C)(C)C1=CC=CC2=C(N)C(C(=O)NCCC)=NN=C21 FYNPIPMUJCTETE-UHFFFAOYSA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 1
- NOQPNKGAYWBKIV-UHFFFAOYSA-N 4-oxo-3h-cinnoline-3-carboxamide Chemical class C1=CC=C2C(=O)C(C(=O)N)N=NC2=C1 NOQPNKGAYWBKIV-UHFFFAOYSA-N 0.000 description 1
- 125000004487 4-tetrahydropyranyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- CYBHWCLUGRHMCK-UHFFFAOYSA-N 4aH-carbazole Chemical compound C1=CC=C2C3C=CC=CC3=NC2=C1 CYBHWCLUGRHMCK-UHFFFAOYSA-N 0.000 description 1
- FQIUCPGDKPXSLL-UHFFFAOYSA-N 5-bromopyridine-3-carboxylic acid Chemical compound OC(=O)C1=CN=CC(Br)=C1 FQIUCPGDKPXSLL-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QYFHCFNBYQZGKW-BDQAORGHSA-N 8-[4-[[(3s)-5-methoxy-3,4-dihydro-2h-chromen-3-yl]-propylamino]butyl]-8-azaspiro[4.5]decane-7,9-dione;hydrochloride Chemical compound Cl.CCCN([C@H]1CC2=C(OC)C=CC=C2OC1)CCCCN(C(C1)=O)C(=O)CC21CCCC2 QYFHCFNBYQZGKW-BDQAORGHSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000008811 Agoraphobia Diseases 0.000 description 1
- FDQGNLOWMMVRQL-UHFFFAOYSA-N Allobarbital Chemical compound C=CCC1(CC=C)C(=O)NC(=O)NC1=O FDQGNLOWMMVRQL-UHFFFAOYSA-N 0.000 description 1
- WKEMJKQOLOHJLZ-UHFFFAOYSA-N Almogran Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1CS(=O)(=O)N1CCCC1 WKEMJKQOLOHJLZ-UHFFFAOYSA-N 0.000 description 1
- 102100028116 Amine oxidase [flavin-containing] B Human genes 0.000 description 1
- 108091006515 Anion channels Proteins 0.000 description 1
- 102000037829 Anion channels Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- VCCBCXVFGHTDQN-UODBTFMRSA-N BIII-890CL Chemical compound O([C@H](CN1[C@@H]2CC3=C(O)C=CC=C3[C@](C2(C)C)(C)CC1)C)CC1=CC=CC=C1 VCCBCXVFGHTDQN-UODBTFMRSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- VMIYHDSEFNYJSL-UHFFFAOYSA-N Bromazepam Chemical compound C12=CC(Br)=CC=C2NC(=O)CN=C1C1=CC=CC=N1 VMIYHDSEFNYJSL-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- UMSGKTJDUHERQW-UHFFFAOYSA-N Brotizolam Chemical compound C1=2C=C(Br)SC=2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl UMSGKTJDUHERQW-UHFFFAOYSA-N 0.000 description 1
- QORQZMBCPRBCAB-UHFFFAOYSA-M Butabarbital sodium Chemical compound [Na+].CCC(C)C1(CC)C(=O)NC([O-])=NC1=O QORQZMBCPRBCAB-UHFFFAOYSA-M 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- RZZPDXZPRHQOCG-OJAKKHQRSA-O CDP-choline(1+) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-O 0.000 description 1
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- 206010010305 Confusional state Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- 108010057987 Desmodus rotundus salivary plasminogen activator alpha 1 Proteins 0.000 description 1
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 208000003164 Diplopia Diseases 0.000 description 1
- 206010013496 Disturbance in attention Diseases 0.000 description 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 229940122601 Esterase inhibitor Drugs 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- JMBQKKAJIKAWKF-UHFFFAOYSA-N Glutethimide Chemical compound C=1C=CC=CC=1C1(CC)CCC(=O)NC1=O JMBQKKAJIKAWKF-UHFFFAOYSA-N 0.000 description 1
- WYCLKVQLVUQKNZ-UHFFFAOYSA-N Halazepam Chemical compound N=1CC(=O)N(CC(F)(F)F)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 WYCLKVQLVUQKNZ-UHFFFAOYSA-N 0.000 description 1
- 101000768078 Homo sapiens Amine oxidase [flavin-containing] B Proteins 0.000 description 1
- 206010020853 Hypertonic bladder Diseases 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 108090000543 Ligand-Gated Ion Channels Proteins 0.000 description 1
- 102000004086 Ligand-Gated Ion Channels Human genes 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- JEYCTXHKTXCGPB-UHFFFAOYSA-N Methaqualone Chemical compound CC1=CC=CC=C1N1C(=O)C2=CC=CC=C2N=C1C JEYCTXHKTXCGPB-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- 102000006538 Nitric Oxide Synthase Type I Human genes 0.000 description 1
- 108010008858 Nitric Oxide Synthase Type I Proteins 0.000 description 1
- 208000001294 Nociceptive Pain Diseases 0.000 description 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010052794 Panic disorder with agoraphobia Diseases 0.000 description 1
- 206010033668 Panic disorder without agoraphobia Diseases 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- SCKXCAADGDQQCS-UHFFFAOYSA-N Performic acid Chemical compound OOC=O SCKXCAADGDQQCS-UHFFFAOYSA-N 0.000 description 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- MWQCHHACWWAQLJ-UHFFFAOYSA-N Prazepam Chemical compound O=C1CN=C(C=2C=CC=CC=2)C2=CC(Cl)=CC=C2N1CC1CC1 MWQCHHACWWAQLJ-UHFFFAOYSA-N 0.000 description 1
- QPCVHQBVMYCJOM-UHFFFAOYSA-N Propiverine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OCCC)C(=O)OC1CCN(C)CC1 QPCVHQBVMYCJOM-UHFFFAOYSA-N 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- IKMPWMZBZSAONZ-UHFFFAOYSA-N Quazepam Chemical compound FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=CC=C(Cl)C=C12 IKMPWMZBZSAONZ-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 1
- ZRIHAIZYIMGOAB-UHFFFAOYSA-N Secbutobarbitone Natural products CCC(C)C1(CC)C(=O)NC(=O)NC1=O ZRIHAIZYIMGOAB-UHFFFAOYSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 description 1
- YYQRGCZGSFRBAM-UHFFFAOYSA-N Triclofos Chemical compound OP(O)(=O)OCC(Cl)(Cl)Cl YYQRGCZGSFRBAM-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- ACIAHEMYLLBZOI-ZZXKWVIFSA-N Unsaturated alcohol Chemical compound CC\C(CO)=C/C ACIAHEMYLLBZOI-ZZXKWVIFSA-N 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- GDSCFOSHSOWNDL-UHFFFAOYSA-N Zolasepam Chemical compound N=1CC(=O)N(C)C(N(N=C2C)C)=C2C=1C1=CC=CC=C1F GDSCFOSHSOWNDL-UHFFFAOYSA-N 0.000 description 1
- BBAWTPDTGRXPDG-UHFFFAOYSA-N [1,3]thiazolo[4,5-b]pyridine Chemical compound C1=CC=C2SC=NC2=N1 BBAWTPDTGRXPDG-UHFFFAOYSA-N 0.000 description 1
- ZUSWDTWYONAOPH-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]hydrazine;hydrochloride Chemical group [Cl-].[NH3+]NC1=CC=CC=C1C(F)(F)F ZUSWDTWYONAOPH-UHFFFAOYSA-N 0.000 description 1
- YVMXEHZEYONARR-UHFFFAOYSA-N [2-chloro-5-(trifluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC(C(F)(F)F)=CC=C1Cl YVMXEHZEYONARR-UHFFFAOYSA-N 0.000 description 1
- KUHVVLFCTMTYGR-UHFFFAOYSA-N [2-fluoro-5-(trifluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC(C(F)(F)F)=CC=C1F KUHVVLFCTMTYGR-UHFFFAOYSA-N 0.000 description 1
- BPTABBGLHGBJQR-UHFFFAOYSA-N [3,5-bis(trifluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 BPTABBGLHGBJQR-UHFFFAOYSA-N 0.000 description 1
- YZQQHZXHCXAJAV-UHFFFAOYSA-N [3-(dimethylamino)phenyl]boronic acid Chemical compound CN(C)C1=CC=CC(B(O)O)=C1 YZQQHZXHCXAJAV-UHFFFAOYSA-N 0.000 description 1
- RIIPFHVHLXPMHQ-UHFFFAOYSA-N [4-(dimethylamino)phenyl]boronic acid Chemical compound CN(C)C1=CC=C(B(O)O)C=C1 RIIPFHVHLXPMHQ-UHFFFAOYSA-N 0.000 description 1
- ZBCRZEJNAADYKG-UHFFFAOYSA-N [4-methoxy-2-(trifluoromethyl)phenyl]boronic acid Chemical compound COC1=CC=C(B(O)O)C(C(F)(F)F)=C1 ZBCRZEJNAADYKG-UHFFFAOYSA-N 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- 229940056213 abilify Drugs 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 229940099983 activase Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000026345 acute stress disease Diseases 0.000 description 1
- 125000005042 acyloxymethyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960003148 adinazolam Drugs 0.000 description 1
- GJSLOMWRLALDCT-UHFFFAOYSA-N adinazolam Chemical compound C12=CC(Cl)=CC=C2N2C(CN(C)C)=NN=C2CN=C1C1=CC=CC=C1 GJSLOMWRLALDCT-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000004849 alkoxymethyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229960000880 allobarbital Drugs 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- 229960002133 almotriptan Drugs 0.000 description 1
- 229950000420 alnespirone Drugs 0.000 description 1
- 229950003674 alonimid Drugs 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229960001301 amobarbital Drugs 0.000 description 1
- 229960002519 amoxapine Drugs 0.000 description 1
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002205 anti-dementic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 238000010913 antigen-directed enzyme pro-drug therapy Methods 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 229940127236 atypical antipsychotics Drugs 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- 125000004931 azocinyl group Chemical group N1=C(C=CC=CC=C1)* 0.000 description 1
- 229950001957 bentazepam Drugs 0.000 description 1
- AIZFEOPQVZBNGH-UHFFFAOYSA-N bentazepam Chemical compound C1=2C=3CCCCC=3SC=2NC(=O)CN=C1C1=CC=CC=C1 AIZFEOPQVZBNGH-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- GNRXCIONJWKSEA-UHFFFAOYSA-N benzoctamine Chemical compound C12=CC=CC=C2C2(CNC)C3=CC=CC=C3C1CC2 GNRXCIONJWKSEA-UHFFFAOYSA-N 0.000 description 1
- 229960001303 benzoctamine Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- IEPBPSSCIZTJIF-UHFFFAOYSA-N bis(2,2,2-trichloroethyl) carbonate Chemical compound ClC(Cl)(Cl)COC(=O)OCC(Cl)(Cl)Cl IEPBPSSCIZTJIF-UHFFFAOYSA-N 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 229960002729 bromazepam Drugs 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960003051 brotizolam Drugs 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229960001058 bupropion Drugs 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- 229940015694 butabarbital Drugs 0.000 description 1
- UZVHFVZFNXBMQJ-UHFFFAOYSA-N butalbital Chemical compound CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O UZVHFVZFNXBMQJ-UHFFFAOYSA-N 0.000 description 1
- 229960002546 butalbital Drugs 0.000 description 1
- OVBXTKIWZAHFAC-UHFFFAOYSA-N butane;pyrazine;tin Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CN=CC=N1 OVBXTKIWZAHFAC-UHFFFAOYSA-N 0.000 description 1
- 229960004596 cabergoline Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- HLSLSXBFTXUKCY-UHFFFAOYSA-N capuride Chemical compound CCC(C)C(CC)C(=O)NC(N)=O HLSLSXBFTXUKCY-UHFFFAOYSA-N 0.000 description 1
- 229950003152 capuride Drugs 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000004623 carbolinyl group Chemical group 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- IQNQAOGGWGCROX-UHFFFAOYSA-N cartazolate Chemical compound CCCCNC1=C(C(=O)OCC)C=NC2=C1C=NN2CC IQNQAOGGWGCROX-UHFFFAOYSA-N 0.000 description 1
- 229950007168 cartazolate Drugs 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- UKFDTMNJMKWWNK-UHFFFAOYSA-N chembl2104165 Chemical compound C12=CC(Cl)=CC=C2N\C(=N\CC2CC2)C[N+]([O-])=C1C1=CC=CC=C1 UKFDTMNJMKWWNK-UHFFFAOYSA-N 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- MSOCOAIQDCLPOL-UHFFFAOYSA-N cinnolin-8-yl(trimethyl)stannane Chemical class C1=NN=C2C([Sn](C)(C)C)=CC=CC2=C1 MSOCOAIQDCLPOL-UHFFFAOYSA-N 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 229960001284 citicoline Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229950000551 cloperidone Drugs 0.000 description 1
- 229960004362 clorazepate Drugs 0.000 description 1
- XDDJGVMJFWAHJX-UHFFFAOYSA-N clorazepic acid Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(C(=O)O)N=C1C1=CC=CC=C1 XDDJGVMJFWAHJX-UHFFFAOYSA-N 0.000 description 1
- 229940068796 clozaril Drugs 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000037411 cognitive enhancing Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229950005056 crobenetine Drugs 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- IGSKHXTUVXSOMB-UHFFFAOYSA-N cyclopropylmethanamine Chemical compound NCC1CC1 IGSKHXTUVXSOMB-UHFFFAOYSA-N 0.000 description 1
- 229950010040 cyprazepam Drugs 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 229950001282 desmoteplase Drugs 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- UPMOVJBGNREKJV-CQOQZXRMSA-N dexclamol Chemical compound C12=CC=CC=C2CCC2=CC=CC3=C2[C@@H]1CN1CC[C@@](C(C)C)(O)C[C@@H]13 UPMOVJBGNREKJV-CQOQZXRMSA-N 0.000 description 1
- 229950005215 dexclamol Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- QPMLSUSACCOBDK-UHFFFAOYSA-N diazepane Chemical compound C1CCNNCC1 QPMLSUSACCOBDK-UHFFFAOYSA-N 0.000 description 1
- ATKXDQOHNICLQW-UHFFFAOYSA-N dichloralphenazone Chemical compound OC(O)C(Cl)(Cl)Cl.OC(O)C(Cl)(Cl)Cl.CN1C(C)=CC(=O)N1C1=CC=CC=C1 ATKXDQOHNICLQW-UHFFFAOYSA-N 0.000 description 1
- 229960005422 dichloralphenazone Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- XLZOVRYBVCMCGL-BPNVQINPSA-L disodium;4-[(z)-[tert-butyl(oxido)azaniumylidene]methyl]benzene-1,3-disulfonate Chemical compound [Na+].[Na+].CC(C)(C)[N+](\[O-])=C\C1=CC=C(S([O-])(=O)=O)C=C1S([O-])(=O)=O XLZOVRYBVCMCGL-BPNVQINPSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 239000000221 dopamine uptake inhibitor Substances 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229960002472 eletriptan Drugs 0.000 description 1
- OTLDLQZJRFYOJR-LJQANCHMSA-N eletriptan Chemical compound CN1CCC[C@@H]1CC1=CN=C2[C]1C=C(CCS(=O)(=O)C=1C=CC=CC=1)C=C2 OTLDLQZJRFYOJR-LJQANCHMSA-N 0.000 description 1
- 229950007566 elzasonan Drugs 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 1
- 229960004341 escitalopram Drugs 0.000 description 1
- CDCHDCWJMGXXRH-UHFFFAOYSA-N estazolam Chemical compound C=1C(Cl)=CC=C(N2C=NN=C2CN=2)C=1C=2C1=CC=CC=C1 CDCHDCWJMGXXRH-UHFFFAOYSA-N 0.000 description 1
- 229960002336 estazolam Drugs 0.000 description 1
- 239000002329 esterase inhibitor Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 229960004447 ethchlorvynol Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 229960001690 etomidate Drugs 0.000 description 1
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
- 229960004945 etoricoxib Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 229950002489 fenobam Drugs 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229960003528 flurazepam Drugs 0.000 description 1
- SAADBVWGJQAEFS-UHFFFAOYSA-N flurazepam Chemical compound N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F SAADBVWGJQAEFS-UHFFFAOYSA-N 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- 229950006306 fosazepam Drugs 0.000 description 1
- JMYCGCXYZZHWMO-UHFFFAOYSA-N fosazepam Chemical compound N=1CC(=O)N(CP(C)(=O)C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 JMYCGCXYZZHWMO-UHFFFAOYSA-N 0.000 description 1
- 229960002284 frovatriptan Drugs 0.000 description 1
- SIBNYOSJIXCDRI-SECBINFHSA-N frovatriptan Chemical compound C1=C(C(N)=O)[CH]C2=C(C[C@H](NC)CC3)C3=NC2=C1 SIBNYOSJIXCDRI-SECBINFHSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229940003380 geodon Drugs 0.000 description 1
- QOIGKGMMAGJZNZ-UHFFFAOYSA-N gepirone Chemical compound O=C1CC(C)(C)CC(=O)N1CCCCN1CCN(C=2N=CC=CN=2)CC1 QOIGKGMMAGJZNZ-UHFFFAOYSA-N 0.000 description 1
- 229960000647 gepirone Drugs 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229960002972 glutethimide Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036433 growing body Effects 0.000 description 1
- 229960002158 halazepam Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004475 heteroaralkyl group Chemical group 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- 125000006588 heterocycloalkylene group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
- 229960000930 hydroxyzine Drugs 0.000 description 1
- 229940053999 hypnotics and sedatives melatonin receptor agonists Drugs 0.000 description 1
- 208000006278 hypochromic anemia Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 125000004926 indolenyl group Chemical group 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910001411 inorganic cation Inorganic materials 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 125000006303 iodophenyl group Chemical group 0.000 description 1
- 230000001057 ionotropic effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229950003599 ipsapirone Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 125000005438 isoindazolyl group Chemical group 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940060977 lidoderm Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229960003587 lisuride Drugs 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 229960004033 lormetazepam Drugs 0.000 description 1
- 229960002373 loxoprofen Drugs 0.000 description 1
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960000994 lumiracoxib Drugs 0.000 description 1
- KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960004090 maprotiline Drugs 0.000 description 1
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- SFITWQDBYUMAPS-UHFFFAOYSA-N mecloqualone Chemical compound CC1=NC2=CC=CC=C2C(=O)N1C1=CC=CC=C1Cl SFITWQDBYUMAPS-UHFFFAOYSA-N 0.000 description 1
- 229950007403 mecloqualone Drugs 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000006883 memory enhancing effect Effects 0.000 description 1
- ALARQZQTBTVLJV-UHFFFAOYSA-N mephobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)N(C)C1=O ALARQZQTBTVLJV-UHFFFAOYSA-N 0.000 description 1
- 229960004815 meprobamate Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229960002803 methaqualone Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 229960001703 methylphenobarbital Drugs 0.000 description 1
- 229950010642 midaflur Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229940101972 mirapex Drugs 0.000 description 1
- 239000004050 mood stabilizer Substances 0.000 description 1
- 229940127237 mood stabilizer Drugs 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- XCRCEOVIKRPCQV-UHFFFAOYSA-N n-(2-fluoroanilino)-2-oxo-2-(propylamino)ethanimidoyl cyanide Chemical compound CCCNC(=O)C(C#N)=NNC1=CC=CC=C1F XCRCEOVIKRPCQV-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- GTWJETSWSUWSEJ-UHFFFAOYSA-N n-benzylaniline Chemical compound C=1C=CC=CC=1CNC1=CC=CC=C1 GTWJETSWSUWSEJ-UHFFFAOYSA-N 0.000 description 1
- NDVZIUGCCMZHLG-UHFFFAOYSA-N n-methyl-3-(2-methylsulfanylphenoxy)-3-phenylpropan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=CC=C1SC NDVZIUGCCMZHLG-UHFFFAOYSA-N 0.000 description 1
- IHPHPGLJYCDONF-UHFFFAOYSA-N n-propylacetamide Chemical compound CCCNC(C)=O IHPHPGLJYCDONF-UHFFFAOYSA-N 0.000 description 1
- KPTRDYONBVUWPD-UHFFFAOYSA-N naphthalen-2-ylboronic acid Chemical compound C1=CC=CC2=CC(B(O)O)=CC=C21 KPTRDYONBVUWPD-UHFFFAOYSA-N 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-M naproxen(1-) Chemical compound C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-M 0.000 description 1
- 229960005254 naratriptan Drugs 0.000 description 1
- UNHGSHHVDNGCFN-UHFFFAOYSA-N naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229960001800 nefazodone Drugs 0.000 description 1
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000008587 neuronal excitability Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- CBDPCXYQNVDTMW-UHFFFAOYSA-N nisobamate Chemical compound NC(=O)OCC(C)(C(C)CC)COC(=O)NC(C)C CBDPCXYQNVDTMW-UHFFFAOYSA-N 0.000 description 1
- 229950008643 nisobamate Drugs 0.000 description 1
- 229960001454 nitrazepam Drugs 0.000 description 1
- KJONHKAYOJNZEC-UHFFFAOYSA-N nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 229960001158 nortriptyline Drugs 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 125000004930 octahydroisoquinolinyl group Chemical group C1(NCCC2CCCC=C12)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 208000020629 overactive bladder Diseases 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 229960004535 oxazepam Drugs 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- QNNHQVPFZIFNFK-UHFFFAOYSA-N oxazolo[4,5-b]pyridine Chemical compound C1=CC=C2OC=NC2=N1 QNNHQVPFZIFNFK-UHFFFAOYSA-N 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 229960005434 oxybutynin Drugs 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 229960004851 pergolide Drugs 0.000 description 1
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000004624 phenarsazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3[As]=C12)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 229960000964 phenelzine Drugs 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000005954 phenoxathiinyl group Chemical group 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000004928 piperidonyl group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229960003089 pramipexole Drugs 0.000 description 1
- 229960004856 prazepam Drugs 0.000 description 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 229960003510 propiverine Drugs 0.000 description 1
- 229960004134 propofol Drugs 0.000 description 1
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229960002601 protriptyline Drugs 0.000 description 1
- BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- ABMYEXAYWZJVOV-UHFFFAOYSA-N pyridin-3-ylboronic acid Chemical compound OB(O)C1=CC=CN=C1 ABMYEXAYWZJVOV-UHFFFAOYSA-N 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 229960001964 quazepam Drugs 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- ZTHJULTYCAQOIJ-WXXKFALUSA-N quetiapine fumarate Chemical compound [H+].[H+].[O-]C(=O)\C=C\C([O-])=O.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 ZTHJULTYCAQOIJ-WXXKFALUSA-N 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- YGDICLRMNDWZAK-UHFFFAOYSA-N quinolin-3-ylboronic acid Chemical compound C1=CC=CC2=CC(B(O)O)=CN=C21 YGDICLRMNDWZAK-UHFFFAOYSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 description 1
- 229960000245 rasagiline Drugs 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 229960003770 reboxetine Drugs 0.000 description 1
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- MQGIGGJUPITZSE-UHFFFAOYSA-N reclazepam Chemical compound C12=CC(Cl)=CC=C2N(C=2OCC(=O)N=2)CCN=C1C1=CC=CC=C1Cl MQGIGGJUPITZSE-UHFFFAOYSA-N 0.000 description 1
- 229950004797 reclazepam Drugs 0.000 description 1
- YGYBFMRFXNDIPO-QGZVFWFLSA-N repinotan Chemical compound O=S1(=O)C2=CC=CC=C2C(=O)N1CCCCNC[C@@H]1OC2=CC=CC=C2CC1 YGYBFMRFXNDIPO-QGZVFWFLSA-N 0.000 description 1
- 229950009693 repinotan Drugs 0.000 description 1
- 229940113775 requip Drugs 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229940106887 risperdal Drugs 0.000 description 1
- 229960000425 rizatriptan Drugs 0.000 description 1
- TXHZXHICDBAVJW-UHFFFAOYSA-N rizatriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1CN1C=NC=N1 TXHZXHICDBAVJW-UHFFFAOYSA-N 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 229950004692 roletamide Drugs 0.000 description 1
- 229960001879 ropinirole Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
- 229940035004 seroquel Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229960004249 sodium acetate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- ILJOYZVVZZFIKA-UHFFFAOYSA-M sodium;1,1-dioxo-1,2-benzothiazol-3-olate;hydrate Chemical compound O.[Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 ILJOYZVVZZFIKA-UHFFFAOYSA-M 0.000 description 1
- DCQXTYAFFMSNNH-UHFFFAOYSA-M sodium;2-[bis(2-hydroxyethyl)amino]ethanol;acetate Chemical compound [Na+].CC([O-])=O.OCCN(CCO)CCO DCQXTYAFFMSNNH-UHFFFAOYSA-M 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- FBOUYBDGKBSUES-VXKWHMMOSA-N solifenacin Chemical compound C1([C@H]2C3=CC=CC=C3CCN2C(O[C@@H]2C3CCN(CC3)C2)=O)=CC=CC=C1 FBOUYBDGKBSUES-VXKWHMMOSA-N 0.000 description 1
- 229960003855 solifenacin Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 201000001716 specific phobia Diseases 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical compound COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 1
- WZAIVXXKOAWTGQ-UHFFFAOYSA-N spiro[2,3-dihydronaphthalene-4,3'-piperidine]-1,2',6'-trione Chemical compound O=C1NC(=O)CCC11C2=CC=CC=C2C(=O)CC1 WZAIVXXKOAWTGQ-UHFFFAOYSA-N 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 229960003708 sumatriptan Drugs 0.000 description 1
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
- 229940034173 symbyax Drugs 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-O tacrine(1+) Chemical compound C1=CC=C2C([NH3+])=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-O 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940000238 tasmar Drugs 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 229960003188 temazepam Drugs 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- VOVUARRWDCVURC-UHFFFAOYSA-N thiirane Chemical compound C1CS1 VOVUARRWDCVURC-UHFFFAOYSA-N 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 125000005309 thioalkoxy group Chemical group 0.000 description 1
- 125000005505 thiomorpholino group Chemical group 0.000 description 1
- QERYCTSHXKAMIS-UHFFFAOYSA-N thiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-N 0.000 description 1
- 150000003606 tin compounds Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 description 1
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 description 1
- 229960004045 tolterodine Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229950005135 traxoprodil Drugs 0.000 description 1
- 229960003991 trazodone Drugs 0.000 description 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
- 229950002464 trepipam Drugs 0.000 description 1
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 1
- 229960003386 triazolam Drugs 0.000 description 1
- GYUURHMITDQTRU-UHFFFAOYSA-N tributyl(pyridin-2-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CC=CC=N1 GYUURHMITDQTRU-UHFFFAOYSA-N 0.000 description 1
- UNEPXPMBVGDXGH-UHFFFAOYSA-N tributyl(pyridin-4-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CC=NC=C1 UNEPXPMBVGDXGH-UHFFFAOYSA-N 0.000 description 1
- HFFLGKNGCAIQMO-UHFFFAOYSA-N trichloroacetaldehyde Chemical compound ClC(Cl)(Cl)C=O HFFLGKNGCAIQMO-UHFFFAOYSA-N 0.000 description 1
- 229960001147 triclofos Drugs 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- 229960002431 trimipramine Drugs 0.000 description 1
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- DTMPGSXFUXZBDK-UHFFFAOYSA-N uldazepam Chemical compound C12=CC(Cl)=CC=C2N=C(NOCC=C)CN=C1C1=CC=CC=C1Cl DTMPGSXFUXZBDK-UHFFFAOYSA-N 0.000 description 1
- 229950004526 uldazepam Drugs 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- HUNXMJYCHXQEGX-UHFFFAOYSA-N zaleplon Chemical compound CCN(C(C)=O)C1=CC=CC(C=2N3N=CC(=C3N=CC=2)C#N)=C1 HUNXMJYCHXQEGX-UHFFFAOYSA-N 0.000 description 1
- 229960004010 zaleplon Drugs 0.000 description 1
- 229960001366 zolazepam Drugs 0.000 description 1
- 229960001360 zolmitriptan Drugs 0.000 description 1
- ULSDMUVEXKOYBU-ZDUSSCGKSA-N zolmitriptan Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1C[C@H]1COC(=O)N1 ULSDMUVEXKOYBU-ZDUSSCGKSA-N 0.000 description 1
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 1
- 229960001475 zolpidem Drugs 0.000 description 1
- 229940039925 zyprexa Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/28—Cinnolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Definitions
- the present invention relates to novel cinnoline compounds, their pharmaceutical compositions, methods of use and processes to make such compounds.
- the present invention relates to therapeutic methods for the treatment and/or prevention of anxiety disorders, cognitive disorders, and/or mood disorders.
- the present invention comprises, inter alia, cinnoline compounds, their use as central nervous system (CNS) depressants (especially anxiolytics), and pharmacological tools, methods for their preparation, pharmaceutical compositions containing the same, and intermediates used in their preparation.
- CNS central nervous system
- GABA ⁇ -Aininobutyric acid
- GABAA GABA type A receptors
- GABAB GABA type B receptors
- GABA type C receptors GABA type C receptors
- GABAA receptors function as ligand-gated ion channels to mediate fast inhibitory synaptic transmissions that regulate neuronal excitability involved in such responses as seizure threshold, skeletal muscle tone, and emotional status.
- GABAA receptors are targets of many sedating drugs, such as benzodiazepines, barbiturates and neurosteroids.
- GABAA receptors are pentameric, ligand-gated chloride ion (Cl " ) channels belonging to a superfamily of ligand-gated ionotropic receptors that includes the nicotinic acetylcholine receptor. GABAA receptors are very heterogeneous, with at least 16 different subunits producing potentially thousands of different receptor types.
- GABAA receptor subunits aggregate into complexes that form chloride ion selective channels and contain sites that bind GABA along with a variety of pharmacologically active substances.
- the anion channel is activated, causing it to open and allowing chloride ions (Cl " ) to enter the neuron.
- Cl " chloride ions
- This influx of Cl " ions hyperpolarizes the neuron, making it less excitable.
- the resultant decrease in neuronal activity following activation of the GABAA receptor complex can rapidly alter brain function, to such an extent that consciousness and motor control may be impaired.
- GABAA receptor subunits and the widespread distribution of these receptors in the nervous system likely contributes to the diverse and variable physiological functions of GABAA receptors, which have been implicated in many neurological and psychiatric disorders, and related conditions, including: stroke, head trauma, epilepsy, pain, migraine, mood disorders, anxiety, post traumatic stress disorder, obsessive compulsive disorders, schizophrenia, seizures, convulsions, tinnitus, neurodegenerative disorders including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's Chorea, Parkinson's disease, depression, bipolar disorders, mania, trigeminal and other neuralgia, neuropathic pain, hypertension, cerebral ischemia, cardiac arrhythmia, myotonia, substance abuse, myoclonus, essential tremor, dyskinesia and other movement disorders, neonatal cerebral hemorrhage, and spasticity.
- GABAA receptors are also believed to play a role in cognition, consciousness, and sleep.
- drugs for modulating GABAA receptor activity include barbiturates, such as pentobarbital and secobarbital, and benzodiazepines such as diazepam, chlordiazepoxide and midazolam.
- Barbiturates can directly activate GABAA receptors, significantly increasing Cl " currents in the absence of further intervention by GABA itself and can also indirectly augment GABAergic neural transmission.
- benzodiazepines act as indirect allosteric modulators, and are largely incapable of increasing Cl " currents in the absence of GABA, but enhance GABA-activated increases in Cl " conductance.
- This latter property is thought to be responsible for the usefulness of benzodiazepines for treating a number of disorders, including generalized anxiety disorder, panic disorder, seizures, movement disorders, epilepsy, psychosis, mood disorders, and muscle spasms, as well as the relative safety of benzodiazepines compared to barbiturates.
- Both barbiturates and benzodiazepines are addictive and can cause drowsiness, poor concentration, ataxia, dysarthria, motor incoordination, diplopia, muscle weakness, vertigo and mental confusion. These side effects can interfere with an individual's ability to perform daily routines such as driving, operating heavy machinery or performing other complex motor tasks while under therapy, making barbiturates and benzodiazepines less than optimal for treating chronic disorders involving GABA and GABAA receptors.
- GABAA receptors and GABAergic neural transmissions are implicated as targets for therapeutic intervention in a myriad of neurological and psychiatric disorders.
- Adverse side effects including addictive properties exhibited by currently available GABA and GABAA receptor modulating drugs, make these drugs unsuitable in many therapeutic contexts.
- compositions, methods and tools that will be useful in broad clinical applications to modulate the function and activity of GABA and GABA receptors in mammalian subjects, including humans, and/or to target GABAergic neural transmission.
- the present invention is also, inter alia, directed toward this end.
- R 1 is Q -6 alkyl, Ci -6 haloalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, each optionally substituted by 1, 2, 3, 4 or 5 R 7 ;
- R 6 is aryl, cycloalkyl, heteroaryl or heterocycloalkyl, each optionally substituted by 1, 2, 3, 4 or 5 A 1 ;
- R b and R b are each, independently, H, Ci- 6 alkyl, C ⁇ s haloalkyl, C 2- 6 alkenyl, C 2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, wherein the Ci_ 6 alkyl, Ci_ 6 haloalkyl, C 2-6 alkenyl, C 2- ⁇ alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with OH, amino, halo, Q. 6 alkyl, Q.6 haloalkyl, C ⁇ haloalkyl, aryl, arylalkyl, heteroaryl
- R c and R d are each, independently, H, Ci -I0 alkyl, C ⁇ haloalkyl, C 2-6 alkenyl, C 2- 6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, wherein the Ci-io alkyl, Ci-6 haloalkyl, C 2- 6 alkenyl, C 2- 6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with OH, amino, halo, C h alky!, Q.6 haloalkyl, C ⁇ haloalkyl, aryl, arylalkyl, heteroaryl, hetero
- Ci -I0 alkyl, Ci_6 haloalkyl, C2-6 alkenyl, C 2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with OH, amino, halo, C 1 ⁇ alkyl, Q- ⁇ haloalkyl, C ⁇ g haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl or heterocycloalkyl; or R 0' and R d together with the N
- R 6 is other than unsubstituted phenyl or unsubstituted cycloalkyl.
- R 1 is Ci-6 alkyl, Ci- ⁇ haloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, each optionally substituted by 1, 2, 3, 4 or 5 R 7 .
- R 1 is Q-6 alkyl, Ci_ 6 haloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, each optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, C 1 .
- R 1 is Ci- 6 alkyl, Ci- ⁇ haloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl.
- R 1 is Ci. 6 alkyl or Ci- 6 haloalkyl. In some embodiments, R 1 is Ci_ 6 alkyl. In some embodiments, R 1 is n-propyl.
- R 2 is H.
- R 3 , R 4 and R 5 are each, independently, H, Ci -4 alkoxy, halo, Ci-6 alkyl or Q.6 haloalkyl.
- R 3 , R 4 and R 5 are each, independently, H, Ci -4 alkoxy, halo or Ci -3 haloalkyl.
- R 3 , R 4 and R 5 are each, independently, H, Ci -4 alkoxy, or halo.
- R 6 is aryl or heteroaryl, each optionally substituted by 1 , 2, 3, 4 Or S A 1 .
- R 6 is aryl optionally substituted by 1, 2, 3, 4 or 5 A 1 .
- R 6 is aryl substituted by 1, 2, 3, 4 or 5 A 1 . In some embodiments, R 6 is heteroaryl optionally substituted by 1, 2, 3, 4 or 5
- R 6 is phenyl, naphthyl, pyridyl, pyrimidinyl, pyrazinyl, pyrazolyl, quinolyl or indolyl, each optionally substituted by 1, 2, 3, 4 or 5 A 1 .
- R 6 is phenyl, 2-naphthyl, 3-pyridyl, 4-pyridyl, pyrimidin- 5-yl, pyrazin-2-yl, pyrazol-3-yl, pyrazol-4-yl, 3-quinolyl, 6-quinolyl, or indol-5-yl, each optionally substituted by 1, 2, 3, 4 or 5 A 1 .
- R c and R d together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group; and R c and R d together with the N atom to which they are attached form a A-, 5-, 6- or 7-membered heterocycloalkyl group.
- R 6 is phenyl, naphthyl, pyridyl, pyrimidinyl, pyrazinyl, pyrazolyl, quinolyl or indolyl, each optionally substituted by 1, 2, 3, 4 or 5 halo, CN, OH, Ci ⁇ alkoxy, CM haloalkoxy, amino, Ci -4 alkylamino, C 2 .
- R c and R d together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group.
- R c and R d together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group.
- R 1 is Ci -6 alkyl or Ci -6 haloalkyl
- R 5 is H, Ci -4 alkoxy, halo, Ci -6 alkyl or Ci -6 haloalkyl;
- R 6 is phenyl, naphthyl, pyridyl, pyrimidinyl, pyrazinyl, pyrazolyl, quinolyl or indolyl, each optionally substituted by 1, 2 or 3 halo, CN, OH, Ci -4 alkoxy, Ci -4 haloalkoxy, amino, Ci -4 alkylamino, C 2-8 dialkylamino, NR°R d ,
- R° and R d together with the N atom to which they are attached form a A-, 5-, 6- or 7-membered heterocycloalkyl group.
- R 6 is other than unsubstituted phenyl.
- R 1 is Ci -6 alkyl.
- R 1 is n-propyl.
- R 2 is H.
- R 5 is H, C 1-4 alkoxy or halo.
- R c and R d together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group.
- R 6 is phenyl, naphthyl, pyridyl, pyrimidinyl, pyrazinyl, pyrazolyl, quinolyl or indolyl, each substituted by 1 , 2 or 3 Ci -4 alkoxy or Ci -4 alkyl.
- R 6 is phenyl, naphthyl, pyridyl, pyrimidinyl, pyrazinyl, pyrazolyl, quinolyl or indolyl, each substituted by 2 Ci -4 alkoxy or Ci -4 alkyl.
- R 1 is n-propyl and R 2 is H.
- compositions comprising a compound of any of the formulas described herein, or a pharmaceutically acceptable salt, tautomer, atropisomer, or in vivo-hydrolysable precursor thereof, and at least one pharmaceutically acceptable carrier, diluent or excipient.
- the present invention further provides methods of treating or preventing an anxiety disorder in a patient, comprising administering to the patient a therapeutically effective amount of a compound of any of the formulas described herein, or a pharmaceutically acceptable salt, tautomer, atropisomer, or in vzvo-hydrolysable precursor thereof.
- the present invention further provides methods of treating or preventing a cognitive disorder in a patient, comprising administering to the patient a therapeutically effective amount of a compound of any of the formulas described herein, or a pharmaceutically acceptable salt, tautomer, atropisomer, or in vzv ⁇ -hydrolysable precursor thereof.
- the present invention further provides methods of treating or preventing a mood disorder in a patient, comprising administering to the patient a therapeutically effective amount of a compound of any of the formulas described herein, or a pharmaceutically acceptable salt, tautomer, atropisomer, or in vfvo-hydrolysable precursor thereof.
- the present invention further provides a compound of any of the formulas described herein, or a pharmaceutically acceptable salt, tautomer, atropisomer, or in vfvo-hydrolysable precursor thereof, described herein for use as a medicament.
- the present invention further provides a compound of any of the formulas described herein, or a pharmaceutically acceptable salt, tautomer, atropisomer, or in vfvo-hydrolysable precursor thereof, described herein for the manufacture of a medicament.
- the present invention further provides methods of modulating activity of GABAA receptor comprising contacting the GABAA receptor with a compound of any of the formulas described herein, or a pharmaceutically acceptable salt, tautomer, atropisomer, or in vfvo-hydrolysable precursor thereof.
- the present invention further provides synthetic methods of making a compound of any of the formulas described herein, or a pharmaceutically acceptable salt, tautomer, atropisomer, or in vfvo-hydrolysable precursor thereof.
- R 1 is Ci -6 alkyl, Ci -6 haloalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, each optionally substituted by 1, 2, 3, 4 or 5 R 7 ;
- R 6 is aryl, cycloalkyl, heteroaryl or heterocycloalkyl, each optionally substituted by 1, 2, 3, 4 or 5 A 1 ;
- R a and R a are each, independently, H, Q- ⁇ alkyl, Q- ⁇ haloalkyl, C2-6 alkenyl, C 2 - 6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, wherein the Ci_ 6 alkyl, Q.
- R b and R b' are each, independently, H, Ci-6 alkyl, Q. 6 haloalkyl, C 2- O alkenyl,
- haloalkyl C 2 -6 alkenyl, C 2 - 6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with OH, amino, halo, Q.6 alkyl, Ci-6 haloalkyl, Q- ⁇ haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl or heterocycloalkyl;
- R c and R d are each, independently, H, Q-io alkyl, Q- ⁇ haloalkyl, C 2- 6 alkenyl, C 2 - 6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, wherein the Q.io alkyl, C 1 .6 haloalkyl, C2-6 alkenyl, C 2 - 6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with OH, amino, halo, Q.6 alkyl, Q-6 haloalkyl, Q- ⁇ haloalkyl, aryl, arylalky
- R c and R d are each, independently, H, Cno alkyl, Q. ⁇ haloalkyl, C 2- 6 alkenyl, Q>- 6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, wherein the Q-io alkyl, Q. ⁇ haloalkyl, C 2- 6 alkenyl, C 2- 6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with OH, amino, halo, Q-6 alkyl, Q-6 haloalkyl, Q.6 haloalkyl, aryl, arylalkyl, heteroaryl, hetero
- R 6 is other than unsubstituted phenyl or unsubstituted cycloalkyl.
- R 1 is Q -6 alkyl, Q -6 haloalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, each optionally substituted by 1, 2, 3, 4 or 5 R 7 , or any subgroup thereof.
- R 1 is Ci -6 alkyl, Ci- 6 haloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, each optionally substituted by 1, 2, 3, 4 or 5 R 7 .
- R 1 is C 1-6 alkyl, Ci- 6 haloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl. In some embodiments, R 1 is Ci -6 alkyl or Ci- 6 haloalkyl. In some embodiments, R is Ci- 6 alkyl. In some embodiments, R 1 is n-propyl.
- R 2 is H, C(O)R b , C(O)NR c R d , C(O)0R a , S(O) 2 R b , Ci-6 alkyl, Ci-6 haloalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, or any subgroup thereof, wherein each of the Ci -6 alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4 or 5 R 8 , or any subgroup thereof.
- R 2 is H, C(O)-(C 1-4 alkyl), C(O)-(arylalkyl), C(O)O-(Ci -4 alkyl), C(O)0-(arylalkyl), C(O)NH 2 , C(O)NH(Ci -4 alkyl), C(O)N(Q -4 alkyl) 2 , Ci -6 alkyl, Ci -6 haloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, wherein each of the Ci -6 alkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Ci -4 alkyl, Ci -4 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkylalkyl
- R 3 , R 4 and R 5 are each, independently, H, halo, CN, NO 2 , OH, Ci -4 alkoxy, Ci -4 haloalkoxy, amino, Ci -4 alkylamino, C 2-8 dialkylamino, SH, -S-(Ci -4 alkyl), C(O)H, C(O)-(Ci -4 alkyl), C(O)- (arylalkyl), C(O)NH 2 , C(O)NH(Ci -4 alkyl), C(O)N(C 1-4 alkyl) 2 , C(O)OH, C(O)O- (Ci -4 alkyl), C(O)0-(arylalkyl), OC(O)H, OC(O)-(Ci -4 alkyl), 0C(O)-(arylalkyl), OC(O)NH 2 , OC(O)NH(Ci -4 alkyl), 0C(O)-(ary
- R 3 , R 4 and R 5 are each, independently, H, Ci -4 alkoxy, halo, Ci_6 alkyl or C 1 ⁇ haloalkyl. In some embodiments, R 3 , R 4 and R 5 are each, independently, H, Ci -4 alkoxy, halo or C 1 - 3 haloalkyl. In some embodiments, R 3 , R 4 and R 5 are each, independently, H, Ci -4 alkoxy, or halo.
- R 6 is aryl, cycloalkyl, heteroaryl or heterocycloalkyl, or any subgroup thereof, each optionally substituted by 1, 2, 3, 4 or 5 A 1 , or any subgroup thereof.
- R 6 is aryl or heteroaryl, each optionally substituted by 1, 2, 3, 4 or 5 A 1 .
- R 6 is aryl optionally substituted by 1, 2, 3, 4 or 5 A 1 .
- R 6 is aryl substituted by 1, 2, 3, 4 or 5 A 1 .
- R 6 is heteroaryl optionally substituted by 1, 2, 3, 4 or 5 A 1 .
- R 6 is phenyl, naphthyl, pyridyl, pyrimidinyl, pyrazinyl, pyrazolyl, quinolyl or indolyl, each optionally substituted by 1, 2, 3, 4 or 5 A 1 .
- R 6 is phenyl, 2-naphthyl, 3-pyridyl, 4-pyridyl, pyrimidin-5-yl, pyrazin-2-yl, pyrazol-3-yl, pyrazol-4-yl, 3-quinolyl, 6-quinolyl, or indol-5-yl, each optionally substituted by 1, 2, 3, 4 or 5 A 1 .
- R a and R a are each, independently, H, Q -6 alkyl, haloalkyl, C 2-6 alkenyl, C 2- 6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, or any subgroup thereof, wherein the C 1 ⁇ alkyl, Ci- ⁇ haloalkyl, C 2-6 alkenyl, C 2- 6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with OH, amino, halo, Q -6 alkyl, Ci- 6 haloalkyl, aryl, arylalkyl, heteroaryl, heteroaryl, or heterocycl
- R and R b are each, independently, H, Ci- ⁇ alkyl, Q -6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, or any subgroup thereof, wherein the Q- 6 alkyl, C 1 ⁇ haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with OH, amino, halo, Q.6 alkyl, C 1 ⁇ haloalkyl, Ci- 6 haloalkyl, aryl, ary
- R° and R d are each, independently, H, Ci -I0 alkyl, Ci-6 haloalkyl, C 2 -6 alkenyl, C 2 -6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, or any subgroup thereof, wherein the Ci -I0 alkyl, C 1 ⁇ haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with OH, amino, halo, Ci.6 alkyl, Ci_6 haloalkyl, Q. 6 haloalkyl,
- R c and R d together with the N atom to which they are attached form a A-, 5-, 6- or 7-membered heterocycloalkyl group, or any subgroup thereof.
- R c and R d are each, independently, H, Ci -I0 alkyl, C ⁇ haloalkyl, C 2 -6 alkenyl, C 2 -6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, or any subgroup thereof, wherein the Ci-I 0 alkyl, Ci_6 haloalkyl, C2-6 alkenyl, C 2- 6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with OH, amino, halo, Ci- ⁇ alkyl, Q- ⁇ haloalkyl, Q. 6 haloalkyl,
- R c and R d together with the N atom to which they are attached form a A-, 5-, 6- or 7-membered heterocycloalkyl group, or any subgroup thereof.
- R 6 is other than unsubstituted phenyl or unsubstituted cycloalkyl.
- R° and R d together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group.
- R 1 is Ci- 6 alkyl or Ci_6 haloalkyl
- R 5 is H, Ci -4 alkoxy, halo, Ci_6 alkyl or C ⁇ haloalkyl;
- R c and R d together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group.
- R 6 when R 2 and R 5 are each H, then R 6 is other than unsubstituted phenyl.
- R 1 is Ci- 6 alkyl or Ci_ 6 haloalkyl, or any subgroup thereof.
- R 1 is Ci- 6 alkyl. In some embodiments, R 1 is n-propyl.
- R 2 is H.
- R 5 is H, Q -4 alkoxy, halo, Ci_6 alkyl or Ci_6 haloalkyl, or any subgroup thereof. In some embodiments, R 5 is H, Ci -4 alkoxy or halo.
- R 6 is phenyl, naphthyl, pyridyl, pyrimidinyl, pyrazinyl, pyrazolyl, quinolyl or indolyl, each substituted by 1, 2 or 3 C 1-4 alkoxy or Ci -4 alkyl. In some embodiments, R 6 is phenyl, naphthyl, pyridyl, pyrimidinyl, pyrazinyl, pyrazolyl, quinolyl or indolyl, each substituted by 2 Ci -4 alkoxy or Ci -4 alkyl.
- R c and R d together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group, or any subgroup thereof.
- the present invention provides the following compounds:
- the present invention provides the following compounds: 4-aniino-8-(2,4-dimemoxypyrimidin-5-yl)-N-propyl-cinnoline-3-carboxamide; 4-amino- 8-(2,5-dimethoxyphenyl)-N-propyl-cinnoline-3-carboxamide; 4-amino-8-(4-methoxy-3- pyridyl)-N-propyl-cinnoline-3-carboxamide; and 4-amino-8-(2-methoxy-5-methyl- phenyl)-N-propyl-cinnoline-3-carboxamide; or a pharmaceutically acceptable salt thereof, or any subgroup thereof.
- the present invention provides 4-amino-8-(2,4- dimethoxypyrimidin-5-yl)-N-propyl-cinnoline-3-carboxamide, or a pharmaceutically acceptable salt thereof, or any subgroup thereof.
- the present invention provides the following compounds:
- the present invention provides the following compounds:
- Compounds of the present invention also include pharmaceutically acceptable salts, tautomers and in vzvo-hydrolysable precursors of the compounds of any of the formulas described herein. Compounds of the invention further include hydrates and solvates. Compounds of the invention can be used as medicaments. In some embodiments, the present invention provides compounds of any of the formulas described herein, or pharmaceutically acceptable salts, tautomers or in vzvo-hydrolysable precursors thereof, for use as medicaments. In some embodiments, the present invention provides compounds described herein for use as medicaments for treating or preventing an anxiety disorder, cognitive disorder, or mood disorder.
- the present invention provides compounds of any of the formulas described herein, or pharmaceutically acceptable salts, tautomers or in vzvo-hydrolysable precursors thereof, in the manufacture of a medicament for the treatment or prophylaxis of an anxiety disorder, cognitive disorder, or mood disorder.
- the present invention provides a method for the treatment or prophylaxis of an anxiety disorder comprising administering to a mammal (including a human) a therapeutically effective amount of a compound of any of the formulas described herein, or a pharmaceutically acceptable salt, tautomer or in vzvo-hydrolysable precursor thereof.
- anxiety disorder includes, but is not limited to, one or more of the following: panic disorder, panic disorder without agoraphobia, panic disorder with agoraphobia, agoraphobia without history of panic disorder, specific phobia, social phobia, social anxiety disorder, obsessive-compulsive disorder, posttraumatic stress disorder, acute stress disorder, generalized anxiety disorder, generalized anxiety disorder due to a general medical condition, and the like.
- the present invention provides a method for the treatment or prophylaxis of a cognitive disorder comprising administering to a mammal (including a human) a therapeutically effective amount of a compound of any of the formulas described herein, or a pharmaceutically acceptable salt, tautomer or in vzvo-hydrolysable precursor thereof.
- a mammal including a human
- a therapeutically effective amount of a compound of any of the formulas described herein, or a pharmaceutically acceptable salt, tautomer or in vzvo-hydrolysable precursor thereof includes, but is not limited to, one or more of the following: Alzheimer's disease, dementia, dementia due to Alzheimer's disease, dementia due to Parkinson's disease, and the like.
- the present invention provides a method for the treatment or prophylaxis of a mood disorder comprising administering to a mammal (including a human) a therapeutically effective amount of a compound of any of the formulas described herein, or a pharmaceutically acceptable salt, tautomer or in vzVohydrolysable precursor thereof.
- the phrase "mood disorder” is a depressive disorder including, but is not limited to, one or more of the following: major depressive disorder, dysthymic disorder, bipolar depression and/or bipolar mania, bipolar I with or without manic, depressive or mixed episodes, bipolar II, cyclothymic disorder, mood disorder due to a general medical condition, manic episodes associated with bipolar disorder, mixed episodes associated with bipolar disorder, and the like.
- Anxiety disorders, cognitive disorders, and mood disorders are defined, for example, in the American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, Washington, DC, American Psychiatric Association, 2000.
- the present invention provides a method of treating or preventing an anxiety disorder, cognitive disorder, or mood disorder (such as any of those described herein), by administering to a mammal (including a human) a compound of any of the formulas described herein or a pharmaceutically acceptable salt, tautomer or in vzvo-hydrolysable precursors and a cognitive and/or memory enhancing agent.
- the present invention provides a method of treating or preventing an anxiety disorder, cognitive disorder, or mood disorder (such as any of those described herein), by administering to a mammal (including a human) a compound of any of the formulas described herein or a pharmaceutically acceptable salt, tautomer or in vzvo-hydrolysable precursors thereof wherein constituent members are provided herein, and a choline esterase inhibitor or anti-inflammatory agent.
- the present invention provides a method of treating or preventing an anxiety disorder, cognitive disorder, or mood disorder (such as any of those described herein), by administering to a mammal (including human) a compound of the present invention, and an atypical antipsychotic agent.
- Atypical antipsychotic agents include, but not limited to, Olanzapine (marketed as Zyprexa), Aripiprazole (marketed as Abilify), Risperidone (marketed as Risperdal), Quetiapine (marketed as Seroquel), Clozapine (marketed as Clozaril), Ziprasidone (marketed as Geodon) and Olanzapine/Fluoxetine (marketed as Symbyax).
- the mammal or human being treated with a compound of the present invention has been diagnosed with a particular disease or disorder, such as those described herein. In these cases, the mammal or human being treated is in need of such treatment. Diagnosis, however, need not be previously performed.
- the present invention also includes pharmaceutical compositions which contain, as the active ingredient, one or more of the compounds of the invention herein together with at least one pharmaceutically acceptable carrier, diluent or excipent.
- compounds of the present invention When used for pharmaceutical compositions, medicaments, manufacture of a medicament, or treating or preventing an anxiety disorder, cognitive disorder, or mood disorder (such as any of those described herein), compounds of the present invention include the compounds of any of the formulas described herein, and pharmaceutically acceptable salts, tautomers and in vzVo-hydrolysable precursors thereof. Compounds of the present invention further include hydrates and solvates.
- substitution means that substitution is optional and therefore it is possible for the designated atom or moiety to be unsubstituted.
- substitution means that any number of hydrogens on the designated atom or moiety is replaced with a selection from the indicated group, provided that the normal valency of the designated atom or moiety is not exceeded, and that the substitution results in a stable compound.
- a methyl group i.e., CH3
- 3 hydrogens on the carbon atom can be replaced.
- a variety of compounds in the present invention may exist in particular stereoisomeric forms.
- the present invention takes into account all such compounds, including cis- and trans isomers, R- and S- enantiomers, diastereomers, (D)-isomers, (L)-isomers, the racemic mixtures thereof, and other mixtures thereof, as being covered within the scope of this invention.
- Additional asymmetric carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this invention.
- the compounds herein described may have asymmetric centers. Compounds of the present invention containing an asymmetrically substituted atom may be isolated in optically active or racemic forms.
- optically active forms such as by resolution of racemic forms or by synthesis from optically active starting materials.
- separation of the racemic material can be achieved by methods known in the art.
- Cis and trans isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms. All chiral, diastereomeric, racemic forms and all stereoisomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated.
- the compounds of the invention may form isolable atropisomers in certain solvents (e.g. supercritical CO 2 containing 25-35% methanol) at room temperature.
- the atropisomers of the compounds may be isolated using chiral LC. All atropisomers of a structure are intended, unless the specific atropisomer is specifically indicated.
- C m-n or "C m-n group” used alone or as a prefix, refers to any group having m to n carbon atoms.
- alkyl used alone or as a suffix or prefix, refers to a saturated monovalent straight or branched chain hydrocarbon radical comprising 1 to about 12 carbon atoms.
- alkyls include, but are not limited to, Ci- ⁇ alkyl groups, such as methyl, ethyl, propyl, isopropyl, 2-methyl-l -propyl, 2-methyl-2-propyl, 2-methyl-l-butyl, 3-methyl-l -butyl, 2-methyl-3-butyl, 2,2-dimethyl-l -propyl, 2-methyl- 1-pentyl, 3 -methyl- 1-pentyl, 4-methyl-l-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4- methyl-2-pentyl, 2,2-dimethyl-l -butyl, 3, 3 -dimethyl- 1 -butyl, 2-ethyl-l -butyl, butyl,
- alkylene used alone or as suffix or prefix, refers to divalent straight or branched chain hydrocarbon radicals comprising 1 to about 12 carbon atoms, which serves to links two structures together.
- alkenyl refers to an alkyl group having one or more double carbon-carbon bonds.
- Example alkenyl groups include ethenyl, propenyl, cyclohexenyl, and the like.
- alkenylenyl refers to a divalent linking alkenyl group.
- alkynyl refers to an alkyl group having one or more triple carbon-carbon bonds.
- Example alkynyl groups include ethynyl, propynyl, and the like.
- alkynylenyl refers to a divalent linking alkynyl group.
- aromatic refers to hydrocarbyl groups having one or more polyunsaturated carbon rings having aromatic characters, (e.g., 4n + 2 delocalized electrons) and comprising up to about 14 carbon atoms.
- aryl refers to an aromatic ring structure made up of from 5 to 14 carbon atoms. Ring structures containing 5, 6, 7 and 8 carbon atoms would be single-ring aromatic groups, for example, phenyl. Ring structures containing 8, 9, 10, 11, 12, 13, or 14 would be a poly cyclic moiety in which at least one carbon is common to any two adjoining rings therein (for example, the rings are "fused rings"), for example naphthyl.
- the aromatic ring can be substituted at one or more ring positions with such substituents as described above.
- aryl also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings (the rings are "fused rings") wherein at least one of the rings is aromatic, for example, the other cyclic rings can be cycloalkyls, cycloalkenyls or cycloalkynyls.
- ortho, meta and para apply to 1,2-, 1,3- and 1,4-disubstituted benzenes, respectively.
- the names 1,2-dimethylbenzene and ortho-dimethylbenzene are synonymous.
- cycloalkyl refers to a saturated monovalent ring-containing hydrocarbon radical comprising at least 3 up to about 12 carbon atoms.
- cycloalkyls include, but are not limited to, C3 -7 cycloalkyl groups, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cyclohepryl, and saturated cyclic and bicyclic terpenes.
- a cycloalkyl can be unsubstituted or substituted by one or two suitable substituents.
- the cycloalkyl is a monocyclic ring or bicyclic ring.
- cycloalkenyl refers to ring-containing hydrocarbyl groups having at least one carbon-carbon double bond in the ring, and having from 3 to 12 carbons atoms.
- halo or “halogen” refers to fluoro, chloro, bromo, and iodo.
- Counterrion is used to represent a small, negatively or positively charged species such as chloride (Cl “ ), bromide (Br “ ), hydroxide (OH “ ), acetate (CH 3 COO “ ) , sulfate (SO 4 2” ), tosylate (CHa-phenyl-SCV), benezensulfonate (phenyl-SCV), sodium ion (Na + ), potassium (K + ), ammonium (NH 4 + ), and the like.
- heterocycle used alone or as a suffix or prefix, refers to a ring- containing structure or molecule having one or more multivalent heteroatoms, independently selected from N, O, P and S, as a part of the ring structure and including at least 3 and up to about 20 atoms in the ring(s).
- Heterocycle may be saturated or unsaturated, containing one or more double bonds, and heterocycle may contain more than one ring.
- the rings may be fused or unfused.
- Fused rings generally refer to at least two rings share two atoms therebetween.
- Heterocycle may have aromatic character or may not have aromatic character.
- heteromatic used alone or as a suffix or prefix, refers to a ring- containing structure or molecule having one or more multivalent heteroatoms, independently selected from N, O, P and S, as a part of the ring structure and including at least 3 and up to about 20 atoms in the ring(s), wherein the ring-containing structure or molecule has an aromatic character (e.g., 4n + 2 delocalized electrons).
- heterocyclic group refers to a radical derived from a heterocycle by removing one or more hydrogens therefrom.
- heterocyclyl used alone or as a suffix or prefix, refers a monovalent radical derived from a heterocycle by removing one hydrogen therefrom.
- heterocyclylene used alone or as a suffix or prefix, refers to a divalent radical derived from a heterocycle by removing two hydrogens therefrom, which serves to links two structures together.
- heteroaryl used alone or as a suffix or prefix, refers to a heterocyclyl having aromatic character.
- heterocycloalkyl used alone or as a suffix or prefix, refers to a monocyclic or polycyclic ring comprising carbon and hydrogen atoms and at least one heteroatom, preferably, 1 to 3 heteroatoms selected from nitrogen, oxygen, and sulfur, and having no unsaturation.
- heterocycloalkyl groups include pyrrolidinyl, pyrrolidino, piperidinyl, piperidino, piperazinyl, piperazino, morpholinyl, morpholino, thiomorpholinyl, thiomorpholino, and pyranyl.
- a heterocycloalkyl group can be unsubstituted or substituted with one or two suitable substituents.
- the heterocycloalkyl group is a monocyclic or bicyclic ring, more preferably, a monocyclic ring, wherein the ring comprises from 3 to 6 carbon atoms and form 1 to 3 heteroatoms, referred to herein as Cs-eheterocycloalkyl.
- heteroarylene used alone or as a suffix or prefix, refers to a heterocyclylene having aromatic character.
- heterocycloalkylene used alone or as a suffix or prefix, refers to a heterocyclylene that does not have aromatic character.
- suffix or prefix refers to a heterocyclylene that does not have aromatic character.
- ix-membered used as prefix refers to a group having a ring that contains six ring atoms.
- five-membered used as prefix refers to a group having a ring that contains five ring atoms.
- a five-membered ring heteroaryl is a heteroaryl with a ring having five ring atoms wherein 1, 2 or 3 ring atoms are independently selected from N, O and S.
- Exemplary five-membered ring heteroaryls are thienyl, furyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl, tetrazolyl, 1,2,3- thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4-thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-triazolyl, 1,3,4-thiadiazolyl, and 1,3,4- oxadiazolyl.
- a six-membered ring heteroaryl is a heteroaryl with a ring having six ring atoms wherein 1, 2 or 3 ring atoms are independently selected from N, O and S.
- Exemplary six-membered ring heteroaryls are pyridyl, pyrazinyl, pyrimidinyl, triazinyl and pyridazinyl.
- heterocyclyls include, but are not limited to, lH-indazole, 2-pyrrolidonyl, 2H, 6H- 1, 5,2-dithiazinyl, 2H-pyrrolyl, 3H-indolyl, 4-piperidonyl, 4aH-carbazole, 4H-quinolizinyl, 6H-1, 2,5-thiadiazinyl, acridinyl, azabicyclo, azetidine, azepane, aziridine, azocinyl, benzimidazolyl, benzodioxol, benzofuranyl, benzotbiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benzotriazolyl, benzote
- alkoxy or "alkyloxy” represents an alkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge.
- alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, t-butoxy, n-pentoxy, isopentoxy, cyclopropylmethoxy, allyloxy and propargyloxy.
- alkylthio or “thioalkoxy” represent an alkyl group as defined above with the indicated number of carbon atoms attached through a sulphur bridge.
- Halogenated used as a prefix of a group, means one or more hydrogens on the group is replaced with one or more halogens.
- X is a bond or represents an oxygen or sulfur
- R represents a hydrogen, an alkyl, an alkenyl, -(CH2) m -R" or a pharmaceutically acceptable salt
- R' represents a hydrogen, an alkyl, an alkenyl or -(CH 2 ) m -R", where m is an integer less than or equal to ten
- R" is alkyl, cycloalkyl, alkenyl, aryl, or heteroaryl.
- X is an oxygen, and R is as defined above, the moiety is referred to herein as a carboxyl group, and particularly when R' is a hydrogen, the fo ⁇ nula represents a "carboxylic acid.”
- R' is a hydrogen
- the formula represents a "formate.” In general, where the oxygen atom of the above formula is replaced by sulfur, the formula represents a "thiolcarbonyl" group.
- R is represented by but not limited to hydrogen, alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, aralkyl, or heteroaralkyl.
- protecting group means temporary substituents which protect a potentially reactive functional group from undesired chemical transformations.
- protecting groups examples include esters of carboxylic acids, silyl ethers of alcohols, and acetals and ketals of aldehydes and ketones respectively.
- the field of protecting group chemistry has been reviewed (Greene, T.W.; Wuts, P.G.M. Protective Groups in Organic Synthesis, 3 rd ed.; Wiley: New York, 1999).
- pharmaceutically acceptable is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- pharmaceutically acceptable salts refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof (i.e., also include counterions).
- pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
- the pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
- such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, phosphoric, and the like; and the salts prepared from organic acids such as lactic, maleic, citric, benzoic, methanesulfonic, and the like.
- the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound that contains a basic or acidic moiety by conventional chemical methods.
- such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile can be used.
- in vivo hydrolysable precursors means an in vivo hydroysable (or cleavable) ester of a compound of any of the formulas described herein that contains a carboxy or a hydroxy group.
- amino acid esters Ci_6 alkoxymethyl esters like methoxymethyl; Ci- ⁇ alkanoyloxymethyl esters like pivaloyloxymethyl; C3.8cycloalkoxycarbonyloxy Q ⁇ alkyl esters like 1-cyclohexylcarbonyloxyethyl, acetoxymethoxy, or phosphoramidic cyclic esters.
- tautomer means other structural isomers that exist in equilibrium resulting from the migration of a hydrogen atom. For example, keto-enol tautomerism where the resulting compound has the properties of both a ketone and an unsaturated alcohol.
- stable compound and “stable structure” are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
- the present invention further includes isotopically-labeled compounds of the invention.
- An “isotopically” or “radio-labeled” compound is a compound of the invention where one or more atoms are replaced or substituted by an atom having an atomic mass or mass number different from the atomic mass or mass number typically found in nature (i.e., naturally occurring).
- Suitable radionuclides that may be incorporated in compounds of the present invention include but are not limited to 2 H (also written as D for deuterium), 3 H (also written as T for tritium), 11 C, 13 C, 14 C, 13 N, 15 N, 15 0, 17 0, 18 O, 18 F, 35 S, 36 Cl, 82 Br, 75 Br, 76 Br, 77 Br, 123 1, 124 1, 125 I and 131 I.
- the radionuclide that is incorporated in the instant radio-labeled compounds will depend on the specific application of that radio-labeled compound. For example, for in vitro receptor labeling and competition assays, compounds that incorporate 3 H, 14 C, 82 Br, 125 1 , 131 1, 35 S or will generally be most useful. For radio-imaging applications 11 C, 18 F, 125 1, 123 1, 124 1, 131 1, 75 Br, 76 Br or 77 Br will generally be most useful.
- a "radio-labeled compound” is a compound that has incorporated at least one radionuclide.
- the radionuclide is selected from the group consisting of 3 H, 14 C, 125 1 , 35 S and 82 Br.
- the antidementia treatment defined herein may be applied as a sole therapy or may involve, in addition to the compound of the invention, conventional chemotherapy. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of the treatment. Such combination products employ the compounds of this invention.
- Compounds of the present invention may be administered orally, parenteral, buccal, vaginal, rectal, inhalation, insufflation, sublingually, intramuscularly, subcutaneously, topically, intranasally, intraperitoneally, intrathoracially, intravenously, epidurally, intrathecally, intracerebroventricularly and by injection into the joints.
- the dosage will depend on the route of administration, the severity of the disease, age and weight of the patient and other factors normally considered by the attending physician, when determining the individual regimen and dosage level as the most appropriate for a particular patient.
- An effective amount of a compound of the present invention for use in therapy of dementia is an amount sufficient to symptomatically relieve in a warm-blooded animal, particularly a human the symptoms of dementia, to slow the progression of dementia, or to reduce in patients with symptoms of dementia the risk of getting worse.
- inert, pharmaceutically acceptable carriers can be either solid or liquid.
- Solid form preparations include powders, tablets, dispersible granules, capsules, cachets, and suppositories.
- a solid carrier can be one or more substances, which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; it can also be an encapsulating material.
- the carrier is a finely divided solid, which is in a mixture with the finely divided active component.
- the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
- a low-melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture is then poured into convenient sized molds and allowed to cool and solidify.
- Suitable carriers include magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, txagacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter, and the like.
- Some of the compounds of the present invention are capable of forming salts with various inorganic and organic acids and bases and such salts are also within the scope of this invention.
- such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, phosphoric, and the like; and the salts prepared from organic acids such as lactic, maleic, citric, benzoic, methanesulfonic, trifluoroacetate and the like.
- the present invention provides a compound of any of the formulas described herein or a pharmaceutically acceptable salt thereof for the therapeutic treatment (including prophylactic treatment) of mammals including humans, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.
- the pharmaceutical composition of this invention may also contain, or be co-administered (simultaneously or sequentially) with, one or more pharmacological agents of value in treating one or more disease conditions referred to herein.
- composition is intended to include the formulation of the active component or a pharmaceutically acceptable salt with a pharmaceutically acceptable carrier.
- this invention may be formulated by means known in the art into the form of, for example, tablets, capsules, aqueous or oily solutions, suspensions, emulsions, creams, ointments, gels, nasal sprays, suppositories, finely divided powders or aerosols or nebulisers for inhalation, and for parenteral use (including intravenous, intramuscular or infusion) sterile aqueous or oily solutions or suspensions or sterile emulsions.
- Liquid form compositions include solutions, suspensions, and emulsions.
- Sterile water or water-propylene glycol solutions of the active compounds may be mentioned as an example of liquid preparations suitable for parenteral administration.
- Liquid compositions can also be formulated in solution in aqueous polyethylene glycol solution.
- Aqueous solutions for oral administration can be prepared by dissolving the active component in water and adding suitable colorants, flavoring agents, stabilizers, and thickening agents as desired.
- Aqueous suspensions for oral use can be made by dispersing the finely divided active component in water together with a viscous material such as natural synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose, and other suspending agents known to the pharmaceutical formulation art.
- the pharmaceutical compositions can be in unit dosage form.
- compositions are divided into unit doses containing appropriate quantities of the active component.
- the unit dosage form can be a packaged preparation, the package containing discrete quantities of the preparations, for example, packeted tablets, capsules, and powders in vials or ampoules.
- the unit dosage form can also be a capsule, cachet, or tablet itself, or it can be the appropriate number of any of these packaged forms.
- Compositions may be formulated for any suitable route and means of administration.
- Pharmaceutically acceptable carriers or diluents include those used in formulations suitable for oral, rectal, nasal, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural) administration.
- the formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy.
- conventional non-toxic solid carriers include, for example, pharmaceutical grades of mannitol, lactose, cellulose, cellulose derivatives, starch, magnesium stearate, sodium saccharin, talcum, glucose, sucrose, magnesium carbonate, and the like may be used.
- Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc, an active compound as defined above and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline aqueous dextrose, glycerol, ethanol, and the like, to thereby form a solution or suspension.
- the pharmaceutical composition to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, sorbitan monolaurate, triethanolamine oleate, etc.
- auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, sorbitan monolaurate, triethanolamine oleate, etc.
- the compounds of the invention may be derivatised in various ways.
- derivatives of the compounds includes salts (e.g. pharmaceutically acceptable salts), any complexes (e.g. inclusion complexes or clathrates with compounds such as cyclodextrins, or coordination complexes with metal ions such as Mn 2+ and Zn 2+ ), esters such as in vivo hydrolysable esters, free acids or bases, polymorphic forms of the compounds, solvates (e.g. hydrates), prodrugs or lipids, coupling partners and protecting groups.
- prodrugs is meant for example any compound that is converted in vivo into a biologically active compound.
- Salts of the compounds of the invention are preferably physiologically well tolerated and non toxic. Many examples of salts are known to those skilled in the art. All such salts are within the scope of this invention, and references to compounds include the salt forms of the compounds.
- Compounds having acidic groups can form salts with alkaline or alkaline earth metals such as Na, K, Mg and Ca, and with organic amines such as triethylamine and Tris (2-hydroxyethyl)amine. Salts can be formed between compounds with basic groups, e.g. amines, with inorganic acids such as hydrochloric acid, phosphoric acid or sulfuric acid, or organic acids such as acetic acid, citric acid, benzoic acid, fumaric acid, or tartaric acid. Compounds having both acidic and basic groups can form internal salts. Acid addition salts may be formed with a wide variety of acids, both inorganic and organic.
- acid addition salts include salts formed with hydrochloric, hydriodic, phosphoric, nitric, sulphuric, citric, lactic, succinic, maleic, malic, isethionic, fumaric, benzenesulphonic, toluenesulphonic, methanesulphonic, ethanesulphonic, naphthalenesulphonic, valeric, acetic, propanoic, butanoic, malonic, glucuronic and lactobionic acids.
- a salt may be formed with a suitable cation.
- suitable inorganic cations include, but are not limited to, alkali metal ions such as Na + and K + , alkaline earth cations such as Ca 2+ and Mg 2+ , and other cations such as Al 3+ .
- suitable organic cations include, but are not limited to, ammonium ion (i.e., NH 4 + ) and substituted ammonium ions (e.g., NH 3 R + , NH 2 R 2 + , NHR 3 + , NR 4 + ).
- Examples of some suitable substituted ammonium ions are those derived from: ethylamine, diethylamine, dicyclohexylamine, triethylamine, butylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, benzylamine, phenylbenzylamine, choline, meglumine, and tromethamine, as well as amino acids, such as lysine and arginine.
- An example of a common quaternary ammonium ion is N(CH 3 ) 4 + .
- the compounds may contain an amine function, these may form quaternary ammonium salts, for example by reaction with an alkylating agent according to methods well known to the skilled person. Such quaternary ammonium compounds are within the scope of the invention.
- N-oxides may also form N-oxides.
- a reference herein to a compound that contains an amine function also includes the N-oxide.
- one or more than one nitrogen atom may be oxidised to form an N-oxide.
- Particular examples of N-oxides are the N-oxides of a tertiary amine or a nitrogen atom of a nitrogen-containing heterocycle.
- N-Oxides can be formed by treatment of the corresponding amine with an oxidizing agent such as hydrogen peroxide or a per-acid (e.g. a peroxycarboxylic acid), see for example Advanced Organic Chemistry, by Jerry March, 4 th Edition, Wiley
- N-oxides can be made by the procedure of L. W. Deady (Syn. Comm. ⁇ 911, 7, 509-514) in which the amine compound is reacted with wz-chloroperoxybenzoic acid (MCPBA), for example, in an inert solvent such as dichloromethane.
- MCPBA wz-chloroperoxybenzoic acid
- Esters can be formed between hydroxyl or carboxylic acid groups present in the compound and an appropriate carboxylic acid or alcohol reaction partner, using techniques well known in the art.
- R is an ester substituent, for example, a Ci 7 alkyl group, a C 320 heterocyclyl group, or a C520 aryl group, preferably a Cn alkyl group.
- R is an acyloxy substituent, for example, a Ci 7 alkyl group, a C3 2 0 heterocyclyl group, or a C520 aryl group, preferably a Cn alkyl group.
- prodrugs which are prodrugs of the compounds are convertible in vivo or in vitro into one of the parent compounds. Typically, at least one of the biological activities of compound will be reduced in the prodrug form of the compound, and can be activated by conversion of the prodrug to release the compound or a metabolite of it.
- metabolically labile esters include those of the formula
- R is: Q 7 alkyl (e.g., Me, Et, -nPr, -iPr, -nBu, -sBu, -iBu, tBu); Ci ⁇ aminoalkyl (e.g., aminoethyl; 2-(N,N-diethylamino)ethyl; 2(4mo ⁇ holino)ethyl); and acyloxy-C ⁇ alkyl (e.g., acyloxymethyl; acyloxyethyl; pivaloyloxymethyl; acetoxymethyl;
- Q 7 alkyl e.g., Me, Et, -nPr, -iPr, -nBu, -sBu, -iBu, tBu
- Ci ⁇ aminoalkyl e.g., aminoethyl; 2-(N,N-diethylamino)ethyl; 2(4mo ⁇ holino)ethyl
- prodrugs are activated enzymatically to yield the active compound, or a compound which, upon further chemical reaction, yields the active compound (for example, as in ADEPT, GDEPT, LIDEPT, etc.).
- the prodrug may be a sugar derivative or other glycoside conjugate, or may be an amino acid ester derivative.
- Coupled derivatives include coupling partners of the compounds in which the compounds is linked to a coupling partner, e.g. by being chemically coupled to the compound or physically associated with it.
- Examples of coupling partners include a label or reporter molecule, a supporting substrate, a carrier or transport molecule, an effector, a drug, an antibody or an inhibitor.
- Coupling partners can be covalently linked to compounds of the invention via an appropriate functional group on the compound such as a hydroxyl group, a carboxyl group or an amino group.
- Other derivatives include formulating the compounds with liposomes.
- the quantity of the compound to be administered will vary for the patient being treated and will vary from about 100 ng/kg of body weight to 100 mg/kg of body weight per day and preferably will be from 10 pg/kg to 10 mg/kg per day.
- dosages can be readily ascertained by those skilled in the art from this disclosure and the knowledge in the art.
- the skilled artisan can readily determine the amount of compound and optional additives, vehicles, and/or carrier in compositions and to be administered in methods of the invention.
- the compounds described herein are central nervous system depressants and may be used as tranquilizers or ataractic agents for the relief of anxiety and tension states, for example, in mice, cats, rats, dogs and other mammalian species such as humans, in the same manner as chlordiazepoxide.
- a compound or mixture of compounds of any of the formulas described herein, or non-toxic physiologically acceptable salts, such as acid addition salts thereof may be administered orally or parenterally in a conventional dosage form such as tablet, pill, capsule, injectable or the like.
- the dosage in mg/kg of body weight of compounds of the present invention in mammals will vary according to the size of the animal and particularly with respect to the brain/body weight ratio.
- a minimum effective dosage for a compound of formula (I) will be at least about 0.1 mg/kg of body weight per day for mammals with a maximum dosage for a small mammal such as a dog, of about 100 mg/kg per day.
- a dosage of about 0.1 to 12 mg/kg per day will be effective, for example, about 5 to 600 mg/day for an average man.
- the dosage can be given once daily or in divided doses, for example, 2 to 4 doses daily, and such dosage will depend on the duration and maximum level of activity of a particular compound.
- the dose may be conventionally formulated in an oral or parenteral dosage form by compounding about 5 to 250 mg per unit of dosage of conventional vehicle, excipient, binder, preservative, stabilizer, flavor or the like as called for by accepted pharmaceutical practice, for example, as described in U.S. Pat. No. 3,755,340.
- the compounds of this invention may be used in pharmaceutical compositions comprising a compound of any of the formulas described herein or can be contained in the same formulation with or co-administered with one or more known drugs.
- Some example tests that can be conducted to demonstrate the anxiolytic activity of the present compounds include binding tests of GABAA receptors.
- the binding test was directed to a subtype of GABAA receptors, such as GABAAl receptors (i.e., those containing the ⁇ i subunit), GABAA2 receptors (i.e., those containing the ⁇ 2 subunit), GABAA3 receptors (i.e., those containing the 01 3 subunit) and GABAA5 receptors (i.e., those containing the 0C5 subunit).
- GABAAl receptors i.e., those containing the ⁇ i subunit
- GABAA2 receptors i.e., those containing the ⁇ 2 subunit
- GABAA3 receptors i.e., those containing the 01 3 subunit
- GABAA5 receptors i.e., those containing the 0C5 subunit
- anxiolytics lack GABAA receptor subtype-selectivity.
- the subtype-selective GABAA receptor modulators may offer more advantages. For example, a growing body of work suggests that desirable anxiolytic activity is driven primarily by interactions with GABAA receptors containing the ⁇ 2 subunit. Sedation, a side-effect common to all marketed benzodiazepines, is believed to be mediated by interactions at GABAARs containing the ⁇ 1 subunit. To develop anxiolytics with minimal liabilities due to interactions with other subunits, an electrophysiological assay was developed to screen modulatory effects of various compounds on different GABA subunit combinations heterologously expressed in Xenopus oocytes.
- GABAA receptors were heterologously expressed in Xenopus oocytes by injecting cRNA corresponding to human 04, 01 2 , 013, 0, 5 , ⁇ 2 , ⁇ 3 and 7 2 subunits of the GABAA receptor genes.
- the specific subunit combinations (subtypes) were as follows: o. ⁇ 2j2, 0 ⁇ 372, «3 ⁇ 3 ⁇ 2, and ⁇ 5 ⁇ 3 ⁇ 2.
- the EClO of GABA was approximated for each cell. Stability of GABA-mediated (EClO) current was established. Modulatory effect of test compound was determined and compared across subtypes.
- the assay developed has reproducibility which allows discrimination of modulatory activity down to minimal effect of about 25% potentiation (prior to normalization to standard) for all four subtypes.
- the assay can characterize modulatory effects and determine subtype selectivity of test compounds on major subtypes of GABAA receptors.
- a compound can selectively bind to one subtype of GABAA receptor (by showing about 25% or more of binding comparing to another subtype of GABAA receptor).
- Anxiolytic activity is indicated in the GABAA binding test by a displacement of the flunitrazepam such as is exhibited by benzodiazepines or by enhancement of the binding such as is shown by cartazolate and tracazolate.
- the compounds of the invention can bind to GABAA rrreeeceptors. In some embodiments, the compounds of the invention can bind to GABAA receptors by displacement of benzodiazepines. Accordingly, the compounds of the invention can be used to modulate activities of GABAA receptors.
- the compounds of the invention can selectively bind to a subtype of GABAA receptors, such as such as GABAAl receptors (i.e., those containing the ⁇ i subunit), GABAA2 receptors (i.e., those containing the ci 2 subunit), GABAA3 receptors (i.e., those containing the 013 subunit) or GABAA5 receptors (i.e., those containing the 01 5 subunit).
- the compounds of the invention can selectively bind to a subtype of GABAA receptors by displacement of benzodiazepines. Accordingly, the compounds of the invention can be used to selectively modulate activities of a subtype of GABAA receptors, such as GABAAl receptors, GABAA2 receptors, GABAA3 receptors or GABAA5 receptors.
- certain compounds of the invention are GABAAl receptor antagonists and GABAA2 receptor agonists.
- the compounds of the invention can be used to modulate activities of GABAA receptors, or to selectively modulate activities of a subtype of GABAA receptors, the compounds of the invention are envisioned to be useful for treating or preventing diseases mediated by GABAA receptors or a subtype of GABAA receptors.
- Such disease include, but is not limited to, stroke, head trauma, epilepsy, pain, migraine, mood disorders, anxiety, post traumatic stress disorder, obsessive compulsive disorders, schizophrenia, seizures, convulsions, tinnitus, neurodegenerative disorders including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's Chorea, Parkinson's disease, depression, bipolar disorders, mania, trigeminal and other neuralgia, neuropathic pain, hypertension, cerebral ischemia, cardiac arrhythmia, myotonia, substance abuse, myoclonus, essential tremor, dyskinesia and other movement disorders, neonatal cerebral hemorrhage, spasticity, cognitive disorder, and sleeping disorder.
- melatonin receptor agonists are effective in treating depression.
- the compounds of the invention can selectively modulate activities of a subtype of melatonin receptors, melatonin receptor 1 (MT-I).
- certain compounds of the invention are MTl agonists.
- the compounds of the invention may be effective in treating depression disorders such as major depressive disorder, dysthymic disorder, bipolar depression and/or bipolar mania, bipolar I with or without manic, depressive or mixed episodes, bipolar II, cyclothymic disorder, mood disorder due to a general medical condition, manic episodes associated with bipolar disorder, or mixed episodes associated with bipolar disorder.
- an effective amount of one or more compounds of the invention is administered to a patient with such a need.
- certain compounds of the present invention may be effective in treating insomnia.
- a compound of formula I or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof, or a pharmaceutical composition or formulation comprising a compound of formula I may be administered concurrently, simultaneously, sequentially or separately with one or more pharmaceutically active compound(s) selected from the following:
- antidepressants such as amitriptyline, amoxapine, bupropion, citalopram, clomipramine, desipramine, doxepin duloxetine, elzasonan, escitalopram, fluvoxamine, fluoxetine, gepirone, imipramine, ipsapirone, maprotiline, nortriptyline, nefazodone, paroxetine, phenelzine, protriptyline, reboxetine, robalzotan, sertraline, sibutramine, thionisoxetine, tranylcypromaine, trazodone, trimipramine, venlafaxine and equivalents and pharmaceutically active isomer(s) and metabolite(s) thereof;
- atypical antipsychotics including for example quetiapine and pharmaceutically active isomer(s) and metabolite(s) thereof; amisulpride, aripiprazole, asenapine, benzisoxidil, bifeprunox, carbamazepine, clozapine, chlorpromazine, debenzapine, divalproex, duloxetine, eszopiclone, haloperidol, iloperidone, lamotrigine, lithium, loxapine, mesoridazine, olanzapine, paliperidone, perlapine, perphenazine, phenothiazine, phenylbutlypiperidine, pimozide, prochlorperazine, risperidone, quetiapine, sertindole, sulpiride, suproclone, suriclone, thioridazine, trifluoperazine,
- antipsychotics including for example amisulpride, aripiprazole, asenapine, benzisoxidil, bifeprunox, carbamazepine, clozapine, chlorpromazine, debenzapine, divalproex, duloxetine, eszopiclone, haloperidol, iloperidone, lamotrigine, loxapine, mesoridazine, olanzapine, paliperidone, perlapine, perphenazine, phenothiazine, phenylbutlypiperidine, pimozide, prochlorperazine, risperidone, sertindole, sulpiride, suproclone, suriclone, thioridazine, trifluoperazine, trimetozine, valproate, valproic acid, zopiclone, zotepine, ziprasidone and
- anticonvulsants including, for example, carbamazepine, valproate, lamotrogine, gabapentin and equivalents and pharmaceutically active isomer(s) and metabolite(s) thereof;
- Alzheimer's therapies including, for example, donepezil, memantine, tacrine and equivalents and pharmaceutically active isomer(s) and metabolite(s) thereof;
- Parkinson's therapies including, for example, deprenyl, L-dopa, Requip, Mirapex, MAOB inhibitors such as selegine and rasagiline, comP inhibitors such as Tasmar, A-2 inhibitors, dopamine reuptake inhibitors, NMDA antagonists, Nicotine agonists, Dopamine agonists and inhibitors of neuronal nitric oxide synthase and equivalents and pharmaceutically active isomer(s) and metabolite(s) thereof;
- migraine therapies including, for example, almotriptan, amantadine, bromocriptine, butalbital, cabergoline, dichloralphenazone, eletriptan, frovatriptan, lisuride, naratriptan, pergolide, pramipexole, rizatriptan, ropinirole, sumatriptan, zolmitriptan, zomitriptan, and equivalents and pharmaceutically active isomer(s) and metabolite(s) thereof;
- (ix) stroke therapies including, for example, abciximab, activase, NXY-059, citicoline, crobenetine, desmoteplase,repinotan, traxoprodil and equivalents and pharmaceutically active isomer(s) and metabolite(s) thereof;
- (x) over active bladder urinary incontinence therapies including, for example, darafenacin, falvoxate, oxybutynin, propiverine, robalzotan, solifenacin, tolterodine and and equivalents and pharmaceutically active isomer(s) and metabolite(s) thereof;
- neuropathic pain therapies including, for example, gabapentin, lidoderm, pregablin and equivalents and pharmaceutically active isomer(s) and metabolite(s) thereof;
- nociceptive pain therapies such as celecoxib, etoricoxib, lumiracoxib, rofecoxib, valdecoxib, diclofenac, loxoprofen, naproxen, paracetamol and equivalents and pharmaceutically active isomer(s) and metabolite(s) thereof;
- insomnia therapies including, for example, allobarbital, alonimid, amobarbital, benzoctamine, butabarbital, capuride, chloral, cloperidone, clorethate, dexclamol, ethchlorvynol, etomidate, glutethimide, halazepam, hydroxyzine, mecloqualone, melatonin, mephobarbital, methaqualone, midaflur, nisobamate, pentobarbital, phenobarbital, propofol, roletamide, triclofos,secobarbital, zaleplon, Zolpidem and equivalents and pharmaceutically active isomer(s) and metabolite(s) thereof; and
- mood stabilizers including, for example, carbamazepine, divalproex, gabapentin, lamotrigine, lithium, olanzapine, quetiapine, valproate, valproic acid, verapamil, and equivalents and pharmaceutically active isomer(s) and metabolite(s) thereof.
- Such combinations employ the compounds of this invention within the dosage range described herein and the other pharmaceutically active compound or compounds within approved dosage ranges and/or the dosage described in the publication reference.
- the compounds of the present invention can be prepared in a number of ways well known to one skilled in the art of organic synthesis.
- the compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art.
- the starting materials and precursors used in the processes described herein were either commercially available or readily prepared by established organic synthesis methods. It is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule must be compatible with the reagents and reactions proposed. Such restrictions to the substituents which are compatible with the reaction conditions will be readily apparent to one skilled in the art and alternate methods should then be used.
- a compound 1-3 can be made by coupling of a halogenated cinnoline derivative 1-1 (wherein X 1 is halo such as bromo or iodo) to a boron compound 1-2 wherein R 6 can be an optionally substituted aryl or heteroaryl (suitable substituents can be alkyl, CN etc.), R 101 and R 102 are each, independently, hydrogen or Q -6 alkyl; or R 101 and R 102 , together with the two oxygen atoms to which they are attached and the boron atom to which the two oxygen atoms are attached, form a 4-7 membered heterocyclic ring whose ring-forming atoms comprises B, O and C atoms and which is optionally substituted by 1, 2, 3, or 4 C 1 ⁇ alkyl (i.e., a moiety shown as 1- 2B-R wherein tl is 0, 1, 2 or 3; t2 is 0, 1, 2, 3 or 4; and R 400 is each,
- the coupling reaction can be carried out in the presence of a suitable catalyst, such as a metal catalyst.
- a suitable catalyst such as a metal catalyst.
- metal catalysts include palladium catalyst, such as bis(triphenylphosphme)palladium(II) dichloride and tetrakis(triphenylphosphine)palladium(0).
- the coupling reaction can be carried out in the presence of a suitable base such as an inorganic base.
- a suitable inorganic base include cesium carbonate, sodium carbonate, and potassium phosphate.
- the coupling reaction can be carried out in a suitable solvent such as an organic solvent.
- suitable organic solvent include polar organic solvents, such as an ether and an alcohol.
- Suitable ethers include 1,2-dimethoxyethane and tetrahydrofuran.
- Suitable alcohols include ethanol, propanol and isopropanol.
- a suitable solvent also includes a mixture of two or more individual solvents. Suitable solvents can further contain water.
- the coupling reaction can be carried out at a suitable temperature to afford the compound 1-3. In some embodiments, the reaction mixture is heated to an elevated temperature (i.e., above the room temperature).
- the reaction mixture is heated to a temperature of about 40 0 C, about 50 0 C, about 60 0 C, about 70 0 C, about 80 0 C, about 90 0 C, about 100 0 C, about 110 0 C, about 120 0 C, about 130 0 C, about 140 0 C, about 150 0 C, about 160 0 C.
- the reaction progress can be monitored by conventional methods such as TLC or NMR.
- a compound 2-3 can be made by coupling of a halogenated cinnoline derivative 2-1 (wherein X 2 is halo such as bromo or iodo) to a tin compound 2-2 wherein R 6 can be an optionally substituted aryl or heteroaryl (suitable substituents can be alkyl, CN etc.) , R 201 , R 202 and R 203 are each, independently, Ci -6 alkyl.
- the coupling reaction can be carried out in the presence of a suitable catalyst, such as a metal catalyst.
- Some exemplary metal catalysts include palladium catalysts, such as bis(triphenylphosphine)palladium(II) dichloride and tetrakis(triphenylphosphine)palladium(0).
- the coupling reaction can be carried out in a suitable organic solvent.
- Some suitable organic solvent include polar organic solvent.
- Some suitable organic solvent include aprotic solvent.
- Some suitable organic solvent include polar aprotic organic solvent such as N,N-dimethylformamide.
- the coupling reaction can be carried out at a suitable temperature for a time sufficient to afford the compound 2-3. In some embodiments, the reaction mixture is heated to an elevated temperature (i.e., above the room temperature).
- the reaction mixture is heated to a temperature of about 40 0 C, about 50 0 C, about 60 °C, about 70 °C, about 80 0 C, about 90 0 C, about 100 0 C, about 110 0 C, about 120 0 C, about 130 0 C, about 140 0 C, about 150 0 C, about 160 0 C.
- the reaction progress can be monitored by conventional methods such as TLC or NMR.
- a compound 3-3 can be made by coupling of a trialkylstannyl-cinnoline derivative 3-1 (wherein R 301 , R 302 and R 303 are each, independently, Q- ⁇ alkyl) to a halogenated compound R 6 X 3 3-2 wherein X 3 is halo such as bromo or iodo, and wherein R 6 can be an optionally substituted aryl or heteroaryl (suitable substituents can be alkyl, CN etc.).
- the coupling reaction can be carried out in the presence of a suitable catalyst, such as a metal catalyst.
- Some exemplary metal catalysts include palladium catalysts, such as bis(triphenylphosphine)palladium(II) dichloride and tetrakis(triphenylphosphine)palladium(0).
- the coupling reaction can be carried out in a suitable organic solvent.
- Some suitable organic solvent include polar organic solvent.
- Some suitable organic solvents include aprotic organic solvent.
- Some suitable organic solvents include polar aprotic organic solvents such as N,N- dimethylformamide.
- the coupling reaction can be carried out at a suitable temperature for a time sufficient to afford the compound 2-3. In some embodiments, the reaction mixture is heated to an elevated temperature (i.e., above the room temperature).
- the reaction mixture is heated to a temperature of about 40 0 C, about 50 0 C, about 60 °C, about 70 0 C, about 80 0 C, about 90 0 C, about 100 0 C, about 110 0 C, about 120 0 C, about 130 0 C, about 140 0 C, about 150 0 C, about 160 0 C.
- the reaction progress can be monitored by conventional methods such as TLC or NMR.
- the trialkylstannyl-cinnoline derivative 3-1 can be made by coupling of a halogenated cinnoline derivative 3-0-1 (wherein X 4 is halo such as bromo or iodo) to a di-tin compound 3-0-2 (wherein R 301 , R 302 and R 303 are each, independently, Ci -6 alkyl) in the presence of a suitable catalyst, such as a palladium catalyst.
- a suitable catalyst such as a palladium catalyst.
- palladium catalysts include bis(triphenylphosphine)palladium(II) dichloride and tetrakis(triphenylphosphine)palladium(0).
- a CN group can be hydrolyzed to afford an amide group; a carboxylic acid can be converted to an amide; a carboxylic acid can be converted to a ester, which in turn can be reduced to an alcohol, which in turn can be further modified.
- an OH group can be converted into a better leaving group such as mesylate, which in turn is suitable for nucleophilic substitution, such as by CN.
- reacting refers to the bringing together of designated chemical reactants such that a chemical transformation takes place generating a compound different from any initially introduced into the system. Reacting can take place in the presence or absence of solvent.
- the mixture was stirred for 30 minutes and then filtered through a pad of celite.
- the celite was washed with ethyl acetate (3 x 150 mL).
- the filtrates were placed in a separatory funnel and the water layer was removed.
- the organic layer was concentrated under reduced pressure to a volume of ⁇ 200 mL, placed in a separatory funnel, diluted with ethyl acetate (400 mL), washed with brine, dried over sodium sulfate, filtered and concentrated to dryness.
- the crude product was taken up in ether (300 mL) and made acidic to pH 1 with 2M hydrochloric acid/ether (Aldrich).
- the phases of the filtrate were separated and the organic phase was transferred to a separatory funnel. Separation of the organic phase from the aqueous base as quickly as possible helped avoid undue hydrolysis of the propyl amide in the product.
- the solids remaining in the reaction flask were dissolved with 2:1 tetrahydrofuran:methanol (4 L) and then 10% methanol in chloroform (4 L). The layers were separated and the organic layer was washed with brine (500 mL), dried over magnesium sulfate, filtered, and concentrated under reduced pressure to a dark brown solid. The solid was slurried in diethyl ether, collected by filtration and dried.
- the mixture was diluted with chloroform (2L) until all of the precipitate was dissolved, washed twice with water, dried through magnesium sulfate, and concentrated to a volume of approximately 200 mL to leave a suspension of the product.
- the title compound as a light beige solid (11.06 g) was collected by filtration and washed with methylene chloride (50 mL x 2), methanol (50 mL) and hexane (100 mL x 2).
- the mother liquor was concentrated, and purified by flash chromatography using a gradient of ethyl acetate in hexane to give an additional 400 mg of the title compound as a beige solid.
- Solution B To a mechanically stirred solution of N-propyl-2-cyanoacetamide (15.69 g, 124.37 mmol) in ethanol (220 mL) was added a solution of sodium acetate (136.00 g, 1.66 moles) in water (600 mL), and chilled to between 0 ° C and -5 ° C.
- Solution A was poured into solution B, maintaining the internal temperature below 0 ° C. An orange precipitate was formed gradually after 10 minutes. The mixture was stirred below 0 ° C for another hour, and was then diluted with water (500 mL). After 30 minutes, the orange precipitate was collected by filtration, washed with water (100 mL x 3), and dried at 50 C under high vacuum to remove water. An orange solid (9.5Og) was obtained, which was the "E" isomer, and used for the next step without further purification.
- the aqueous layer contained a thick white precipitate and was quickly removed.
- the organic layer was washed with Rochelle's salt and brine, dried over magnesium sulfate, filtered and concentrated to give 2.6 g slightly crude product which was purified on silica gel using a gradient of 20 to 60% ethyl acetate in hexane. Recrystallization from ethyl acetate/hexanes (10 mL each, 0 0 C overnight) afforded the title compound as a white solid (650 mg, 26%).
- Zf ⁇ e intermediate compounds were prepared as follows: 2-[(2-Bromophenyl)-hydrazono]-N-methyl-2-cyanoacetamide
- PRECURSOR 12 4-Dimethoxy-5-(4, 4, 5, 5-tetramethyl-[l, 3,2]dioxaborolan-2-yl)-pyrimidine
- PRECURSOR 14 4-Amino-7-fluoro-8-iodo ⁇ N-cyclopropyl-cinnoline-3'Carboxamide
- Method A The cinnoline-halide, an optionally substituted arylboronic acid, heteroaryl boronic acid, or a boron compound 1-2B of Scheme 2 (typically 2-3 molar equivalents), cesium carbonate (2 molar equivalents) and bis(triphenylphosphine)palladium(II) dichloride (0.025 molar equivalents) were placed in a microwave reaction vessel and dissolved in 7:3:2 (v/v/v) 1,2-dimethoxyethane: water: ethanol (5 mL/mmol cinnoline-halide) at ambient temperature.
- reaction vessel was capped, the head-space purged with dry nitrogen and the stirred mixture was heated on a Biotage Optimizer (300W) microwave system maintaining a reaction temperature of 150 0 C for 30- 90 minutes, reaction pressures of 7 bar were typically observed.
- the reaction was then cooled to ambient temperature and extracted with ethyl acetate.
- the residue from the organic extracts was purified by flash chromatography on silica gel eluting with increasingly polar gradient of ethyl acetate in hexanes to afford the desired compound.
- Method B To a solution of the cinnoline-halide in 1,2-dimethoxyethane (10 mL/mmol cinnoline-halide) under nitrogen at ambient temperature was added tetrakis(triphenylphosphine)palladium (0) (0.05-0.15 molar equivalents). After stirring 10-20 min an arylboronic acid, heteroaryl boronic acid, or a boron compound 1-2B of Scheme 2 (1- 4 molar equivalents) was added followed by a solution of sodium carbonate (2.5 molar equivalents) in water (3 mL/mmol halide). The resulting mixture was heated at reflux for 2- 24h.
- Method C To a stirred solution of the cinnoline-halide in anhydrous N,N- dimethylformamide (2 mL/mmol cinnoline-halide) at ambient temperature was added an optionally substituted aryl- or heteroaryl- tin reagent (1.2 molar equivalents) and tetrakis(triphenylphosphine)palladium(0) (0.05 molar equivalents).
- the mixture was heated at 100 0 C for 8-48h.
- the reaction was then cooled to ambient temperature and extracted with ethyl acetate.
- the residue from the organic extracts was purified by flash chromatography on silica gel eluting with an increasingly polar gradient of ethyl acetate in hexanes to afford the desired compound.
- Method D The cinnoline-halide, an optionally substituted aryl- or heteroaryl- tin reagent (1.2-3 molar equivalents) and tetrakis(triphenylphosphine) palladium(O) (0.05- 0.10 molar equivalents) were placed in a microwave reaction vessel and dissolved in 2-4 mL of anhydrous N,N-dimethylformamide at ambient temperature. The reaction vessel was purged with nitrogen, capped, and the stirred mixture was heated on a Biotage Optimizer (300W) microwave system maintaining a reaction temperature of 150 0 C for 30 minutes.
- a Biotage Optimizer 300W
- Method E To a stirred solution of 8-trimethylstannyl-cinnoline derivative and tetrakis(triphenylphosphine) palladium(O) (0.05-0.10 molar equivalents) in anhydrous N,N-dimethylformamide at ambient temperature under nitrogen was added an optionally substituted aryl- or heteroaryl bromide(l .2-3 molar equivalents).
- Method G The cinnoline-halide, an optionally substituted arylboronic acid, heteroaryl boronic acid, or a boron compound 1-2B of Scheme 2 (4-5 molar equivalents), cesium carbonate (4-5 molar equivalents), 2-dicyclohexylphosphino-2',4',6'- trisopropylbiphenyl (0.24 molar equivalents) and tris(dibenzylidene- acetone)dipalladium(O) (0.06 molar equivalents) were placed in a 3-neck flask under N 2 and dissolved in 7:3:2 (v/v/v) THF: water: 2-propanol (5 mL/mmol cinnoline-halide) at ambient temperature.
- reaction vessel was fitted with a reflux condenser, capped, vacuum degassed (3x) backfilling with N 2 and placed in a preheated oil bath (7O 0 C) and heated for 20 hours. (* if reaction not complete more boronic acid and cesium carbonate in equal proportions were added with additional heating time). The reaction was then cooled to ambient temperature, decanted organic layer and concentrated under reduced pressure. Residue partitioned between ethyl acetate and 5% sodium bicarbonate (aq).
- Method H The cinnoline-halide, an optionally substituted arylboronic acid, heteroaryl boronic acid, or a boron compound 1-2B of Scheme 2 (3-5 molar equivalents), sodium carbonate (4-5 molar equivalents), [l,r-bis(diphenylphospino)-ferrocene] dichloropalladium(II) complex with dichloromethane (1:1) (0.075 molar equivalents) were placed in a 3-neck flask under N 2 and dissolved in 7:3:2 (v/v/v) THF: water: 2- propanol (5 mL/mmol cinnoline-halide) at ambient temperature.
- reaction vessel was fitted with a reflux condenser, under N 2 and placed in a preheated oil bath (85 0 C) and refluxed 2-20 hours (* if reaction not complete added more boronic acid with additional heating time).
- the reaction was then cooled to ambient temperature, reduced volume under reduced pressure, partitioned between ethyl acetate and water.
- the residue from the organic extracts was purified by flash chromatography on silica gel eluting with increasingly polar gradient of ethyl acetate in hexanes to afford the desired compound.
- Example 3 4-amino-7-methoxy-8-phenyl-N-propyl-cinnoline-3-carboxamide Using Method F, 4-ammo-7-methoxy-8-iodo-N-propyl-cinnoline-3- carboxamide (311 mg, 0.81 mmol) and phenylboronic acid (394mg, 3.24 mmol) were reacted (refluxed overnight) to afford the title compound (140 mg, 52 % yield) as a white solid.
- Example 5 4-amino-8-(2,4-dimethoxypyrimidin-5-yl)-N-propyl-cinnoIine-3- carboxamide Using method A, 4-amino-8-bromo-N-propyl-cinnoline-3-carboxamide (100 mg, 0.324 mmol) and (2,4-dimethoxypyrimidin-5-yl)boronic acid (125 mg, 0.68 mmol) were reacted to afford the title compound (33 mg, 28% yield) as a white solid.
- Example 13 4-amino-8-(3,5-dichlorophenyl)-N-propyl-cinnoline-3-carboxamide Using method B, 4-amino-8-bromo-N-propyl-cinnoline-3-carboxamide (100 mg, 0.33 mmol) and 3,5-dichlorophenyl boronic acid (252 mg, 1.32 mmol) were reacted to afford the title compound (65 mg, 52.5 % yield) as a pale-yellow solid.
- Example 14 4-amino-8-(3,5-difluorophenyl)-N-propyl-cinnoIine-3-carboxamide Using method B, 4-amino-8-bromo-N-propyl-cinnoline-3-carboxamide (200 mg, 0.65 mmol), 3,5-difluorophenyl boronic acid (300 mg, 1.90 mmol) and bis(triphenylphosphine) palladium(II) dichloride (24 mg, 0.034 mmol) were reacted to afford the title compound (200 mg, 89.7 % yield) as an off-white solid.
- the reaction mixture was diluted with methylene chloride, quenched with water, washed with 10% potassium carbonate aqueous solution twice, dried through magnesium sulfate, and the solvent was evaporated to dry.
- the residue was purified by flash chromatography using a gradient of methanol in methylene chloride to give a yellow liquid as 3-bromo-5-(azetidin-l-ylcarbonyl)-pyridine (846 mg, 70.9 % yield).
- Example 24 4-amino-8-(2,3-difluorophenyl)-N-propyl-cinnoline-3-carboxamide Using method A, 4-amino-8-bromo-N-propyl-cinnoline-3-carboxamide (100 mg, 0.33 mmol) and 2,3-difluorophenyl boronic acid (153 mg, 0.97 mmol) were reacted to afford the title compound (63 mg, 57.6 % yield) as a pale-yellow solid.
- Example 28 4-amino-8-(2-naphthyl)-N-propyl-cinnoline-3-carboxamide Using method A, 4-amino-8-bromo-N-propyl-cinnoline-3-carboxamide (100 mg, 0.33 mmol) and 2-naphthalene boronic acid (167 mg, 0.97 mmol) were reacted to afford the title compound (99 mg, 86.9 % yield) as a pale-yellow solid.
- Example 29 4-amino-8-(lH-indol-5-yl)-N-propyl-cinnoline-3-carboxamide Using method A, 4-amino-8-bromo-N-propyl-cinnoline-3-carboxamide (100 mg, 0.33 mmol) and 5-indolyl boronic acid (156 mg, 0.97 mmol) were reacted to afford the title compound (105 mg, 95.1 % yield) as a pale-yellow solid.
- Example 30 4-amino-8-(4-methoxy-3-pyridyl)-N-propyl-cinnoline-3-carboxamide To a stirred solution of 4-amino-8-iodo-N-propyl-cinnoline-3-carboxamide
- the reaction mixture was diluted with methylene chloride (300 mL), washed with water twice, dried through MgSO 4 , and then the solvent was evaporated. The residual was purified by flash chromatography using a gradient of methanol in methylene chloride to give a yellow solid. The yellow solid was crystallized from methylene chloride/methanol (2/1) to give an off-white needle crystal as the title compound (570 mg, 60.2 % yield).
- Example 38 4-amino-8-(2,5-dimethylphenyl)-N-propyl-cinnoline-3-carboxamide Using method B, 4-amino-8-iodo-N-propyl-cinnoline-3-carboxamide (250 mg, 0.702 mmol) and 2,5-dimethylphenylboronic acid (150 mg, 1.00 mmol) were reacted to afford the title compound (195 mg, 83 % yield) as a white solid.
- Example 39 3-[4-amino-3-(propylcarbamoyI)cinnolin-8-yl]benzoic acid hydrochloride Using method B, 4-amino-8-iodo-N-propyl-cinnoline-3-carboxamide (150 mg,
- Example 40 4-amino ⁇ 8-(3-azetidin-l-ylcarbonylphenyl)-N-propyI-cinnoline-3 ⁇ carboxamide
- S- ⁇ -amino-S- ⁇ ropylcarbamoy ⁇ cinnolm- ⁇ -ylJbenzoic acid 67 mg, 0.191 mmol
- azetidine 6.4 mg, 0.287 mmol
- N-methylmorpholine 29 mg, 0.287 mmol
- 1-hydroxybenzotriazole 44 mg, 0.287 mmol
- N-(3- dimethylaminopropyl)-N'-ethylcabodiimide hydrochloride 55 mg, 0.287 mmol.
- Example 43 4-amino-8-(3-methylsulfonylphenyl)-N-propyl-cinnoline-3- carboxamide Using method A, 4-amino-8-bromo-N-propyl-cinnoline-3-carboxamide (150 mg, 0.485 mmol) and 3-(methylsulfonyl)phenylboronic acid (200 mg, 1.000 mmol) were reacted to afford the title compound (155 mg, 83% yield) as a white solid.
- Example 48 4-amino-8-[2-chloro-5-(trifluoromethyl)phenyl]-N-propyl-cinnoline-3- carboxamide Using method A, 4-amino-8-bromo-N-propyl-cinnoline-3-carboxamide (150 mg, 0.485 mmol) and 2-chloro-5-(trifluoromethyl)phenylboronic acid (224 mg, 1.000 mmol) were reacted to afford the title compound (85mg, 44% yield) as a white solid.
- Example 49 4-amino-8-(2 ⁇ methoxy-5-methyl-phenyl)-N-propyl-cinnoline-3- carboxamide ; Using method A, 4-amino-8-bromo-N-propyl-cinnoline-3-carboxamide (150 mg, 0.485 mmol) and 2-methoxy-5-methyl-phenylboronic acid (166 mg, 1.000 mmol) were reacted to afford the title compound (141mg, 83% yield) as a white solid.
- Example 50 4-amino-N-propyl-8-[2-(trifluoromethyl)phenyl]-cinnoIxne-3- carboxamide Using method A, 4-amino-8-bromo-N-propyl-cinnoline-3-carboxamide (150 mg, 0.485 mmol) and 2-trifluroromethyl-phenylboronic acid (190 mg, 1.000 mmol) were reacted to afford the title compound (115 mg, 64% yield) as a white solid.
- Example 52 4-amino-N-propyl-8-(4-pyridyl)cinnoIine-3-carboxamide Using method C, 4-amino-8-iodo-N-propyl-cinnoline-3-carboxamide (178 mg,
- Example 55 4-amino-8-(l-methyl-lH-pyrazol-4-yl)-N-propyl-cinnoline-3- carboxamide Using method A, 4-amino-8-bromo-N-propyl-cinnoline-3-carboxamide (150 mg, 0.485 mmol) and l-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH- pyrazole (212 mg, 1.020 mmol) were reacted to afford the title compound (123 mg, 82% yield) as a white solid.
- This precursor was prepared according to the method of A.V. Ivanchatchenko as described in the Journal of Heterocyclic Chemistry (2004) vol.41 p. 931
- Example 58 4-amino-8-[2-fluoro-5 ⁇ (trifluoromethyI)phenyl]-N-propyl-cinnoIine-3- carboxamide Using method A, 4-amino-8-bromo-N-propyl-cinnoline-3-carboxamide (150 mg, 0.485 mmol) and 2-fluoro-5-(trifluoromethyl)phenylboronic acid (208 mg, 1.000 mmol) were reacted to afford the title compound (148 mg, 78% yield) as a white solid.
- Example 59 4-amino-8-(2-fluoro-5-methyl-phenyl)-N-propyl-cinnoline-3- carboxamide Using method A, 4-amino-8-bromo-N-propyl-cinnoline-3-carboxamide (150 mg, 0.485 mmol) and 2-fluoro-5-methyl-phenylboronic acid (154 mg, 1.000 mmol) were reacted to afford the title compound (127 mg, 77% yield) as a white solid.
- Example 60 4-amino-8-(2-fluoro-4-methyl ⁇ phenyl)-N-propyl-cinnoIine-3- carboxamide Using method A, 4-amino-8-bromo-N-propyl-cinnoline-3-carboxamide (150 mg, 0.485 mmol) and 2-fluoro-4-methyl-phenylboronic acid (154 mg, 1.000 mmol) were reacted to afford the title compound (141 mg, 86 % yield) as a white solid.
- Example 61 4-amino-8-(5-fluoro-2-methyI ⁇ phenyl)-N-propyl-cinnoline-3- carboxamide Using method A, 4-amino-8-bromo-N-propyl-cinnoline-3-carboxamide (150 mg, 0.485 mmol) and 5-fluoro-2-methyl-phenylboronic acid (154mg, 1.000 mmol) were reacted to afford the title compound (142 mg, 86 % yield) as a white solid.
- Example 63 4-amino-8-(3-fluoro-4-methoxy-phenyl)-N-propyl-cinnoline-3- carboxamide Using method A, 4-amino-8-bromo-N-propyl-cinnoline-3-carboxamide (150 mg, 0.485 mmol) and 3-fluoro-4-methoxy-phenylboronic acid (170 mg, 1.000 mmol) were reacted to afford the title compound (135 mg, 78 % yield) as a white solid.
- Example 64 4-amino-8-(2-fluoro-6-methoxy-phenyl)-N-propyl-cinnoline-3- carboxamide Using method A, 4-amino-8-bromo-N-propyl-cinnoline-3-carboxamide (150 mg, 0.485 mmol) and 2-fluoro-6-methoxy-phenylboronic acid (170 mg, 1.000 mmol) were reacted to afford the title compound (73 mg, 42 % yield) as a white solid.
- Tetrahydrofuran (515 mL, anhydrous) and isopropanol (147 mL, anhydrous) were added and the resulting red suspension was stirred at room temperature for 15 minutes.
- a solution of sodium carbonate (57.0 g, 537.7 mmol) in water (220 mL) was added rapidly through the addition funnel and the resulting mixture immediately placed into a pre-heated 8O 0 C oil bath. After 90 minutes at reflux (observed internal temperature 65°C), the reaction mixture was cooled to room temperature and filtered though a bed of Celite supported on a sintered glass funnel topped with Norite decolorizing carbon (30 g).
- Example 72 4-amino-8-(4-methoxy-3,5-dimethyl-phenyl)-N-propyI-cinnoline-3- carboxamide
- the mixture was stirred for 30 minutes and then filtered through a pad of Celite.
- the Celite was washed with EtOAc (3 x 150 mL).
- the filtrates were placed in a separatory funnel and the water layer was removed.
- the organic layer was concentrated under reduced pressure to reduce volume to ⁇ 200 mL, placed in a separatory funnel, diluted with EtOAc (400 mL), washed organic with brine, dried over sodium sulfate, filtered and concentrated to dryness.
- the crude product was taken up in ether (300 mL) and made acidic to pH 1 with 2M HCl/ether (Aldrich). After 1 hour, the tan solid was isolated by filtration (39.2 g, 80%).
- the title compound may form isolable atropisomers in certain organic solvents (e.g. 25-35% methanol) at room temperature.
- the two atropisomers of the title compound may be isolated using chiral LC. However, these isomers will racimize rapidly under neutral or acidic aqueous solutions.
- the title compound was prepared from 4-arnino7-fluoro-8 ⁇ iodo-N-propylcinnoline-3- carboxamide (200 mg, 0.535 mmol) and 2,5-dimethoxyphenyl boronic acid (194 mg, 1.07 mmol) according to Method A.
- the off-white solid from chromatography was slurried in ether, filtered and dried under vacuum at room temperature to afford the desired product (147 mg, 71%).
- Example 80 4-Amino-8-(2,4-dimethoxypyrimidin-5-yI)-7-fluoro-N-propylcinnoline- 3-carboxamide
- the title compound was prepared from 4-amino-7-flouro-8-iodo-N- propylcinnoline-3 -carboxamide (220 mg, 58.8 mmol) and 2,4-dimethoxy-5-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-pyrimidine (312 mg, 1.62 mmol) according to
- the title compound was prepared from4-amino-8-bromo-N-ethyl-cinnoline-3- carboxamide (70.0 mg, 0.237 mmol) and 4-methoxy-3 -pyridine boronic acid (153.0 mg, 0.3439 mmol) according to Method A except that the extraction was carried out with methylene chloride rather than ethyl acetate and the flash column was eluted with a gradient of 10 to 60% methanol in dichloromethane. The concentrated product was then recrystallized from chloroform (with a few drops of methanol) and hexanes to afford the i title compound as a yellow solid (19.6 mg, 26% yield).
- Example 82 4-Amino-N-butyl-8-(2,5-dimethoxyphenyl)cinnoline-3-carboxamide
- the title compound was prepared from 4-amino-8-bromo-N-butyl-cinnoline-3- carboxamide (100 mg, 0.31 mmol) and 2,5-dimethoxyphenyl boronic acid (112.6 mg,
- the title compound was prepared from 4-amino-8-bromo-N-methyl-cinnoline-3- carboxamide (20.0 g, 63.1 mmol) and 2,5-dimethoxyphenyl boronic acid (22.3 g, 122.4 mmol) according to Method B except that potassium carbonate was used as the base and tetrahydrofuran:ethanol:water (1:1:1) was used as the solvent system.
- the reaction mixture was filtered and the yellow solids were slurried in 10% methanol in chloroform and filtered. The combined filtrates were concentrated to a solid, slurried in hot ethyl acetate, and filtered.
- the title compound was prepared from 4-amino-8-bromo-N-butyl- cinnoline-3-carboxamide (200.0 mg, 0.62 mmol) and 2,4-dimethoxy-5-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-pyrimidine (987.9 mg, 3.72 mmol) according to
- the title compound was prepared from 4-amino-8-bromo-N-ethyl-cinnoline-3- carboxamide (200.0 mg, 0.678 mmol) and 2,4-dimethoxyprimidine-5-boronic acid pinacol ester (363.1 mg, 1.362 mmol) according to Method B except that the reaction was heated at 9O 0 C to fully dissolve the starting materials. After 4 hours, additional 2,4- dimethoxyprimidine-5-boronic acid pinacol ester (363.1 mg, 1.362 mmol) was added and the reaction was refluxed overnignt.
- Example 87 4-Amino-8-(2,5-dimethoxyphenyl)-cinnoline-3-carboxylic acid allylamide
- the title compound was prepared from 4-amino-8-bromo-cinnoline-3-carboxylic acid allylamide (273 mg, 0.89 mmol) and 2,5-dimethoxyphenyl boronic acid (201.1 mg,
- Example 89 4-Amino-8-(m-tolyl)-N-propyl-cinnoline-3-carboxamide
- the title compound was prepared from 4-amino-8-bromo-N-propyl-cinnoline-3- carboxamide (450 mg, 1.46 mmol) and 3-methylphenyl boronic acid (408 mg, 3.00 mmol) according to Method A to afford an off-white solid (321 mg, 69%).
- Example 90 4-Amino-8-(2-fluoro-6-methylpyridin-3-yl)-cinnoline-3-carboxylic acid propylamide
- the title compound was prepared from 4-amino-8-bromo-N-propyl-cinnoline-3- carboxamide (300.0 mg, 0.97 mmol) and 2-fluoro-6-methylpyridine-3-boronic acid (426.7 mg, 2.75 mmol) according to Method A to afford a white solid (124.2 mg, 38%).
- the title compound was prepared from 4-amino-7-fluoro-8-iodo-N-propylcinnoline-3- carboxamide (250 mg, 0.67 mmol) and 2-chloro-5-methoxyphenyl boronic acid (279 mg,
- Example 100 4-amino-7-cyano-8-(2,4-dimethoxyphenyl)-N-propyl-cinnoline-3- carboxamide Using Method G, 4-amino-8-bromo-7-cyano-N-propyl-cinnoline-3-carboxamide and 2,4-dimethoxyphenyl boronic acid were reacted to afford the title compound as a white solid.
- Example 104 4-amino-7-fluoro-8-(2-fluoro-3-methoxyphenyl)-N-propyI-cinnoIine-3- carboxamide
- Example 110 4-amino-7-fluoro-8-(2-methyl-5-fluorophenyl)-N-propyl-cinnoline-3- carboxamide Using method A, 4-amino-7-fluoro-8-iodo-N-propyl-cinnoline-3-carboxamide
- Example 113 4-amino-7-fluoro-8-(2,5-difluorophenyl)-N-propyl-cinnoline-3- carboxamide Using method B, 4-amino-7-fluoro-8-iodo-N-propyl-cinnoline-3-carboxamide
- Example 125 4-amino-N-cyclobutyl-7-fluoro-8-(5-fluoro-2-methoxy- phenyl)cinnoline-3-carboxamide
- Example 128 4-amino-N-cyclobutyl-8-(2,4-dimethoxyphenyl)-7-fluoro-cinnoIine-3- carboxamide
- Example 131 4-ammo-N-cyclobutyl-8-(2,6-dimethoxypyridin-3-yl)-7-fluoro- cinnoline-3-carboxamide
- Example 142 4-amino-N-cycIobutyl-8-(4-methoxypyridin-3-yl)cinnoIine ⁇ 3- carboxamide Using Method A, 4-amino-8-bromo-N-cyclobutyl-cinnoline-3-carboxamide (145 mg) and 4-methoxypyridin-3-yl boronic acid (172 mg) were reacted to afford the title compound (31 mg) as white solid.
- Example 147 4-amino-N-cyclobutyl-8-(3,5-dimethyIphenyl)cinnoline-3-carboxamide Using Method A, 4-amino-8-bromo-N-cyclobutyl-cinnoline-3-carboxamide (145 mg) and 3,5-dimethylphenyl boronic acid (169 mg) were reacted to afford the title compound (59 mg) as white solid.
- Example 154 4-amino-8-(4-chlorophenyl)-N-cyclobutyI-cinnoline-3-carboxamide
- Example 156 4-amino-N-cyclopropyl-8-(2-fluoro-6-methylpyridin-3-yl)cinnoline-3- carboxamide Using Method A, 4-amino-8-bromo-N-cyclopropyl-cinnoline-3-carboxamide
- Example 157 4-amino-N-cyclopropyl-7-fluoro-8-(5-fluoro-6-methoxypyridin-3- yl)cinnoline-3-carboxamide
- Example 163 4-amino ⁇ N-cyclopropyl-7-fluoro-8-(2,4-dimethoxypyrimidin-5- yl)cinnoline-3-carboxamide
- Example 166 4-amino-N-cyclopropyl-7-fluoro-8-(2-fluoro-6- methoxyphenyl)cinnoline-3-carboxamide
- Example 180 4-amino-N-cyclopropyl-8-(5-fluoro-6-methoxypyridin-3-yl)cinnoline- 3-carboxamide
- Example 182 4-amino-N-cycIopropyl-8-(6-methylpyridin-3yl)cinnoIine-3- carboxamide Using Method A, 4-amino-8-bromo-N-cyclopropyl-cinnoline-3-carboxamide
- Xenopus laevis frogs (Xenopus I, Kalamazoo, MI) were anesthetized using 0.15% tricaine. Surgically removed ovarian lobes were teased out in OR2 solution (82 NaCl, 2.5 KCl 5 5 HEPES, 1.5 NaH 2 PO 4 , 1 MgCl 2 , 0.1 EDTA, in mM, pH 7.4).
- OR2 solution 82 NaCl, 2.5 KCl 5 5 HEPES, 1.5 NaH 2 PO 4 , 1 MgCl 2 , 0.1 EDTA, in mM, pH 7.4
- the oocytes were defolliculated by incubation in 25 mL OR2 containing 0.2% collagenase IA (SIGMA) two times for about 60 minutes on a platform shaker and stored in Leibovitz's L-15 medium. Oocytes were injected the following day in 0.5 X Leibovitz's L-15 medium containing 50mg/
- Capped cRNAs from the linearized vectors containing human ⁇ ⁇ , ⁇ 2 and ⁇ 2 subunits of the GABAA receptor genes were mixed in ratio of 1 : 1 :30. Oocytes were injected with 25-50 nL of mixed RNA with an appx molar ratio for a ⁇ , ⁇ 2 , and ⁇ 2 as
- Oocyte recordings were done 2-10 days after injection. The same methods apply to subtypes derived from ⁇ 2 ⁇ 3 ⁇ 2 , ⁇ 3 ⁇ 3 ⁇ 2 , and ⁇ 5 ⁇ 3 ⁇ 2 , except for 1:1:1 ratio was used for ⁇ , ⁇ , and ⁇ subunits.
- Typical leak currents were between 0-40 nA, and rarely if a few cells did have a relatively high leak ( >100 nA) they were not used.
- GABA EClO For the determination of the GABA EClO, a series of 30 s pulses with increasing concentrations of GABA were applied to the cells every 5 minutes. After calculating EClO for GABA for each oocyte, a series of 30 s GABA pulses were applied at 5 minutes interval, with increasing doses of the modulator. The concentration of GABA corresponded to the EClO value calculated for each oocyte. The modulator pulses started 30 s before the GABA pulse so as to allow preincubation with the modulator.
- Reagents Assay and Wash Buffer 50 mM Tris-Citrate, 200 mM NaCl, pH 7.8
- PlateMate 1 lpt-dilut one-third GABAA 96/300ul head, 5516 tips in column 1 of serial dilution magazine, compound plate in left stacker A
- PlateMate 2 ul addition of cmpd dry new wash 96/30ul head, 5506 tips, compound plate in left stacker A, dilution plate in right stacker A, 100% DMSO in reservoir on stage 2, must change to fresh DMSO every 4-6 plates.
- PlateMate tip chg mix and disp 25 ul to assay plate 96w 96/300ul head, 5516 tips, dilution plate in left stacker A, assay plates in right stacker A, auto fill assay buffer reservoir on stage 2, need to change tips after every plate.
- PlateMate add 200ul membranes 96w: 96/300ul head, 5516 tips, assay plates in left stacker A, membrane reservoir on stage 2.
- RapidPlate add microscint 40ul (number of plates): 200 ⁇ l (burgundy box) tips in position 1 , Microscint 40 reservoir in position 2, plates beginning in position 3.
- Ki IC50 l+[ligand]/K D
- Assay and Wash Buffer 50 mM Tris-Citrate, 200 mM NaCl, pH 7.8 Compounds at 1OmM in DMSO: Put 75 ⁇ l in column 1 of compound plate.
- PlateMate add 60ul DMSO for dilutions 96w: 96/300ul head, 5516 tips in columns 2-12, compound plate in left stacker A, DMSO reservoir on stage 2.
- PlateMate 1 lpt-dilut one-third GABAA 96/300ul head, 5516 tips in column 1 of serial dilution magazine, compound plate in left stacker A.
- RapidPlate add microscint 40ul (number of plates): 200 ⁇ l (burgundy box) tips in position 1 , Microscint 40 reservoir in position 2, plates beginning in position 3.
- Data Analysis Data is analyzed by calculating percent of control, IC50, and Ki in an XL/ ⁇ t template.
- the following formula is used in the templates:
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75213705P | 2005-12-20 | 2005-12-20 | |
US82369306P | 2006-08-28 | 2006-08-28 | |
PCT/SE2006/001433 WO2007073283A1 (en) | 2005-12-20 | 2006-12-18 | Substituted cinnoline derivatives as gabaa-receptor modulators and method for their synthesis |
Publications (3)
Publication Number | Publication Date |
---|---|
EP1966158A1 true EP1966158A1 (de) | 2008-09-10 |
EP1966158A4 EP1966158A4 (de) | 2011-01-26 |
EP1966158B1 EP1966158B1 (de) | 2012-08-08 |
Family
ID=38188915
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06824527A Active EP1966158B1 (de) | 2005-12-20 | 2006-12-18 | Substituierte cinnolinderivate als modulatoren des gabaa-rezeptors und verfahren zu ihrer synthese |
Country Status (18)
Country | Link |
---|---|
US (2) | US7425556B2 (de) |
EP (1) | EP1966158B1 (de) |
JP (2) | JP5148507B2 (de) |
KR (1) | KR20080080206A (de) |
CN (1) | CN104592128A (de) |
AR (1) | AR056892A1 (de) |
AU (1) | AU2006327300A1 (de) |
BR (1) | BRPI0620126A2 (de) |
CA (1) | CA2634305A1 (de) |
EC (1) | ECSP088585A (de) |
ES (1) | ES2391472T3 (de) |
IL (1) | IL191762A0 (de) |
NO (1) | NO20083197L (de) |
NZ (1) | NZ569607A (de) |
RU (1) | RU2008122405A (de) |
SA (1) | SA06270474B1 (de) |
UY (1) | UY30032A1 (de) |
WO (1) | WO2007073283A1 (de) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7465795B2 (en) * | 2005-12-20 | 2008-12-16 | Astrazeneca Ab | Compounds and uses thereof |
CA2634305A1 (en) * | 2005-12-20 | 2007-06-28 | Marc Chapdelaine | Substituted cinnoline derivatives as gabaa-receptor modulators and method for their synthesis |
WO2008052139A2 (en) | 2006-10-25 | 2008-05-02 | Somaxon Pharmaceuticals, Inc. | Ultra low dose doxepin and methods of using the same to treat sleep disorders |
WO2008070795A2 (en) * | 2006-12-06 | 2008-06-12 | Somaxon Pharmaceuticals, Inc. | Combination therapy using low-dose doxepin for the improvement of sleep |
AR067028A1 (es) * | 2007-06-19 | 2009-09-30 | Astrazeneca Ab | Compuestos y usos de los mismos 849 |
EP2307400B1 (de) * | 2008-05-30 | 2014-04-23 | Amgen, Inc | Inhibitoren von pi3-kinase |
US9173864B2 (en) * | 2008-10-22 | 2015-11-03 | House Ear Institute | Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor |
WO2010123440A1 (en) * | 2009-04-21 | 2010-10-28 | Astrazeneca Ab | Pharmaceutical composition comprising 4-amino-8-(2-fluoro-6-methoxy-phenyl)-n- propylcinnoline-3-carboxamide hydrogen sulphate and rate-controlling polymer |
WO2010123443A1 (en) * | 2009-04-21 | 2010-10-28 | Astrazeneca Ab | Pharmaceutical composition comprising 4-amino-8-(2-fluoro-6-methoxy-phenyl)-n- propylcinnoline-3-carboxamide hydrogen sulphate. |
WO2010123441A1 (en) * | 2009-04-21 | 2010-10-28 | Astrazeneca Ab | Crystalline form of 4-amino-8-(2-fluoro-6-methoxy-phenyl)-n-propylcinnoline-3- carboxamide hydrogen sulphate, for treatment of anxiety disorders |
WO2011021979A1 (en) * | 2009-08-18 | 2011-02-24 | Astrazeneca Ab | Cinnoline compounds, their preparation, and their use |
ME02663B (de) | 2010-10-06 | 2017-06-20 | Glaxosmithkline Llc | Benzimidazolderivate als pi3-kinase-hemmer |
RU2017140639A (ru) * | 2011-05-23 | 2019-02-12 | Элан Фармасьютикалз, Инк. | Ингибиторы активности киназы lrrk2 |
US9365566B2 (en) | 2012-03-27 | 2016-06-14 | Takeda Pharmaceutical Company Limited | Cinnoline derivatives |
JP6152260B2 (ja) | 2012-11-01 | 2017-06-21 | 昭和電工パッケージング株式会社 | 電池用外装材及び電池 |
US9844551B2 (en) | 2015-01-14 | 2017-12-19 | Children's Hospital Medical Center | Compositions and methods for treatment of fragile X syndrome |
AU2018293627B2 (en) | 2017-06-30 | 2022-07-21 | Elanco Animal Health Gmbh | New azaquinoline derivatives |
WO2020065642A1 (en) | 2018-09-25 | 2020-04-02 | Pepticom Ltd. | Positive allosteric modulators of gabaa receptor |
CN115667221A (zh) | 2020-04-09 | 2023-01-31 | 拜耳动物保健有限责任公司 | 作为驱虫化合物的取代的稠合嗪类 |
GB202016245D0 (en) * | 2020-10-13 | 2020-11-25 | Univ College Cardiff Consultants Ltd | Compounds |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4230713A (en) | 1979-01-19 | 1980-10-28 | Ici Americas Inc. | Heterocyclic tetrahydro-1-alkyl-4-oxo-1H-imidazol-2-ylidene urea and phenyl esters of tetrahydro-1-alkyl-4-oxo-1H-imidazol-2-ylidene carbamic acid compounds |
US4511568A (en) | 1982-05-12 | 1985-04-16 | Ici Americas Inc. | CNS-Depressant pyrazolopyridines |
US4552883A (en) | 1982-06-15 | 1985-11-12 | Ici Americas Inc. | Pyrazolo[3,4-b]pyridine carboxylic acid esters and their pharmaceutical use |
US4563525A (en) | 1983-05-31 | 1986-01-07 | Ici Americas Inc. | Process for preparing pyrazolopyridine compounds |
GB8329531D0 (en) | 1983-11-04 | 1983-12-07 | Ici America Inc | Pyrazolopyridine cycloalkanones |
GB8421116D0 (en) | 1984-08-20 | 1984-09-26 | Ici America Inc | Alkynyl derivatives |
GB8425104D0 (en) | 1984-10-04 | 1984-11-07 | Ici America Inc | Amide derivatives |
GB8513639D0 (en) | 1985-05-30 | 1985-07-03 | Ici America Inc | Cinnoline compounds |
GB8610980D0 (en) | 1986-05-06 | 1986-06-11 | Ici America Inc | Heterocyclic fused tricyclic compounds |
DD249011A5 (de) | 1986-06-20 | 1987-08-26 | Ici Americas Inc,Us | Verfahren zur herstellung von cinnolin-verbindungen |
US4925844A (en) | 1988-02-09 | 1990-05-15 | Ici Americas Inc. | Antagonizing the pharmacological effects of a benzodiazepine receptor agonist |
EP0328282B1 (de) | 1988-02-09 | 1992-08-19 | Ici Americas Inc. | Pharmazeutische Zusammensetzung |
US5190951A (en) | 1990-10-19 | 1993-03-02 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
US5240934A (en) | 1990-10-19 | 1993-08-31 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
WO1992016497A1 (en) | 1991-03-22 | 1992-10-01 | Japan Tobacco Inc. | Amino acid derivative having renin inhibitory activity |
US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5409930A (en) | 1991-05-10 | 1995-04-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5750088A (en) | 1993-03-30 | 1998-05-12 | The Dupont Merck Pharmaceutical Company | Stable hydrazones linked to a peptide moiety as reagents for the preparation of radiopharmaceuticals |
CZ21198A3 (cs) | 1995-07-25 | 1998-07-15 | Clariant Gmbh | Katalyzátory k provádění křížových kopulačních reakcí |
DE19620023C2 (de) | 1996-05-17 | 2001-03-08 | Celanese Chem Europe Gmbh | Verfahren zur Herstellung von Phosphinat- oder Phosphonatgruppen enthaltenden tertiären Phosphanen und neue Phosphinatgruppen enthaltende tertiäre Phosphane |
GB9607219D0 (en) | 1996-04-04 | 1996-06-12 | Smithkline Beecham Plc | Novel compounds |
EP1062218A1 (de) | 1998-03-12 | 2000-12-27 | Novo Nordisk A/S | Modulatoren der protein-tyrosin-phosphatasen (ptphasen) |
CA2321791A1 (en) | 1998-03-18 | 1999-09-23 | Ciba Specialty Chemicals Holding Inc. | Coupling reactions with palladium catalysts |
US6362216B1 (en) | 1998-10-27 | 2002-03-26 | Array Biopharma Inc. | Compounds which inhibit tryptase activity |
DE19916222A1 (de) | 1999-04-10 | 2000-10-19 | Aventis Res & Tech Gmbh & Co | Verfahren zur Herstellung von Biarylen |
GB9919957D0 (en) | 1999-08-23 | 1999-10-27 | Merck Sharp & Dohme | Therapeutic agents |
GB9921150D0 (en) | 1999-09-07 | 1999-11-10 | Merck Sharp & Dohme | Therapeutic agents |
GB9921351D0 (en) | 1999-09-09 | 1999-11-10 | Merck Sharp & Dohme | Therapeutic agents |
GB9927687D0 (en) | 1999-11-23 | 2000-01-19 | Merck Sharp & Dohme | Therapeutic agents |
FR2801584B1 (fr) | 1999-11-26 | 2003-05-30 | Rhodia Chimie Sa | Procede de preparation d'un compose polyaromatique |
GB9929687D0 (en) | 1999-12-15 | 2000-02-09 | Merck Sharp & Dohme | Therapeutic agents |
GB9929685D0 (en) | 1999-12-15 | 2000-02-09 | Merck Sharp & Dohme | Therapeutic agents |
BR0109391A (pt) | 2000-03-21 | 2003-06-03 | Upjohn Co | 4-hidroxicinolina-3-carboxiamidas como agentes antivirais |
MY137020A (en) * | 2000-04-27 | 2008-12-31 | Abbott Lab | Diazabicyclic central nervous system active agents |
US6984756B2 (en) | 2000-05-19 | 2006-01-10 | Eli Lilly And Company | Process for preparing biphenyl compounds |
PL362893A1 (en) | 2000-05-19 | 2004-11-02 | Eli Lilly And Company | A process for preparing biphenyl compounds |
JP2004501109A (ja) | 2000-05-24 | 2004-01-15 | メルク シャープ エンド ドーム リミテッド | Gaba受容体に対するリガンドとしての3−フェニル−イミダゾ−ピリミジン誘導体 |
AUPQ841300A0 (en) | 2000-06-27 | 2000-07-20 | Fujisawa Pharmaceutical Co., Ltd. | New aminoalcohol derivatives |
GB0018473D0 (en) | 2000-07-27 | 2000-09-13 | Merck Sharp & Dohme | Therapeutic agents |
WO2002063766A2 (en) | 2000-11-01 | 2002-08-15 | Primarion, Inc. | Method and apparatus for detecting valid signal information |
AU1253002A (en) | 2000-11-10 | 2002-05-21 | Merck Sharp & Dohme | Imidazo-triazine derivatives as ligands for gaba receptors |
GB0027561D0 (en) | 2000-11-10 | 2000-12-27 | Merck Sharp & Dohme | Therapeutic agents |
GB0111191D0 (en) | 2001-05-08 | 2001-06-27 | Merck Sharp & Dohme | Therapeutic agents |
WO2003003009A1 (en) | 2001-06-29 | 2003-01-09 | 7Tm Pharma A/S | Use of metal-ion chelates in validating biological molecules as drug targets in test animal models |
GB0117060D0 (en) | 2001-07-12 | 2001-09-05 | Merck Sharp & Dohme | Therapeutic agents |
GB0119828D0 (en) | 2001-08-14 | 2001-10-10 | Merck Sharp & Dohme | Therapeutic agents |
GB0119803D0 (en) | 2001-08-14 | 2001-10-10 | Merck Sharp & Dohme | Therapeutic agents |
GB0120345D0 (en) | 2001-08-21 | 2001-10-17 | Merck Sharp & Dohme | Therapeutic agents |
AUPR738301A0 (en) | 2001-08-30 | 2001-09-20 | Starpharma Limited | Chemotherapeutic agents |
GB0122696D0 (en) | 2001-09-20 | 2001-11-14 | Merck Sharp & Dohme | Therapeutic agents |
US20050113283A1 (en) | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
WO2003062392A2 (en) | 2002-01-18 | 2003-07-31 | Ceretek Llc | Methods of treating conditions associated with an edg receptor |
GB0208394D0 (en) | 2002-04-11 | 2002-05-22 | Merck Sharp & Dohme | Therapeutic agents |
PL189894B1 (pl) * | 2002-04-15 | 2005-10-31 | Univ Medyczny W Lodzi | Sposób wytwarzania 6,7,8-podstawionych kwasów 4-hydroksycynnolino-3-karboksylowych |
GB0210124D0 (en) | 2002-05-02 | 2002-06-12 | Merck Sharp & Dohme | Therapeutic agents |
GB0210127D0 (en) | 2002-05-02 | 2002-06-12 | Merck Sharp & Dohme | Therapeutic agents |
GB0212049D0 (en) | 2002-05-24 | 2002-07-03 | Merck Sharp & Dohme | Therapeutic agents |
GB0212048D0 (en) | 2002-05-24 | 2002-07-03 | Merck Sharp & Dohme | Therapeutic agents |
MXPA05000638A (es) | 2002-07-17 | 2005-03-31 | Warner Lambert Co | Combinacion de un inhibidor alquino alosterico de metaloproteinasa-13 de matriz con un inhibidor selectivo de ciclooxigenasa-2 que no es celecoxib o valdecoxib. |
GB0218876D0 (en) | 2002-08-13 | 2002-09-25 | Merck Sharp & Dohme | Therapeutic agents |
AU2003246979B8 (en) | 2002-08-13 | 2009-08-06 | Merck Sharp & Dohme Limited | Phenylpyridazine derivatives as ligands for GABA receptors |
SE0202461D0 (sv) * | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel compounds |
MXPA05003607A (es) | 2002-10-04 | 2005-11-17 | Prana Biotechnology Ltd | Compuestos neurologicamente activos. |
US20040102360A1 (en) | 2002-10-30 | 2004-05-27 | Barnett Stanley F. | Combination therapy |
CA2502429A1 (en) | 2002-10-31 | 2004-05-21 | Amgen Inc. | Antiinflammation agents |
GB0225501D0 (en) | 2002-11-01 | 2002-12-11 | Merck Sharp & Dohme | Therapeutic agents |
GB0226462D0 (en) | 2002-11-13 | 2002-12-18 | Merck Sharp & Dohme | Therapeutic agents |
US20040167165A1 (en) | 2003-01-16 | 2004-08-26 | Geetha Shankar | Methods of treating conditions associated with an Edg-7 receptor |
GB0301350D0 (en) | 2003-01-21 | 2003-02-19 | Merck Sharp & Dohme | Therapeutic agents |
WO2004076452A1 (en) | 2003-02-26 | 2004-09-10 | Merck Sharp & Dohme Limited | 5,8-DIFLUOROIMIDAZO[1,2-a]PYRIDINES AS GABA-A α2/α3 LIGANDS FOR TREATING ANXIETY AND/OR DEPRESSION |
TW200505902A (en) | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
US7767817B2 (en) | 2003-09-05 | 2010-08-03 | Binghe Wang | Water soluble boronic acid fluorescent reporter compounds and methods of use thereof |
US7790734B2 (en) | 2003-09-08 | 2010-09-07 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
WO2005051302A2 (en) | 2003-11-19 | 2005-06-09 | Array Biopharma Inc. | Bicyclic inhibitors of mek and methods of use thereof |
WO2006124996A2 (en) * | 2005-05-17 | 2006-11-23 | Supergen, Inc. | Inhibitors of polo-like kinase-1 |
CA2634305A1 (en) * | 2005-12-20 | 2007-06-28 | Marc Chapdelaine | Substituted cinnoline derivatives as gabaa-receptor modulators and method for their synthesis |
US7465795B2 (en) * | 2005-12-20 | 2008-12-16 | Astrazeneca Ab | Compounds and uses thereof |
AR067028A1 (es) * | 2007-06-19 | 2009-09-30 | Astrazeneca Ab | Compuestos y usos de los mismos 849 |
-
2006
- 2006-12-18 CA CA002634305A patent/CA2634305A1/en not_active Abandoned
- 2006-12-18 WO PCT/SE2006/001433 patent/WO2007073283A1/en active Application Filing
- 2006-12-18 JP JP2008547160A patent/JP5148507B2/ja active Active
- 2006-12-18 KR KR1020087017686A patent/KR20080080206A/ko not_active Application Discontinuation
- 2006-12-18 ES ES06824527T patent/ES2391472T3/es active Active
- 2006-12-18 CN CN201410662834.9A patent/CN104592128A/zh active Pending
- 2006-12-18 BR BRPI0620126-1A patent/BRPI0620126A2/pt not_active IP Right Cessation
- 2006-12-18 EP EP06824527A patent/EP1966158B1/de active Active
- 2006-12-18 US US11/611,936 patent/US7425556B2/en active Active
- 2006-12-18 RU RU2008122405/04A patent/RU2008122405A/ru not_active Application Discontinuation
- 2006-12-18 AU AU2006327300A patent/AU2006327300A1/en not_active Abandoned
- 2006-12-18 NZ NZ569607A patent/NZ569607A/en unknown
- 2006-12-19 AR ARP060105619A patent/AR056892A1/es not_active Application Discontinuation
- 2006-12-19 SA SA6270474A patent/SA06270474B1/ar unknown
- 2006-12-19 UY UY30032A patent/UY30032A1/es unknown
-
2008
- 2008-05-27 IL IL191762A patent/IL191762A0/en unknown
- 2008-06-27 EC EC2008008585A patent/ECSP088585A/es unknown
- 2008-07-09 US US12/169,824 patent/US20090036454A1/en not_active Abandoned
- 2008-07-17 NO NO20083197A patent/NO20083197L/no not_active Application Discontinuation
-
2012
- 2012-10-03 JP JP2012221312A patent/JP5474153B2/ja active Active
Non-Patent Citations (2)
Title |
---|
See also references of WO2007073283A1 * |
VERHOEFF N P L ET AL: "[<123>I]Iomazenil SPECT benzodiazepine receptor imaging in schizophrenia", PSYCHIATRY RESEARCH: NEUROIMAGING, ELSEVIER, vol. 91, no. 3, 15 October 1999 (1999-10-15), pages 163-173, XP027393275, ISSN: 0925-4927 [retrieved on 1999-10-15] * |
Also Published As
Publication number | Publication date |
---|---|
JP5474153B2 (ja) | 2014-04-16 |
UY30032A1 (es) | 2007-07-31 |
AR056892A1 (es) | 2007-10-31 |
US7425556B2 (en) | 2008-09-16 |
BRPI0620126A2 (pt) | 2011-11-01 |
NZ569607A (en) | 2011-06-30 |
CN104592128A (zh) | 2015-05-06 |
JP2012255041A (ja) | 2012-12-27 |
SA06270474B1 (ar) | 2010-12-07 |
ECSP088585A (es) | 2008-07-30 |
US20070142328A1 (en) | 2007-06-21 |
JP2009520021A (ja) | 2009-05-21 |
NO20083197L (no) | 2008-09-10 |
IL191762A0 (en) | 2008-12-29 |
KR20080080206A (ko) | 2008-09-02 |
RU2008122405A (ru) | 2010-01-27 |
CA2634305A1 (en) | 2007-06-28 |
EP1966158B1 (de) | 2012-08-08 |
AU2006327300A1 (en) | 2007-06-28 |
EP1966158A4 (de) | 2011-01-26 |
WO2007073283A1 (en) | 2007-06-28 |
JP5148507B2 (ja) | 2013-02-20 |
US20090036454A1 (en) | 2009-02-05 |
ES2391472T3 (es) | 2012-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1966158A1 (de) | Substituierte cinnolinderivate als modulatoren des gabaa-rezeptors und verfahren zu ihrer synthese | |
US7465795B2 (en) | Compounds and uses thereof | |
DK2512243T3 (en) | POSITIVE ALLOSTERIC QUINOLINAMIDE M1 RECEPTOR MODULATORS | |
CA2770480C (en) | Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators | |
EP2176263A2 (de) | Fusionierte quinolin derivaten als gaba modulatoren | |
CA2743562A1 (en) | Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators | |
US20100184738A1 (en) | Uses of cinnoline compounds to treat schizophrenia | |
AU2009241392A1 (en) | 4-oxo-1,4-dihydroquinoline M1 receptor positive allosteric modulators | |
CN101379042A (zh) | 作为gabaa受体调节剂的取代的噌啉衍生物及其合成方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20080721 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1121458 Country of ref document: HK |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20101228 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/502 20060101ALI20120131BHEP Ipc: A61P 25/28 20060101ALI20120131BHEP Ipc: A61P 25/22 20060101ALI20120131BHEP Ipc: A61P 25/24 20060101ALI20120131BHEP Ipc: C07D 237/28 20060101AFI20120131BHEP |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: AT Ref legal event code: REF Ref document number: 569696 Country of ref document: AT Kind code of ref document: T Effective date: 20120815 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602006031351 Country of ref document: DE Effective date: 20120927 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2391472 Country of ref document: ES Kind code of ref document: T3 Effective date: 20121127 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: VDEP Effective date: 20120808 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 569696 Country of ref document: AT Kind code of ref document: T Effective date: 20120808 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D Effective date: 20120829 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20121208 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120808 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120808 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120808 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120808 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120808 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120808 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20121210 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120808 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120808 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20121109 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120808 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120808 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120808 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120808 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120808 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120808 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20130510 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20121108 Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20121231 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602006031351 Country of ref document: DE Effective date: 20130510 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20121218 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120808 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20121218 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20061218 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1121458 Country of ref document: HK |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 10 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 11 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20151218 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20151218 |
|
PGRI | Patent reinstated in contracting state [announced from national office to epo] |
Ref country code: IT Effective date: 20170710 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20221220 Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20231121 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20231121 Year of fee payment: 18 Ref country code: FR Payment date: 20231122 Year of fee payment: 18 Ref country code: DE Payment date: 20231121 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20240102 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20240101 Year of fee payment: 18 |